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RÉSUMÉ 
Le glaucome est la première cause de cécité irréversible à travers le monde. À présent 
il n‟existe aucun remède au glaucome, et les thérapies adoptées sont souvent inadéquates. La 
perte de vision causée par le glaucome est due à la mort sélective des cellules rétiniennes 
ganglionnaires, les neurones qui envoient de l‟information visuelle de la rétine au cerveau. Le 
mécanisme principal menant au dommage des cellules rétiniennes ganglionnaires lors du 
glaucome n‟est pas bien compris, mais quelques responsables putatifs ont été proposés tels que 
l‟excitotoxicité, le manque de neurotrophines, la compression mécanique, l‟ischémie, les 
astrocytes réactifs et le stress oxidatif, parmis d‟autres. Indépendamment de la cause, il est 
bien établi que la perte des cellules rétiniennes ganglionnaires lors du glaucome est causée par 
la mort cellulaire programmée apoptotique. Cependant, les mécanismes moléculaires précis 
qui déclenchent l‟apoptose dans les cellules rétiniennes ganglionnaires adultes sont mal 
définis. Pour aborder ce point, j‟ai avancé l‟hypothèse centrale que l‟identification de voies 
de signalisations moléculaires impliquées dans la mort apoptotique des cellules rétiniennes 
ganglionnaires offrirait des avenues thérapeutiques pour ralentir ou même prévenir la mort de 
celles-ci lors de neuropathies oculaires telles que le glaucome. 
Dans la première partie de ma thèse, j‟ai caractérisé le rôle de la famille de protéines 
stimulatrices d‟apoptose de p53 (ASPP), protéines régulatrices de la famille p53, dans la mort 
apoptotique des cellules rétiniennes ganglionnaires. p53 est un facteur de transcription 
nucléaire impliqué dans des fonctions cellulaires variant de la transcription à l‟apoptose. Les 
membres de la famille ASPP, soit ASPP1, ASPP2 et iASPP, sont des protéines de liaison de 
p53 qui régulent l‟apoptose. Pourtant, le rôle de la famille des ASPP dans la mort des cellules 
rétiniennes ganglionnaires est inconnu. ASPP1 et ASPP2 étant pro-apoptotiques, l‟hypothèse 
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de cette première étude est que la baisse ciblée de ASPP1 et ASPP2 promouvrait la survie des 
cellules rétiniennes ganglionnaires après une blessure du nerf optique. Nous avons utilisé un 
modèle expérimental bien caractérisé de mort apoptotique neuronale induite par axotomie du 
nerf optique chez le rat de type Sprague Dawley. Les résultats de cette étude (Wilson et al. 
Journal of Neuroscience, 2013) ont démontré que p53 est impliqué dans la mort apoptotique 
des cellules rétiniennes ganglionnaires, et qu‟une baisse ciblée de ASPP1 et ASPP2 par acide 
ribonucléique d‟interference promeut la survie des cellules rétiniennes ganglionnaires. 
Dans la deuxième partie de ma thèse, j‟ai caractérisé le rôle d‟iASPP, le membre anti-
apoptotique de la famille des ASPP, dans la mort apoptotique des cellules rétiniennes 
ganglionnaires. L‟hypothèse de cette seconde étude est que la surexpression d‟iASPP 
promouvrait la survie des cellules rétiniennes ganglionnaires après axotomie. Mes résultats 
(Wilson et al. PLoS ONE, 2014) démontrent que le knockdown ciblé de iASPP exacerbe la 
mort apoptotique des cellules rétiniennes ganglionnaires, et que la surexpression de iASPP par 
virus adéno-associé promeut la survie des cellules rétiniennes ganglionnaires.  
En conclusion, les résultats présentés dans cette thèse contribuent à une meilleure 
compréhension des mécanismes régulateurs sous-jacents la perte de cellules rétiniennes 
ganglionnaires par apoptose et pourraient fournir des pistes pour la conception de nouvelles 
stratégies neuroprotectrices pour le traitement de maladies neurodégénératives telles que le 
glaucome. 
Mots clés : cellule ganglionnaire de la rétine, mort  neuronale, protéine stimulatrice 
d‟apoptose de p53, axotomie du nerf optique  
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SUMMARY 
Glaucoma is the leading cause of irreversible blindness worldwide. At present, there is 
no cure for glaucoma, and current therapies are often inadequate. Loss of vision in glaucoma 
results from the death of retinal ganglion cells, the neurons that send visual information from 
the retina to the brain. The principal mechanism leading to retinal ganglion cell damage during 
glaucoma is not well understood, however, putative culprits have been proposed including 
excitotoxicity, neurotrophin deprivation, mechanical compression, ischemia, reactive 
astrocytes and oxidative stress. It is well established that retinal ganglion cell loss during 
glaucoma is caused by apoptotic programmed cell death, however, the precise mechanisms 
that lead to apoptotic death of adult retinal ganglion cells are poorly defined. To address this 
point, I put forth the central hypothesis that the identification of signaling pathways involved 
in apoptotic retinal ganglion cell death would offer therapeutic avenues to slow or prevent 
retinal ganglion cell death during ocular neuropathies such as glaucoma.  
In the first part of my thesis, I characterised the role of Apoptosis Stimulating Protein 
of p53 family (ASPP) proteins, which are regulators of p53, in the apoptotic death of retinal 
ganglion cells. p53 is a nuclear transcription factor implicated in cellular functions ranging 
from transcription to apoptosis. ASPP family members ASPP1, ASPP2 and iASPP are p53 
binding proteins that belong to a family of protein regulators of p53-dependent apoptotic 
death. However, the role of ASPP family members in retinal ganglion cell death is unknown. 
As ASPP1 and ASPP2 are pro-apoptotic, the hypothesis of our first study was that the 
knockdown of ASPP1 and ASPP2 gene expression would lead to retinal ganglion cell survival 
after an optic nerve lesion. We used a well-characterized experimental model of neuronal 
apoptosis induced by optic nerve axotomy in Sprague Dawley rats. The results of this study 
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(Wilson et al. Journal of Neuroscience, 2013) demonstrated that p53 is implicated in retinal 
ganglion cell death, and that targeted knockdown of ASPP1 and ASPP2 by short interference 
ribonucleic acid promotes retinal ganglion cell survival. The knockdown of ASPP2 correlates 
with a reduction in the levels of pro-apoptotic p53 regulated targets PUMA and Fas/CD95.  
In the second part of my thesis, I characterized the role of the anti-apoptotic member of 
the ASPP family, iASPP, in the apoptotic death of retinal ganglion cells. The hypothesis of 
this second study is that the overexpression of iASPP would promote retinal ganglion cell 
survival after axotomy. The data (Wilson et al. PLoS ONE, 2014) demonstrate that the 
targeted knockdown of iASPP by short interference ribonucleic acid exacerbates retinal 
ganglion cell death, and that the overexpression of iASPP by adeno-associated virus promotes 
retinal ganglion cell survival. The overexpression of iASPP correlates with a reduction in 
protein levels of PUMA and Fas/CD95. 
In conclusion, the findings presented in this thesis contribute to a better understanding 
of the pathological mechanisms underlying retinal ganglion cell loss by apoptosis and might 
provide insights into the design of novel neuroprotective treatments for neurodegenerative 
diseases such as glaucoma. 
 
Key words : retinal ganglion cell, neuronal death, apoptosis-stimulating protein of p53, 
axotomy 
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I. GENERAL INTRODUCTION 
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I.1. THE RETINA AS AN EXPERIMENTAL MODEL SYSTEM 
 When the Roman physician Galen of Pergamon observed the superficial blood vessels 
spanning across the retina, he concluded that the purpose of the retina was to feed the eye, 
which he described in his manuscript De Usu Partium Corporis Humani (On the Usefulness of 
the Parts of the Body) in the second century A.D. That beneath these blood vessels lay nervous 
tissue only became apparent when Johannes Kepler‟s optical description of the eye identified 
the retina as the sensitive receptor of the eye (Kepler, 1604). William Bowman, a British 
surgeon, furthered this realisation by stating that “the eyeball [...] consists primarily and 
essentially of a sheet of nervous matter visually endowed”, the retina (Bowman, 1849). 
Furthermore, the exquisite drawings of the Spanish histologist Santiago Ramón y Cajal laid 
the groundwork for the understanding of how the retina functions (Ramón y Cajal, 1899).  
 Cajal teased out the inter-relationships between neurons and traced the interweavings 
of neural communities. The quality of Cajal‟s observation revealed that the nervous system 
was made up of many independent, but interlinked, cells. Cajal not only identified a diversity 
of neurons, but also hypothesized that neurons receive electrical impulses through incoming 
dendrites, and conduct signals through outgoing axons (Ramón y Cajal, 1899). His findings 
revealed that the nervous system was to be understood not just through the behaviours of 
individual neurons, but through their connections with other cells. 
I.1.1. Retinal cytoarchitecture  
The retina is comprised of many cell types: photoreceptors, bipolar cells, horizontal 
cells, amacrine cells, retinal ganglion cells (RGC) and Müller glia (Figure 1). There are two 
types of photoreceptors in the retina: rods, which function as low light photoreceptors, and 
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cones, which are responsible for colour vision. Photoreceptors are light-sensitive cells that 
have an outer segment, composed of membranous disks that contain photopigment and lies 
adjacent to the pigment epithelial layer, and an inner segment that contains the cell nucleus 
and gives rise to synaptic terminals that contact bipolar or horizontal cells. Absorption of light 
by the photopigment (rhodopsin or cone opsins) in the outer segment of the photoreceptors 
initiates a cascade of events that changes the membrane potential of the photoreceptor, and 
therefore the amount of neurotransmitter released by the photoreceptor synapses onto the cells 
they contact. The synapses between photoreceptor terminals and bipolar or horizontal cells 
occur in the outer plexiform layer. The cell bodies of photoreceptors make up the outer nuclear 
layer, whereas the cell bodies of bipolar cells lie in the inner nuclear layer. The short axonal 
processes of bipolar cells make synaptic contacts on the dendritic processes of RGCs in the 
inner plexiform layer. The much larger axons of the RGCs form the optic nerve and carry 
retinal nerve impulses to the brain. 
Horizontal and amacrine cells have their cell bodies in the inner nuclear layer and are 
primarily responsible for lateral interactions within the retina. The processes of amacrine cells, 
which extend laterally in the inner plexiform layer, are postsynaptic to bipolar cell terminals 
and presynaptic to the dendrites of ganglion cells. Müller glia, which represent the principal 
glial cells of the retina, span radially across the entire retina, with their endfeet enveloping 
RGCs and displaced amacrine cells in the ganglion cell layer. Their cell bodies are found at 
the level of the inner nuclear layer. 
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Figure 1. A schematic diagram of the retina demonstrating the principal cell types 
involved in retinal signaling. 
The main retinal cell types are depicted as follows, with their respective attributed colour in 
parenthesis: rod photoreceptor (brown), cone photoreceptor (light grey), Müller glia (dark 
blue), horizontal cell (green), bipolar cell (orange), amacrine cell (yellow), retinal ganglion 
cell (red). Source: adapted from Wilson et al., Gene Therapy. 2012 
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I.1.2. The retina as a model system to study neurodegenerative mechanisms  
 RGCs are classified in 10 to 15 subtypes based on morphology or physiology in 
mammalian species (Masland, 2001a, b, Rockhill et al., 2002) but, despite their diversity, 
RGCs display the typical properties of CNS neurons, and comprise a cell body, dendrites and 
an axon. The RGC axons converge at the optic nerve head (ONH) to form the optic nerve 
which projects to four main targets: 1) the lateral geniculate nucleus of the thalamus, 2) the 
superior colliculus, 3) the pretectal nucleus, and 4) the suprachiasmatic nucleus. In rodents, a 
majority of axons project to the superior colliculus, whereas in humans the lateral geniculate 
nucleus is the predominant projection site (Linden and Perry, 1983, Purves, 2001). The optic 
nerve is the second of twelve paired cranial nerves but it is part of the CNS as it is derived 
from an evagination of the diencephalon during embryonic development and, as a 
consequence, the fibers are covered with myelin produced by oligodendrocytes, rather than 
Schwann cells found in the PNS. The accessibility of the retina renders it an ideal model in 
which to study neurodegenerative processes. One such disease is glaucoma, models of which 
will be discussed in the following section. 
I.2. GLAUCOMA MODELS 
I.2.1. Definition, risk factors and pathological features of glaucoma 
Glaucoma refers to a group of chronic optic neuropathies characterized by progressive 
optic nerve damage and selective loss of RGCs, which functionally translates to progressive 
visual field defects leading to irreversible blindness. It is estimated that more than 60 million 
people suffer from glaucoma worldwide (Quigley and Broman, 2006) and according to the 
World Health Organization, glaucoma is the second leading cause of blindness after cataracts, 
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accounting for 12% of total cases of blindness globally (Foster and Resnikoff, 2005). 
Furthermore, glaucoma is the first irreversible cause of blindness worldwide, as vision loss 
from cataracts is reversible. Age and ethnic background are important risk factors for 
developing glaucoma. Individuals over the age of 40 are at a much higher risk of developing 
this ocular neuropathy (Coleman and Miglior, 2008). Individuals of African descent are at 
higher risk of developing glaucoma and have the highest rate of blindness due to this disease 
(Leske et al., 2007). Elevated intraocular pressure (IOP) is also an important risk factor, and 
the only modifiable one, for developing glaucoma. Ocular hypertension is characterized by an 
IOP in the human eye of over 21 mmHg, whereas a value of 15 mmHg is considered normal 
(Quigley et al., 1994). Although IOP is regarded as an important risk factor, it is not an 
accurate predictor of glaucoma since over 30% of glaucoma patients have an IOP in the 
normal range (Nemesure et al., 2007).  
Glaucoma is characterized by damage to the neural components of the visual pathway 
including the retina, the optic tract, and the brain at the level of the lateral geniculate nucleus 
and the visual cortex. One of the determining features of glaucoma pathology is the selective 
loss of RGCs, which is characteristic of all glaucoma patients (Kendell et al., 1995, Quigley, 
1999). 
I.2.2. Implication of the aqueous humour in experimental models of glaucoma 
As IOP is an important risk factor linked to glaucoma pathogenesis, many animal 
models have been developed based on inducible high IOP, which results in ONH damage and 
gradual RGC death. Incidentally, the production, circulation and drainage of the aqueous 
humor -the clear fluid which fills the anterior and posterior chambers of the eye- are 
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determining factors in the regulation of IOP levels. To understand how these animal models of 
glaucoma induce IOP increase, we will review the anatomical structures of the eye involved in 
the production and circulation of the aqueous humour. 
The aqueous humour, produced by the ciliary epithelium in the ciliary body, provides 
nutrients for the lens and removes waste as it flows through the pupil into the anterior chamber 
of the eye (Krupin et al., 1986). The aqueous humor fills the anterior chamber and provides 
nutrients to the cornea as well. Within the anterior chamber, the cornea and iris join and it is 
here where the drainage of the aqueous humour takes place (Figure 2). The angle with which 
the cornea and iris join is of particular interest, as the two major categories of glaucoma are 
defined by the formation of an open or closed angle between the cornea and the iris: primary 
open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). 
Aqueous fluid flows toward the angle where it enters the trabecular meshwork (TM) 
(Tamm, 2009), which filters and directs the aqueous fluid into the Schlemm‟s canal 
(Johnstone, 2004). Several models of inducible and spontaneous glaucoma rely on a blockade 
of the aqueous humour drainage and will be discussed in subsequent sections. 
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Figure 2. Schematic presentation of the aqueous humour circulation within the eye. 
Aqueous humour is produced by the ciliary body and enters the anterior chamber through the 
pupil. The trabecular meshwork (TM) is located in the angle between cornea and iris and 
provides an outlet for aqueous drainage by directing it into the Schlemm's canal. Reproduced 
with permission from (Kwon et al., 2009), Copyright Massachusetts Medical Society. 
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I.2.3. Experimental models of glaucoma 
I.2.3.1. Primary-angle closure glaucoma 
Primary-angle closure glaucoma (PACG) is characterized by the blockade of the 
aqueous humour drainage and/or its circulation. This results in increased IOP and consequent 
damage to the retina and optic nerve. Several breeds of dogs are prone to developing 
spontaneous glaucoma (Reinstein et al., 2009) however the high cost of purchasing and 
housing dogs, and complications of handling dogs in large experimental groups have resulted 
in the limited use of this model. A model of laser photocoagulation to induce the closure of the 
anterior chamber angle has been adapted for mice (Aihara et al., 2003). This model employs a 
diode laser which creates burn spots causing the iris root to attach to the peripheral cornea, 
which consequently obstructs the aqueous outflow and results in an elevation of IOP (Aihara 
et al., 2003). The IOP elevation in this model is accompanied by significant loss of RGC 
axons (Mabuchi et al., 2003). However, the small size of mice eyes demands a high level of 
dexterity by the experimenter, as excessive or misplaced laser burns could result in an 
inflammatory response and retinal damage. 
I.2.3.2. Open-angle glaucoma 
Primary open angle glaucoma (POAG) is the most common form of glaucoma 
worldwide. POAG is characterized by changes in the optic nerve head (also called optic disk), 
damage to RGC axons in the optic nerve, and loss of RGCs in the retina (Quigley, 2005). 
POAG is not necessarily associated with IOP elevation, however high IOP is a major risk 
factor for developing POAG (Leske et al., 2003).  
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In primate models of POAG, Rhesus or Cynomolgus monkeys are subjected to laser 
photocoagulation whereby burn spots are created on the circumference of the TM, resulting in 
moderate IOP increase (Wang et al., 1998). Loss of RGCs and visual deficits are well 
documented in this model (Hood et al., 1999, Morgan et al., 2000, Yücel et al., 2000, Hare et 
al., 2001, Yücel et al., 2003). However, the high cost of monkeys, their limited availability and 
difficulty to work with are drawbacks of this model. 
The laser photocoagulation technique has also been used in rodent models of POAG 
(Ueda et al., 1998, Levkovitch Verbin et al., 2002, Gross et al., 2003, Ji et al., 2005). Another 
rodent model of POAG is the Morrison rat model, in which a hypertonic saline solution is 
injected into an episcleral vein of Brown Norway rat eyes. Hypertonic saline disrupts the 
structure of the TM and gradually reduces the aqueous outflow, resulting in IOP elevation 
(Morrison et al., 1997). Another method of reducing the aqueous outflow is by cauterizing the 
episcleral veins (Shareef et al., 1995). In this model, two to three veins are isolated and 
blocked using an ophthalmic cautery instrument. Obstruction of the TM and elevation of IOP 
can also be achieved by injection of sterile latex microspheres (Weber and Zelenak, 2001, 
Urcola et al., 2006) or microbeads into the anterior chamber of rodent eyes (Sappington et al., 
2010, Chen et al., 2011). Finally, a hereditary mutation in the DBA/2J mice leads to iris 
pigment dispersion and adhesion of the iris to the cornea, which results in significant elevation 
of IOP by 6 months of age (John et al., 1998).  
1.2.4 Glaucoma model caveats 
The aforementioned glaucoma models each have their advantages and disadvantages. 
Chronic animal models of glaucoma rely on OHT induction to ultimately cause RGC 
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neurodegeneration, and yet not all glaucoma patients exhibit an increase in IOP. Furthermore, 
signaling pathways activated in chronic experimental models of glaucoma, much like the 
disease, are complex and variable. The complexity and variability in these models are not ideal 
for the detection of precise molecular mechanisms leading to apoptotic RGC death, a crucial 
aspect in the pathophysiology of all forms of glaucoma. The identification of key molecular 
mechanisms involved in neuronal death in vivo often requires a model that allows reliable, 
reproducible and predictable time-course of RGC death.  
I.3. OPTIC NERVE AXOTOMY MODEL 
Following traumatic injury to the mammalian CNS, neurons die by apoptosis, necrosis, 
or autophagy. Neurons that have their axons sheared open will undergo fundamental cellular 
and biochemical changes. Notably, the physical separation of the cell body from its target 
effectively prevents retrograde transport of neurotrophic factors thought to be required for 
survival (Oppenheim, 1991). Furthermore, calcium influx destabilizes the cytoskeleton and 
contributes to the activation of apoptotic pathways and the ensuing cellular degradation 
(Trump and Berezesky, 1995). Neurons that survive are severely impaired and rendered 
inactive, at least transiently, by the dramatic variations in their ionic and metabolic 
environment. In brief, adult mammalian CNS neurons are unable to regenerate an axon and 
their soma dies or atrophies after lesion (Ramon y Cajal, 1928).  
I.3.1. Acute optic nerve injury and RGC death 
The optic nerve transmits visual input from the retina to the visual cortex where image 
processing occurs. Damage to the optic nerve will affect this transmission of visual 
information, thus compromising vision. Optic nerve afflictions include: 1) glaucoma, in which 
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the optic nerve at the optic nerve head are damaged; 2) optic neuritis, an inflammation of the 
optic nerve which leads to the degradation of the myelin sheath enveloping the optic nerve; 3) 
cancerous tumours such as a pituitary tumour which compresses the nerve at the level of the 
optic chiasm, and 4) acute trauma such as an orbital fracture. Although a full transection 
(axotomy) is unlikely to occur and traumatic injury of the optic nerve is very rare (Steinsapir 
and Goldberg, 1994), the optic nerve axotomy produces a well characterized time course of 
RGC death, permitting the accurate evaluation of neuroprotective and regenerative strategies. 
In addition, RGCs die by apoptosis after optic nerve axotomy as they do in glaucoma (Garcia-
Valenzuela et al., 1995) and other CNS diseases. However, because a larger number of RGCs 
die abruptly after axotomy, the molecular mechanisms that promote neuronal apoptosis might 
be more readily identified in this simpler model of RGC death. Furthermore, the initial wave 
of apoptotic RGC death is more reproducible in an axotomy model than in experimental rat 
glaucoma models, allowing for a spatiotemporal correlation between pro-apoptotic gene 
expression and RGC loss in vivo. Thus, strategies to promote cell survival in this system may 
be extrapolated to other neurodegenerative diseases affecting other neuronal populations. For 
these reasons, the optic nerve axotomy model was selected for the studies presented in this 
dissertation. Importantly, the axotomy model has proved extremely useful in the study and 
treatment of traumatic CNS injuries. Indeed, optic nerve axotomy has been extensively used to 
study the molecular mechanisms underlying retinal neuron death. For example, this model was 
used to detect the activation of apoptosis initiator caspase 9 (Kermer et al., 2000, Koeberle, 
2009) and cleavage of effector caspase 3 in RGCs (Kermer et al., 1999, Hu et al., 2012) after 
optic nerve lesion, and subsequent TUNEL reactivity (Berkelaar et al., 1994, Quigley et al., 
1995). This model has also been useful to evaluate the effect of neuroprotective strategies in 
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vivo; for example with the demonstration that caspase inhibitors reduced RGC loss following 
optic nerve axotomy (Kermer et al., 1998, Chaudhary et al., 1999, Ahmed et al., 2011, 
Monnier et al., 2011). Moreover, this was an effective model to investigate the signal 
transduction pathways involved in RGC survival, including TrkB signaling (Cheng et al., 
2002b), the Erk1/2 pathway (Pernet et al., 2005, Almasieh et al., 2011), and the opposing 
effects of TrkA and p75 receptor signaling pathways (Lebrun-Julien et al., 2009).  
I.3.2. Pattern of RGC cell death in the axotomy model 
Transection of the adult rat optic nerve leads to a bi-phasic pattern of cell death. The 
first phase is prolonged, as within the first 4 to 5 days after lesion only a negligible number of 
RGCs die (Berkelaar et al., 1994, Peinado-Ramón et al., 1996). The second stage is rapid, 
however, and is characterized by massive cell death. Indeed, seven days after axotomy, only 
50% of RGCs survive and less than 10% remain 14 days after injury (Berkelaar et al., 1994, 
Quigley et al., 1995). Interestingly, approximately 5% of RGCs remain  up to 20 months after 
transection (Villegas-Perez et al., 1993), however, the molecular basis for this apparent 
resilience is currently unknown. 
Following optic nerve axotomy, RGC death has been described as apoptotic (Berkelaar 
et al., 1994, Garcia-Valenzuela et al., 1994). Indeed, RGCs die by apoptosis in optic nerve 
acute lesion models, such as the optic nerve axotomy or crush models (Berkelaar et al., 1994), 
experimental glaucoma (Quigley et al., 1995), human glaucoma (Kerrigan LA, 1997), an 
observation that has been confirmed by in vivo real-time visualization in ocular hypertensive 
rat eyes (Cordeiro et al., 2004). Apoptosis is an energy consuming process that requires de 
novo protein synthesis. Apoptosis is a common mechanism of neuronal loss in the injured or 
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degenerating visual system. The hallmark structural features of apoptosis are cellular round-
up, retraction of pseudopodia, reduction of cellular volume, nuclear fragmentation, 
modification of cytoplasmic organelles, plasma membrane blebbing, and engulfment by 
resident phagocytes (Kerr, 1972, Kerr et al., 1995). The apoptotic process can be triggered by 
various stimuli and involves the death receptor and/or mitochondrial apoptotic pathways.  
Autophagy, traditionally defined as a non-apoptotic type of programmed cell death, 
involves lysosomal degradation of dysfunctional cellular components. Mutations in the Toll-
Like Receptor 4 (TLR4) gene, a sensor for autophagy, have been associated with normal 
tension glaucoma in a Japanese cohort study (Shibuya et al., 2008). There is evidence that 
autophagy occurs in glaucoma, as LC3-B and Beclin-1 upregulation as well as an 
accumulation of autophagosomes were detected in RGCs after IOP elevation in a hypertensive 
rat glaucoma model (Park et al., 2012), and in a rhesus monkey hypertensive glaucoma model 
(Deng et al., 2013). In addition, an upregulation of genes linked to autophagy was detected in 
ocular hypertensive astrocyte samples (Tezel et al., 2012). Autophagy is also activated 
following optic nerve transection, and was compellingly revealed to have a neuroprotective 
role following axotomy (Kim et al., 2008, Rodriguez Muela and Boya, 2012).  
Although apoptosis is the active process by which RGCs die after axonal damage, a 
small number of cells die by necrosis due to mechanical or inflammatory damage inflicted by 
the injury (Thanos et al., 1993, Bien et al., 1999). Necrosis typically occurs after toxic insult, 
hypoxia, energy depletion or other exogenous insults. It results in a swelling of the cell body 
and mitochondria, followed by perforation of the cell membrane resulting in the leakage of 
cellular contents and consequent inflammatory response. It is likely that there is a continuum 
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between axotomy-induced apoptotic and necrotic cell death, as both modes share common 
characteristics (Nicotera et al., 1999). While the orchestral role of p53 in apoptotic pathways is 
well established, recent findings have reported a novel role in necrosis, whereby p53 opens the 
mitochondrial permeability transition pore to trigger necrosis (Vaseva et al., 2012). An 
understanding of p53 function in RGC death is therefore warranted. We opted to focus on 
apoptotic cell death in our studies because of the central role apoptosis plays in RGC death 
during glaucoma. Furthermore, despite potential crosstalk amongst apoptotic, necrotic and 
autophagic pathways, there is no strong evidence of necrosis occurring in glaucoma (Osborne 
et al., 1999b), and the understanding of autophagic processes in glaucomatous 
neurodegeneration is incipient. 
I.4. p53 AND ITS REGULATORS 
I.4.1. The p53 family 
The p53 transcription factor belongs to a family of proteins called the p53 family, 
comprised of three evolutionarily conserved transcription factors, p53, p63 and p73. The p53 
family proteins are involved in many important cellular functions, including tumour 
suppression (p53 and p73), epithelial cell stratification (p63), and CNS development (p73). 
Furthermore, p53, p63 and p73 genes can independently mediate apoptosis (Sheikh and 
Fornace, 2000). All p53 family members are expressed during retinal development, but their 
levels are downregulated in the adult eye (Vuong et al., 2012). Upregulation of p63 and p73, 
but not p53, are observed in human retinoblastoma tumour samples, an eye cancer affecting 
the retina (Adithi et al., 2008).  
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All three members of the p53 family share significant homology at the genomic and 
protein levels. They share common structural motifs, including a transactivation domain (TA), 
a DNA-binding domain (DBD) and an oligomerization domain (OD). In addition, p63 and 
p73, but not p53, contain long C-termini containing a sterile alpha motif (SAM), which is a 
protein-protein interaction domain (Chi, 1999) (Figure 3). p63 and p73 genes have been found 
to encode several proteins whose structure and functions are similar yet not identical to those 
of p53 (Kaghad et al., 1997, Yang et al., 1998). p53, p63 and p73 encode differentially spliced 
mRNAs, with most of splicing occurring at the 3‟ end for p63 and p73, creating proteins with 
varying C-termini lengths (Kaghad et al., 1997, De Laurenzi et al., 1998, De Laurenzi et al., 
1999, Ueda et al., 1999). Not only do all three p53 family members express multiple splice 
variants, they also contain different internal promoters in addition to their proximal promoters, 
yielding truncated or full length variants, respectively. This allows for a multitude of transcript 
variants arising from p53, p63 and p73 gene transcription. Altogether, the p53 gene can 
transcribe ten different variants: p53 (α, β, γ), ∆40p53 (α, β, γ), ∆133p53 (α, β, γ) and ∆p53 
(Courtois et al., 2004, Bourdon et al., 2005, Mills, 2005, Rohaly et al., 2005) (Figure 3). In the 
case of p63 and p73, the promoter and differential splicing options yield α, β, γ, δ, ε, δ, ε , and 
φ isoforms for both full length and truncated forms (Figure 3). Furthermore, p73 has 3 
additional truncated forms due to an additional amino-terminal splicing site (Moll and Slade, 
2004). As the N terminus is crucial for the transactivation of target genes, full-length isoforms 
of p53, p63 and p73 can be functionally distinguished from the transactivation-compromised 
∆N isoforms that show anti-apoptotic and dominant–negative properties.  
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Figure 3: p53 family structural motifs. The overall protein architecture of the p53 family is 
highly conserved, and consists of a central sequence-specific DNA binding domain (DBD), an 
N-terminal transactivation domain (TA) and a C-terminal oligomerization domain (OD). Both 
p63 and p73 have a sterile alpha motif (SAM) domain implicated in protein–protein 
interactions, whereas p53 does not. The highest degree of homology is seen within the DBD, 
where >97% of all tumour-associated p53 mutations are located. All three genes express many 
differently spliced isoforms, and contain a second intronic promoter that generates N-
terminally truncated proteins (∆133p53, ∆Np63 and ∆Np73). Alternative splicing of C-
terminal exons yields many different isoforms (α, β, γ, δ, ε, δ, ε , and ζ) with still incompletely 
understood DNA-binding properties, transcriptional activities and biological functions. Source 
of image adapted by permission from Macmillan Publishers Ltd: [Nature Reviews Cancer] 
(Stiewe, 2007), copyright (2007). 
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I.4.2. The p53 transcription factor 
I.4.2.1. p53 in ocular development 
The role of p53 during ocular development has been assessed in p53 knockout mice of 
varying strains, which revealed striking differences. Indeed, in two strains, the C57BL x CBA 
and 129/Sv x C57BL/6 mice, there were no reported ocular developmental defects 
(Donehower et al., 1992, Jacks et al., 1994).  However, abnormalities were detected in the p53 
knockout mice with C57BL/6 and BALB/c OlaHsd backgrounds. Indeed, cataract formation 
was detected in p53-null BALB/c OlaHsd mice, as well as aberrant hyaloid vasculature, which 
is a transient embryonic vasculature that regresses with the formation of adult retinal vessels 
(Reichel et al., 1998). In addition to abnormal hyaloid structure, p53-null mice in a C57BL/6 
background also exhibited retinal folding and underdeveloped (hypoplastic) optic nerves 
(Ikeda et al., 1999). It was hypothesized that the phenotype discrepancy between p53-null 
mice with 129/Sv or C57BL/6 backgrounds was caused by protective and compensatory 
alleles for p53 loss present in 129/Sv mice (Ikeda et al., 1999).  
p53 transcript levels during murine retinal development peak at embryonic days E17-
E18 and decrease gradually until postnatal day P15, where they remain low in the post-mitotic 
retina (Vuong et al., 2012). Likewise, p53 protein was readily detected at E18, after which 
time point protein levels began to decrease, and were undetectable by P7 (Vuong et al., 2012). 
This decrease in p53 levels in the murine retina coincides with the developmental time point 
that retinal cells exit the cell cycle, differentiate, and become postmitotic (Cepko et al., 1996). 
p53 is not required for developmental programmed death of RGCs, as mice deficient for one 
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or both alleles of p53 do not exhibit developmental changes in RGC number in comparison to 
wild-type animals (Li et al., 2002). 
I.4.2.2. p53 in post-mitotic neurons  
The tumour suppressor and nuclear transcription factor p53 mediates the apoptosis of 
post-mitotic neurons exposed to a wide range of insults such as DNA damage, neurotrophic 
factor deprivation, oxidative stress, ischemia and excitotoxicity (Culmsee and Mattson, 2005). 
Stress signals lead to activation and accumulation of p53, which then promotes the 
transcription of pro-apoptotic genes (Michalak et al., 2005). Neuronal apoptosis induced by 
p53 has been well documented in models of neurodegenerative disorders including 
Alzheimer‟s disease, Parkinson‟s disease, Huntington‟s disease and amyotrophic lateral 
sclerosis (de la Monte et al., 1997, González de Aguilar et al., 2000, Martin, 2000, Duan et al., 
2002, Tamagno et al., 2003, Ryan et al., 2006), suggesting a key role for this transcription 
factor in the regulation of neuronal viability after neural injury. Given its critical role in the 
control of cell death, several mechanisms exist to ensure a tight regulation of p53 activity. The 
level of p53 protein is normally kept low in most cell types, including neurons (Soussi, 2000), 
via rapid and continuous degradation following ubiquitination by the E3 ubiquitin ligases 
Mdm2 and MdmX (Wade et al., 2010). Additional control of p53 function is exerted via post-
translational acetylation, phosphorylation or methylation; and by interactions with protein 
partners including the apoptosis-stimulating proteins of p53 (ASPP) family (Iwabuchi, 1994, 
Nagase et al., 1998, Boehme and Blattner, 2009).  
 p53 has been shown to exert an important pro-oxidant activity in the retina (Chatoo et 
al., 2009). Inactivation of the p53 gene, or reduced p53 expression, has been shown to protect 
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RGCs against retinal ischemia or excitotoxic death (Rosenbaum, 1998, Li et al., 2002). Pro-
apoptotic genes induced by p53 including Gadd45a and Ei24 are upregulated in the retina after 
optic nerve transection and in experimental glaucoma models (Levkovitch-Verbin et al., 
2006). Attempts to link single nucleotide polymorphisms in the p53 gene with glaucoma have 
been contradictory: while some studies found a correlation in Caucasian and Chinese 
populations (Ressiniotis et al., 2004, Daugherty et al., 2009) an association has not been found 
in other ethnic groups (Acharya et al., 2002, Dimasi et al., 2005, Mabuchi et al., 2009, Saglar 
et al., 2009, Silva et al., 2009). A recent study demonstrated that loss of WDR36, a gene of 
unknown function identified as causative for glaucoma (Monemi et al., 2005), leads to 
activation of the p53 stress-response pathway in zebrafish (Skarie and Link, 2008). These 
studies suggest that defects in p53 pathway genes may increase the risk of certain populations 
to develop glaucoma (Fan et al., 2010). Furthermore, p53 has been implicated in age-related 
macular degeneration (AMD): AMD is generally believed to start with retinal pigment 
epithelium (RPE) cell death, and p53 is upregulated in RPE cells in response to high-energy 
light exposure, inducing apoptosis (Westlund et al., 2009, Bhattacharya et al., 2012). In 
retinoblastoma, Mdm4 is overexpressed in response to loss of RB1, leading to degradation of 
p53 (Laurie et al., 2006, Wallace, 2006). 
I.4.3. p53 regulation  
There are over 100 known p53 binding proteins, whose interactions with p53 along 
with p53 post-translational modifications frequently dictate p53 function, for example whether 
it induces cell cycle arrest or apoptosis (Braithwaite et al., 2005). These regulating 
mechanisms range from inhibition to coactivation of p53. The identification of p53 in 1979 
has led to nearly 70,000 peer-reviewed publications, and was named the „Molecule of the 
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year‟ in 1993 by the journal Science (Koshland, 1993). p53 is mutated in nearly half of all 
human cancers (Petitjean, 2007), a trait rarely found in p63 and p73 family members (Strano 
et al., 2007). Not only does p53 act as a tumour suppressor, it is activated in response to 
various stress signals. p53 activation occurs via multiple mechanisms including increased p53 
protein concentration, often caused by decreased p53 degradation (Ashcroft et al., 2000), 
nuclear translocation (Liang and Clarke, 2001), and post-translational protein modifications 
including phosphorylation and acetylation (Jayaraman and Prives, 1999). Furthermore, p53 
can also be activated by non-covalent modifications such as electrostatic interactions with 
other proteins (Benyamini and Friedler, 2011). p53 is modified by as many as 50 individual 
posttranslational modifications, which mediate precise protein-protein interactions, an array of 
modifications that is interdependent (Meek and Anderson, 2009). 
 The p53 interactome is continuously being updated, however relatively few of these 
p53 binding partners have been studied in the CNS. The following sections on p53-regulating 
proteins focus on the ASPP family, and additional p53 regulating proteins whose roles have 
been assessed in the retina. 
I.4.3.1. The ASPP family 
The ASPP proteins constitute a recently discovered family of proteins that bind and 
modulate p53-dependent apoptosis (Trigiante and Lu, 2006). Their name is an acryonym 
either based on the domain organization of the proteins (Ankyrin-repeat, SH3, and Proline-rich 
domain containing Protein) or their function (Apoptosis-Stimulating Protein of p53). The 
founding member of the family, ASPP2, was initially identified as 53BP2 (p53 binding protein 
2) in a yeast two-hybrid screen, using the p53 DNA binding core domain as bait (Iwabuchi, 
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1994). ASPP1 was identified later in a homology search (Nagase et al., 1998). Functional 
studies revealed that p53-induced apoptosis was substantially enhanced in the presence of 
ASPP1 or ASPP2 (Lopez et al., 2000, Ao et al., 2001, Samuels-Lev, 2001) and that complexes 
with ASPP1 or ASPP2 increased the affinity of p53 for promoters of pro-apoptotic genes 
(Samuels-Lev, 2001, Bergamaschi et al., 2006). Furthermore ASPP1 and ASPP2 selectively 
enhance the apoptotic-promoting ability of p53 without affecting p53 cell cycle arrest 
functions (Bergamaschi et al., 2003). This preferential activation of apoptotic genes in the 
presence of ASPP1 and ASPP2 was also observed for p63 and p73 (Bergamaschi et al., 2004). 
The third member of the ASPP family, iASPP, was originally identified as an inhibitor of the 
nuclear factor kappa  (NFk) (Yang, 1999). iASPP is the p53 inhibitor within the ASPP 
family, blocking apoptosis by repressing the transactivation potential of p53 (Bergamaschi et 
al., 2003, Bergamaschi et al., 2006) (Figure 4). Notably, the ability of iASPP to inhibit p53 
mediated apoptosis is conserved from C. elegans to humans. 
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Figure 4. ASPP family apoptotic signaling pathway. The pro-apoptotic ASPP1 (ankyrin-
repeats-, SH3-domain- and proline-rich-region-containing protein 1) and ASPP2 are induced 
by the E2F1 transcription factor and cooperate with the p53 transcription factor and its family 
members p63 and p73 in transactivating pro-apoptotic genes to promote apoptosis. The 
inhibitory family member iASPP functions as a transrepressor of the same genes that ASPP1 
and ASPP2 transactivate. (Image generated by Ariel Wilson). 
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The regions of ASPP family members that interact with p53 have been mapped to their 
C-termini (Patel et al., 2008, Robinson, 2008). The N termini of ASPP1 and ASPP2 confers 
their apoptotic activity (Samuels Lev et al., 2001), and show no sequence similarity with the N 
terminal of iASPP (Bergamaschi et al., 2003). ASPP1/2 and iASPP bind to the core domain of 
p53 (Robinson, 2008), and iASPP also binds to the proline-rich region of p53 (Bergamaschi et 
al., 2006) (Figure 5). 
Pro-apoptotic ASPP1 and ASPP2 are frequently downregulated in tumours, and anti-
apoptotic iASPP is frequently upregulated (Bergamaschi et al., 2003, Jiang et al., 2011, Li et 
al., 2011, Li et al., 2012, Mak et al., 2013, Zhao et al., 2013). Post-translational modifications 
of ASPP family members in cancer cells have been discovered. Indeed, ASPP2 is 
phosphorylated by the Ras/MAPK pathway in an osteocarcinoma cell line (Godin Heymann et 
al., 2013), and Cyclin B1/CDK1 phosphorylates iASPP in melanoma cells (Lu et al., 2013). 
Other mechanisms of ASPP regulation have been uncovered, such as the study of ASPP1 and 
ASPP2 epigenetic regulation which revealed that in tumour cells expressing wild-type p53, 
ASPP1 and ASPP2 promoters are hypermethylated and subsequently downregulated in 
hepatocellular carcinoma tumours (Zhao et al., 2010) as well as in breast cancer and lung 
carcinoma tumour cell lines (Liu et al., 2005). Furthermore, microRNA downregulation of 
iASPP protein levels was detected in a cerebral ischemia mouse model (Liu et al., 2013). 
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Figure 5. Amino acid sequences and domain organisation of ASPP and p53 proteins.  A) 
Domain organization of ASPP2, ASPP1 and iASPP. Individual domains are as follows: 
ubiquitin-like (ULD), glutamine-rich (Gln), proline-rich (Pro), ankyrin repeats (ANK), and Src 
homology 3 (SH3). B) Domain organization of p53. Individual domains are the transcription 
activation (TAD), the proline-rich (Pro), the DNA binding or core (CD), the linker (L), the 
oligomerization or tetramerization (OD), and the basic (BD) domains. Source of image: 
adapted from Ahn et al., 2009, originally published in the Journal of Biological Chemistry © 
the American Society for Biochemistry and Molecular Biology. 
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I.4.3.2. MDM2/MDMX  
The murine double minute 2 (MDM2) and murine double minute X (MDMX) (also 
known as MDM4) inhibit p53 activity by engaging its N-terminus transactivation domain 
(Momand et al., 1992, Kussie et al., 1996, Laurie et al., 2006). MDM2 and MDMX are RING 
(Really Interesting New Gene) domain proteins, and many proteins containing a RING 
domain have been shown to play a key role in the ubiquitination pathway (Joazeiro and 
Weissman, 2000). However, despite their similar structures, only MDM2 has intrinsic E3 
ubiquitin ligase activity, conferring MDM2 the ability to target p53 for degradation by the 
proteasome (Honda et al., 1997). Although MDM2 alone can inhibit p53, its RING-dependent 
heterodimerization with MDMX has an important role in p53 inhibition. Indeed, MDM2 
inhibits the transactivation ability of p53 (Momand et al., 1992), and MDMX stabilizes 
MDM2 by preventing it to self-ubiquitinate (Stad et al., 2001).  
Within the retina, the role of MDM2 was assessed in RPE cells, which are essential for 
photoreceptor function by regulating cell homeostasis and serving as blood-retinal barrier 
(Strauss, 2005). Inhibition of MDM2 in primary RPE cultured cells resulted in an increase of 
pro-apoptotic targets, sensitizing RPEs to apoptosis (Bhattacharya et al., 2011). In aged RPEs, 
the MDM2/p53 pathway interaction is disrupted, leading to an age-dependent increase in 
apoptosis (Bhattacharya et al., 2012). Furthermore, MDM2 has been studied in the context of 
retinoblastoma. Mutations in the tumour suppressor RB1 gene are pivotal in the development 
of this early childhood cancer of the retina. Indeed, loss of RB1 function in the developing 
retina leads to MDM2 and MDMX amplification, contributing to p53 pathway inactivation 
(Laurie et al., 2006), which facilitates retinal cell transformation and tumorigenesis.  
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I.4.3.3. YY1 
Yin yang 1 (YY1) is a transcription factor that belongs to the Polycomb family, a 
group of chromatin modulators that are critical to homeobox gene regulation during 
development. First identified in 1991 (Shi et al., 1991), YY1 is a highly conserved and 
multifunctional transcription factor. Its name, representing interconnected yet seemingly 
opposing forces, stems from the fact that YY1 can act as an activator or repressor of 
transcription (Shi et al., 1997). YY1 has been implicated in cell proliferation, differentiation 
and apoptosis (Gordon et al., 2006), and is crucial for embryonic development as YY1 
deficiency results in peri-implantation lethality, i.e. lethality occurring in the period between 
blastocyst formation and uterine implantation (Donohoe et al., 1999). 
YY1 negatively regulates p53 protein levels and activity (Sui et al., 2004). YY1 acts as 
an MDM2 cofactor, facilitating MDM2-p53 interaction, and YY1 downregulation results in 
p53 accumulation due to a decrease in p53 ubiquitination levels. In contrast, YY1 
overexpression increases p53 ubiquitination and degradation (Sui et al., 2004). YY1 is 
ubiquitously expressed in the CNS during early embryonic development (Kwon and Chung, 
2003), and is highly expressed in the adult neural retina (Bernard and Voisin, 2008). In mouse 
embryos and Xenopus oocytes, YY1 was shown to activate Otx2, a transcription factor that 
controls photoreceptor cell fate (Kwon and Chung, 2003, Nishida et al., 2003, Takasaki et al., 
2007). In the adult retina, YY1 is mainly expressed by photoreceptors at the level of the inner 
segments and nuclei in the intact chicken retina, and weakly in the inner nuclear layer 
(Bernard and Voisin, 2008).  
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I.4.3.4. P300/CBP 
p300 and CREB Binding Protein (CBP) are highly homologous nuclear proteins that 
play a key role in transcriptional regulation. The interaction of p53 with p300 and/or CBP 
(p300/CBP) regulates the ability of p53 to bind to its cognate DNA sequences and activate 
transcription. It is specifically the acetyltransferase activity of p300/CBP that has been 
implicated in the regulation of p53 function. Indeed, in response to DNA damage, 
transcription coactivators p300/CBP bind to and acetylate p53, which stimulates the DNA 
binding activity of p53 (Gu and Roeder, 1997, Prives and Hall, 1999, Grossman, 2001). 
There is evidence that p300/CBP are involved in retinal function. For instance, 
mutations in CBP or p300 are responsible for a subset of Rubinstein-Taybi syndrome cases 
(Schepis et al., 2001, Zimmermann et al., 2007), a disease in which retinal dystrophy and 
glaucoma are common (van Genderen et al., 2000). The study of p300/CBP in animal models 
revealed that p300 and CBP knockout mice are embryonic lethal (Yao et al., 1998, Tanaka et 
al., 2000). The development of photoreceptor-specific p300/CBP conditional knockout mice 
was instrumental to demonstrate a key role for p300/CBP in photoreceptor gene expression 
(Hennig et al., 2013). Furthermore, p300 and CBP are expressed by adult RGCs, and 
adenoviral-mediated overexpression of p300 in RGCs has been shown to promote optic nerve 
regeneration (Gaub et al., 2011). Although p53 C-terminal acetylation by p300 is known to be 
involved in the fine-tuning of p53 stress responses (Krummel et al., 2005), these modifications 
do not appear to play a crucial role in RGC death. Indeed, in an acetylation-deficient missense 
mutant mouse model, the loss of p53 acetylation at its C terminus by CBP/p300 was not 
required for p53 transactivation (Krummel et al., 2005).  
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The ASPP family, MDM2/MDMX, YY1, and CBP/p300, along with additional p53 
regulating proteins, are implicated in the apoptotic function of p53. The signaling cascades 
occurring during apoptosis in RGCs will be discussed in the subsequent section.  
I.5. APOPTOTIC PATHWAYS ACTIVATED IN RGCs  
The apoptotic machinery is present in all cells and is therefore considered to be an 
intrinsic suicide program. Neuronal survival relies on a detailed interaction between the cell 
and its environment. The neuron is thought to be continuously on the verge of apoptosis, 
requiring survival signals to prevent its death (Raff, 1992, Raff et al., 1993). Neurotrophins, 
cytokines, growth factors such as brain derive neurotrophic  factor (BDNF) and ciliary 
neurotrophic factor (CNTF), and other peptide ligands stimulate transmembrane receptors, 
which activate intracellular pathways and ultimately inhibit this internal death program 
(Jacobson et al., 1997) (Figure 6). The apoptotic pathway can be induced either through a 
mitochondrial pathway (Green and Reed, 1998), or by stimulation of cell surface death 
receptors (Ashkenazi, 1998), which are referred to as the intrinsic and extrinsic apoptotic 
pathways, respectively.  
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Figure 6. Extrinsic and intrinsic apoptotic pathways regulating retinal ganglion cell 
death. The apoptotic death of RGCs can be triggered by various stimuli and involves extrinsic 
and intrinsic pathways. Extrinsic signals include the death-receptor ligands TNF-α, Fas-L, and 
TRAIL, and their respective receptors, which induce RGC death. Lack of neurotrophic factors 
may result in deficits of pro-survival pathways including Erk1/2 and PI3K. The intrinsic 
pathway converges on the Bcl-2 family members: pro-apoptotic (Bax, Bad, Bid) or anti-
apoptotic (Bcl-2, Bcl-XL), which regulate the mitochondrial outer membrane 
permeabilization. These proteins control the release of cytochrome c into the cytosol which 
can activate the caspases, executioners of apoptosis. Source: from Wilson et al., Gene 
Therapy. 2012  
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I.5.1 The intrinsic apoptotic pathway 
I.5.1.1. Pro-apoptotic kinases 
The mitogen-activated protein kinases (MAPKs) are a large family of protein Ser/Thr 
kinases that relay extracellular signals to the intracellular milieu and, as such, are central 
regulators of many cellular functions (Cargnello and Roux, 2011). The conventional MAPKs 
family comprises extracellular signal-regulated kinases 1 and 2 (Erk1/2), c-Jun N-terminal 
kinases (JNKs), p38 isoforms and Erk5. In contrast to the RGC survival response associated 
with activation of the Erk1/2 pathway, pro-apoptotic MAPK are typically activated by a 
variety of stress signals and have been proposed to contribute to RGC death. One such 
MAPKs subfamily are the JNKs, also known as stress-activated protein kinases (SAPKs), 
which play central roles in the regulation of signal transduction in the mammalian brain 
(Brecht et al., 2005). The elucidation of JNKs function in vivo has been challenging due to the 
presence of ten different JNK isoforms that result from alternative splicing (Kyriakis et al., 
1994) and display differential specificity towards their target proteins (Gupta et al., 1996, 
Kallunki et al., 1996, Chang and Karin, 2001). C-jun, a transcription factor activated by JNK 
phosphorylation, mediates the transcription of pro-apoptotic genes (Curran and Franza, 1988) 
(Figure 6). The JNK/c-jun pathway is upregulated in RGCs after optic nerve axotomy or crush 
(Herdegen et al., 1993, Hull and Bahr, 1994, Robinson, 1994, Isenmann and Bähr, 1997, 
Kreutz et al., 1999, Takeda et al., 2000, Yang et al., 2007), during excitotoxic damage 
(Bessero et al., 2010), in rodent models of experimental glaucoma (Levkovitch-Verbin et al., 
2005, Kwong and Caprioli, 2006, Yang et al., 2007), and in human glaucoma (Tezel et al., 
2003). Of interest, long-term activation of c-Jun has been observed in optic nerve head 
astrocytes of monkeys subjected to experimental ocular hypertension (Hashimoto 2005). Short 
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interfering RNA (siRNA)-mediated knockdown of c-Jun resulted in RGC survival after optic 
nerve lesion (Lingor et al., 2005), and administration of a JNK inhibitor conferred moderate 
RGC protection in an acute ocular hypertension model (Sun et al., 2011). To assess the 
functional role of JNK activation on RGC survival, recent studies have examined the effect of 
genetic deletion of JNK genes in mouse models of optic nerve injury. Induction of ocular 
hypertension in JNK3 null mice did not show significant RGC neuroprotection (Quigley et al., 
2011). In contrast, mice lacking both JNK isoforms (Jnk2-/-Jnk3-/-) displayed marked RGC 
survival after injury and this response involved c-jun and Bim activation  (Harder et al., 2011). 
These results suggest that the different JNK isoforms might act to compensate for deficiencies 
in this pathway to ensure apoptosis of injured RGCs. Future work is required to establish 
whether combined deletion of JNK2 and JNK3 influence RGC fate in experimental glaucoma.  
The p38 MAPKs, a subfamily comprising four isoforms (p38, p38, p38, p38), is a 
group of kinases that are highly responsive to stress stimuli (Cuadrado and Nebreda, 2010). 
p38 is expressed at higher levels than the other isoforms; therefore the majority of the 
published studies to date refer to p38form. p38 is strongly activated by various 
environmental signals such as inflammatory cytokines, chemokines, oxidative stress and 
ischemia, and plays a role in apoptotic death signaling by affecting death receptor function and 
Bcl-2 family members (Cuenda and Rousseau, 2007). The active, phosphorylated form of p38 
has been shown to increase in RGCs following optic nerve axotomy (Kikuchi et al., 2000), in 
a translimbal photocoagulation laser model of rat glaucoma (Levkovitch Verbin et al., 2007) 
and in human glaucomatous eyes (Tezel et al., 2003). A time-course analysis revealed a 
sustained increase in phosphorylated p38, which appeared rapidly after intraocular pressure 
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elevation (Levkovitch Verbin et al., 2007). Intravitreal injection of a p38 inhibitor at the time 
of axotomy increased the number of surviving RGCs (Kikuchi et al., 2000) supporting a 
potential functional role for p38 in the regulation of RGC death. However, functional studies 
to assess the role of p38 in RGC death in experimental glaucoma are currently lacking. 
Both JNKs and p38 are direct protein targets of the apoptosis signal regulating kinase 1 
(ASK1), a SAPK and mitogen-activated protein kinase kinase kinase (MAPKKK) family 
member that plays key roles in human neurodegenerative diseases (Hattori et al., 2009). ASK1 
has been shown to activate JNK and p38 in response to diverse stress stimuli, particularly 
inflammatory cytokines and oxidative stress (Ichijo et al., 1997, Saitoh et al., 1998, Hatai et 
al., 2000, Nishitoh et al., 2002, Zhang et al., 2007, Min et al., 2008). In a recent study, Harada 
et al. demonstrated that ASK1 is primarily expressed by RGCs, and that a substantial number 
of these neurons are protected from ischemic injury in ASK1 null mice (Harada et al., 2010). 
Furthermore, both p38 MAPK and caspase-3 activation were suppressed in mice lacking 
ASK1, suggesting a role for these downstream signaling components. ASK1 deficiency was 
also shown to attenuate RGC death in mice lacking the glial glutamate/aspartate transporter 
(GLAST) (Harada et al., 2010), which display spontaneous RGC death and optic nerve 
degeneration without elevated intraocular pressure (Harada et al., 2007).  
I.5.1.2. The Bcl-2 family 
A major class of intracellular regulators of apoptosis is the Bcl-2 family, which 
comprises evolutionarily conserved proteins from worms to humans (Adams and Cory, 1998). 
Bcl-2, a gene activated by chromosomal translocation in human follicular lymphoma (Bakhshi 
et al., 1985, Tsujimoto et al., 1985, Cleary et al., 1986), was initially found to promote the 
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survival of hematopoietic cells in the absence of an essential cytokine (Vaux et al., 1988). A 
hydrophobic tail on Bcl-2 enables it to bind to the cytoplasmic face of the outer mitochondrial 
membrane, but Bcl-2 can also be present in the endoplasmic reticulum and nuclear envelope 
(Green and Reed, 1998, Zamzami et al., 1998). Bcl-2 can inhibit apoptosis by blocking the 
release of cytochrome C from the mitochondria and consequent activation of proteases 
involved in the dismantling of the cell (Zou et al., 1997, Green and Reed, 1998, Zamzami et 
al., 1998). Several Bcl-2 family members have been identified in mammals: some that inhibit 
apoptosis (e.g. Bcl-2, Bcl-XL) and others that promote programmed cell death (e.g. Bax, Bad 
and Bid) (Figure 6 and 7). Bcl-2-related proteins contain at least one of four Bcl-2 homology 
domains (BH1-4), used for protein-protein interactions among family members (Kelekar and 
Thompson, 1998). A sub-group of Bcl2-related proteins only carry a BH3 domain (e.g. Bim, 
Noxa and PUMA) and have primarily pro-apoptotic functions (Zong et al., 2001) (Figure 7). 
The pro- and anti-apoptotic members of the Bcl-2 family can interact to form heterodimers 
acting as self-regulators of each other‟s function (Oltval et al., 1993). Based on this, it was 
proposed that the relative concentration of these proteins acts as a rheostat for activation of 
apoptosis (Korsmeyer et al., 1993, Nickells, 2010).  
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Figure 7. The Bcl-2 family of proteins. The Bcl-2 family of proteins is comprised of anti-
apoptotic and pro-apoptotic members. The anti-apoptotic members include Bcl-2 and Bcl-XL, 
which contain four Bcl-2 homology (BH) domains: BH1, BH2, BH3 and BH4. They also have 
transmembrane (TM) domains. The pro-apoptotic proteins can be subdivided into two groups: 
effector and BH3-only members. The effectors proteins Bak and Bax also contain BH1-BH4 
domains, while the BH3-only proteins solely have one BH domain, BH3, which is required for 
interactions with anti-apoptotic and effector proteins. The BH3-only proteins include Noxa, 
Puma, Bim, Bid, and Bad. Source of image adapted by permission from Macmillan Publishers 
Ltd: [Nature Reviews Molecular Cell Biology] (Jesenberger and Jentsch, 2002), copyright 
(2002).  
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The function of the Bcl-2 gene family on RGC survival in acute and chronic models of 
optic nerve lesion has been studied by several groups (Nickells et al., 2008). Among anti-
apoptotic Bcl-2 family members, Bcl-XL appears to be the predominant anti-apoptotic protein 
in the rat retina (Levin et al., 1997). Both Bcl-2 and Bcl-XL retinal mRNA levels have been 
shown to decrease after optic nerve axotomy (Chaudhary et al., 1999). Consistent with this, 
AAV-mediated gene transfer of Bcl-XL promoted the survival of axotomized RGCs (Malik et 
al., 2005). Nevertheless, Bcl-2 also seems to play an important role based on initial reports 
showing that increased numbers of RGCs are found in transgenic mice overexpressing Bcl-2, 
both during developmental cell death and after optic nerve axotomy (Bonfanti et al., 1996, 
Cenni et al., 1996). More recently, gene transfer of BAG1, a Bcl-2-associated protein, 
protected RGCs in optic nerve cut or crush rat models (Planchamp et al., 2008).  
Among pro-apoptotic family members, Bax has been shown to play a pivotal role in 
the regulation of RGC death. Deletion of the Bax gene results in RGC neuroprotection 
following developmental pruning, in optic nerve cut or crush models and in DBA/2J mice 
(Mosinger Ogilvie et al., 1998, Li et al., 2000, Libby, 2005). Of interest, deletion of the pro-
apoptotic Bax gene was shown to be neuroprotective for RGC soma but failed to prevent axon 
degeneration in DBA/2J mice (Libby, 2005) suggesting a compartmentalized effect of Bax in 
neurodegeneration. Gene dosage experiments in mice carrying a single wild-type Bax allele 
showed that genetic background can influence neuronal death, including RGC loss in 
experimental glaucoma (Knudson et al., 1995, Deckwerth et al., 1998, Sun and Oppenheim, 
2003, Libby, 2005). Bax heterozygote DBA/2J mice displayed complete protection of RGCs 
while Bax heterozygote 129B6 mice exhibited substantial RGC loss (Libby, 2005, Semaan et 
al., 2010). These distinct phenotypes have been recently attributed to differential Bax 
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transcriptional activity, which leads to higher levels of Bax mRNA in susceptible RGCs from 
the 129B6 genetic background (Nickells, 2010, Semaan et al., 2010). Bax knockdown by 
injection of siRNA into the optic nerve did not enhance the survival of axotomized RGCs 
(Lingor et al., 2005), which may reflect that reduction of Bax levels achieved with this siRNA 
strategy might not have been below a minimum threshold required to confer resistance against 
cell death. 
BH3-only proteins, usually pro-apoptotic, have also been shown to be expressed by 
RGCs including Bad (Rickman et al., 1999, Huang et al., 2005c, Yang et al., 2008, 
Levkovitch-Verbin et al., 2010), Bim (Näpänkangas et al., 2003, McKernan and Cotter, 2007) 
and Bid (Huang et al., 2005a, Das et al., 2006). A recent study demonstrated that the Bad-
interacting protein 14-3-3, a scaffold protein responsible for sequestering Bad in the 
cytoplasm, is phosphorylated in ocular hypertensive eyes resulting in Bad translocation to the 
mitochondria and RGC apoptosis (Yang et al., 2008). Although the functional role of BH3-
only proteins in RGC death in glaucoma is still obscure, they have been proposed to serve as 
important molecular checkpoints in the apoptotic process, therefore future work is warranted 
to assess their contribution to neurodegeneration in this disease.  
I.5.1.3. Mitochondrial dysfunction 
The mitochondria has been aptly named the battleground of cell fate, as this organelle 
is the center stage for interactions between anti- and pro-apoptotic Bcl-2 family members 
(Kroemer, 2007). When the balance is tilted towards apoptosis, there is increased 
mitochondrial membrane permeability and release of a variety of mediators of cell death 
(Scaffidi, 1998). Mitochondrial membrane permeabilization is a point-of-no-return in the 
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apoptotic process, after which cell loss is irreversible, and it is a conserved feature of all cell 
types undergoing this death modality. In healthy cells, mitochondria typically exhibit a high 
transmembrane potential and the permeability transition pore complex (PTPC) mediates the 
exchange of metabolites. Pro-apoptotic signals have been proposed to destabilize the lipid 
organization in the mitochondrial outer membrane allowing the formation of pores and 
subsequent release of intermembrane space molecules. For example, in physiological 
conditions Bax is a cytosolic protein but, upon an apoptotic stimulus, it can insert into the 
outer mitochondrial membrane (Wolter et al., 1997) where it forms Bax homo- or hetero-
oligomeric pores (in association with Bak or truncated Bid) that facilitate the release of death-
promoting factors (Kuwana et al., 2002). Once in the cytoplasm, these proteins can activate 
caspase-dependent and caspase-independent pathways. The first mitochondrial protein shown 
to be released into the cytosol was cytochrome c, an essential protein component of the 
respiratory chain (Kluck et al., 1997, Yang et al., 1997). Once in the cytoplasm, cytochrome c 
binds to the apoptotic protease-activating factor-1 (Apaf-1) to form the apoptosome, a 
complex that recruits and activates procaspase 9 (Li et al., 1997) (Figure 6). Other well-
characterized intermembrane space proteins that are released from mitochondria during 
apoptosis include the second mitochondria-derived activator of caspases (SMAC), also known 
as DIABLO (direct inhibitor of apoptosis (IAP)-binding protein with low pI), the apoptosis-
inducing factor (AIF), endonuclease G (EndoG) and the high-temperature-requirement protein 
A2 (OMI/HTRA2) (Saelens et al., 2004). Optic nerve axotomy leads to early cytochrome c 
release in injured RGCs (Cheung et al., 2003) but, at present, the specific role of toxic 
mitochondrial proteins in RGC death in glaucoma remains ill defined. 
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RGCs have a high metabolic activity and energy demand, which is reflected by the 
numerous mitochondria in RGC soma and the intra-retinal portion of their axons (Hollander et 
al., 1995, Wang et al., 2003). Mitochondria are also present (albeit at lower densities) in the 
myelinated portion of RGC axons within the optic nerve (Bristow et al., 2002). It is possible 
that nuclear and mitochondrial DNA damage increases with age (Brasnjevic et al., 2008), 
especially considering the proximity of the mitochondrial DNA to the source of reactive 
oxygen species (ROS) within this organelle (de Souza-Pinto et al., 2008). Moreover, a study 
using mitochondria isolated from primary open angle glaucoma (POAG) patients showed 
numerous sequence alterations in the mitochondrial DNA, suggesting a pathogenic potential 
due to decreased respiratory activity (Abu Amero et al., 2006). The rate of ATP production by 
mitochondria decreases in the aging brain (Navarro and Boveris, 2007) and, given the age-
related nature of glaucoma onset and progression, it is possible that a decline in mitochondrial 
function is involved. A recent study demonstrated that the ATP content in the mouse optic 
nerve dropped with age, and that the rate of ATP decline was amplified by increased 
intraocular pressure in DBA/2J mice leading to RGC axon dysfunction (Baltan et al., 2010). A 
cellular energy crisis due to reduced ATP availability could negatively impact RGC function 
because it disables Na+/K+ ion pumps, which in turn blocks normal transduction of action 
potentials along RGC axons (Gordon et al., 1990, Ames et al., 1992, Ames, 2000).  
OPA-1, a protein embedded in the inner mitochondrial membrane, is mutated in the 
majority of patients with autosomal-dominant optic atrophy, a condition characterized by RGC 
degeneration and childhood blindness. OPA-1 is a GTPase dynamin-like protein that mediates 
mitochondrial fusion, thus loss of OPA-1 function leads to mitochondrial fragmentation, 
cytochrome C release, mitochondrial DNA damage and increased reactive oxygen species 
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(Cipolat et al., 2006). Of interest, overexpression of OPA-1 by AAV-mediated gene transfer 
increased RGC survival while decreasing the number of reactive astroglia and microglia in 
DBA/2J mice (Ju et al., 2010).  
I.5.1.4. Caspases  
Caspases are a family of aspartate-specific cysteine proteases, with homology to the 
interleukin-1-Converting Enzymes (ICE), that play central roles in the execution of the 
apoptotic death program (Thornberry and Lazebnik, 1998). Caspases are expressed as pro-
enzymes, which have little catalytic activity, and then undergo proteolytic cleavage and 
dimerization to become active (Gu et al., 1995). Caspases are categorized by their roles as 
either initiators of apoptosis (caspase-2, -8, -9, -10), executioners of apoptosis (caspase-3, -6, -
7), or mediators of inflammation (caspase-1, -4, -5, -11, -12, -13, -14) (Fan et al., 2005). 
Initiator caspases (e.g. caspase 9) contain a long N-terminal region (prodomain) with caspase 
recruitment and death effector domains that are essential for their function, including cleavage 
and activation of executioner caspases (e.g. caspase 3). The initiator caspases are thought to 
undergo auto-activation and often require the assembly of multi-component complexes 
(Adams and Cory, 2002). Effector caspases contain short (20-30 residues) prodomain 
sequences (Riedl and Shi, 2004) and, once activated, are responsible for the proteolytic 
cleavage of many protein substrates resulting in cell death. The intrinsic and extrinsic 
apoptotic pathways involve the activation of distinct initiator caspases (Figure 6). In the 
intrinsic pathway, cytochrome C is released from the mitochondria and together with Apaf-1 
and procaspase 9 forms the apoptosome, which facilitates caspase-9 activation and 
downstream cleavage of caspase-3 (Li et al., 1997). In the extrinsic pathway, an active death 
receptor recruits the intracellular adaptor protein Fas-associated death domain which in turn 
 
 
42 
 
recruits procaspase-8 to form a death-inducing signaling complex (Kischkel, 1995). Caspase-8 
is cleaved and activated through autoproteolysis leading to subsequent activation of caspase-3 
(Muzio et al., 1998).   
The expression of both initiator and effector caspases has been investigated in RGCs 
following acute or chronic optic nerve injury. Active, cleaved caspases -3, -8 and -9 have been 
detected after optic nerve transection or crush (Chaudhary et al., 1999, Kermer et al., 1999, 
Kermer et al., 2000, Weishaupt et al., 2003, Cheung et al., 2004, Grosskreutz et al., 2005, 
Homma et al., 2007), ocular hypertension (Hänninen VA, 2002, McKinnon et al., 2002a) as 
well as ischemic injury (Vidal-Sanz et al., 2000, Harada et al., 2006). To assess the role of 
apoptosis on primary and secondary waves of RGC degeneration (Yoles and Schwartz, 1998), 
RGC death was monitored for 6 months after partial lesion of the optic nerve (Levkovitch-
Verbin et al., 2003). Although caspase 3 was implicated in both waves of RGC apoptosis, it 
was active for a longer period of time and with greater intensity during the primary wave of 
RGC loss (Levkovitch Verbin et al., 2010). The inhibition of caspases to extend RGC survival 
after optic nerve injury is a strategy that has been tested with varying degrees of success. 
Intraocular injection of caspase-3 or capase-9 inhibitors promoted some RGC protection from 
axotomy-induced apoptosis (Kermer et al., 1998, Chaudhary et al., 1999, Kermer et al., 2000). 
siRNA-based gene knockdown of Apaf-1, a key mediator of caspase-induced cell death, was 
shown to enhance survival of axotomized RGCs (Lingor et al., 2005). A recent study 
demonstrated that caspase-2 is expressed and activated primarily in RGCs following optic 
nerve injury (Ahmed et al., 2011, Vigneswara et al., 2012). Moreover, inhibition of caspase-2 
expression using a chemically modified siRNA delivered intravitreally led to robust RGC 
survival after optic nerve crush or cut (Ahmed et al., 2011), as did pharmacological inhibition 
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of caspase-2 with z-VDVAD (Vigneswara et al., 2012). Caspase-6 was also recently shown to 
be upregulated in injured RGCs, and selective inhibition of caspase-6 enhanced RGC survival 
and axonal regeneration (Monnier et al., 2011). During development, caspases play an 
important role in dendritic pruning (Kuo et al., 2006, Williams et al., 2006, Schoenmann et al., 
2010), in addition to axonal pruning (Nikolaev et al., 2009, Simon et al., 2012). Although 
caspases are not implicated in Wallerian degeneration, i.e. the process of axonal degeneration 
after injury (Finn et al., 2000, Simon et al., 2012), the question of whether caspases are 
involved in dendritic remodelling occurring in the neurodegenerative context of glaucoma 
(Weber et al., 1998, Weber and Harman, 2005) has not yet been addressed. Although caspases 
do not appear to be involved in dendritic remodelling following axonal injury in drosophila 
(Tao and Rolls, 2011), their role in dendritic remodelling in a mammalian system remains 
unknown. 
The inhibitor of apoptosis (IAP) family is composed of proteins with the ability to bind 
and inhibit caspases through their baculovirus IAP repeat (BIR) domains, thus preventing 
caspase-dependent cell death (Gyrd-Hansen and Meier, 2011). The cellular inhibitor of 
apoptosis-1 (cIAP1), a member of the IAP family, is downregulated during retinal 
development at the time of RGC maturation and is nearly absent in adult RGCs (Kisiswa et al., 
2010). IAP-1, another family member, is upregulated in both the primary and secondary 
phases of RGC death after partial optic nerve lesion (Levkovitch-Verbin et al., 2011). An 
effective approach has been to target the Baculoviral IAP Repeat-Containing 4 (BIRC4), also 
known as X-linked inhibitor of apoptosis protein (XIAP), an IAP family member that can 
directly inhibit several death effectors including caspases 3, 7, and 9 (Deveraux et al., 1997). 
AAV-mediated gene transfer of BIRC4/XIAP successfully promoted RGC protection in 
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chronic and acute ocular hypertension models (McKinnon et al., 2002b, Renwick et al., 2005). 
Of interest, combined administration of adenoviral vectors encoding BIRC4/XIAP or glia-
derived neurotrophic factor (GDNF) had a synergistic effect on the survival of axotomized 
RGCs which was greater than upregulation of each individual pathway (Straten et al., 2002). 
Therefore, the use of strategies that target multiple anti-apoptotic pathways appears to be a 
promising avenue to increase RGC survival after optic nerve damage.  
I.5.1.5. Calcium-dependent mechanisms 
Calcium (Ca2+) is a vital intracellular messenger indispensable for a broad range of 
cellular functions. However, Ca2+ overload can compromise the integrity of organelles such as 
the mitochondria and the endoplasmic reticulum, and leads to activation of intracellular 
proteins that trigger neuronal death (Orrenius et al., 2003). Increased Ca2+ influx into RGC 
soma and axons has been proposed to contribute to neurodegeneration in glaucoma (Osborne 
et al., 2004, Whitmore et al., 2005, Crish and Calkins, 2011). Extracellular Ca2+ accumulation 
in RGC axons occurs through the reversal of the Na+/Ca2+ exchanger and has been implicated 
in neuronal damage following ischemia (Stys et al., 1992). In addition, Ca2+ release from intra-
axonal stores also plays a detrimental role on RGC axon function (Nikolaeva et al., 2005). 
Real-time imaging of Ca2+ dynamics in RGC-5 cells subjected to elevated hydrostatic pressure 
revealed a strong temporal correlation between calcium peak occurrence and morphological 
changes including neurite retraction and cell body shrinkage (Lee et al., 2010). When 
intracellular Ca2+ levels are elevated, either by influx from the extracellular space or by release 
from intracellular calcium stores, multiple Ca2+-dependent pro-apoptotic enzymes are 
activated. Calpain is a Ca2+-dependent, non-lysosomal cysteine protease that is expressed 
ubiquitously in mammalian cells. Calpain becomes active in rat RGCs after axotomy 
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(McKernan et al., 2007a), hypoxia (Tamada et al., 2005), and ocular hypertension (Huang et 
al., 2010). Calcineurin, a Ca2+-dependent phosphatase, is cleaved and activated by calpain in 
experimental glaucoma (Huang et al., 2010). Constitutively active calcineurin has been 
detected in the retinas of ocular hypertensive rats and was associated with Bad 
dephosphorylation, cytochrome C release and RGC death (Huang et al., 2005b).  
Several strategies aimed at the blockade of Ca2+ influx into RGCs or the inhibition of 
pro-apoptotic Ca2+-dependent proteins in these neurons have been examined with relative 
success. Pharmacological agents that reduce intraocular pressure and increase vascular 
nutrition while exerting a dual function as blockers of Ca2+ and Na+ channels have been shown 
to confer RGC neuroprotection (Osborne et al., 2005). ß-adrenoceptor antagonists such as 
betaxolol, levobetaxalol, levobunolol and timolol, compounds that increase impaired blood 
flow and are known to have Na+- and/or Ca2+-blocking activities, promote RGC 
neuroprotection and increase retinal function in experimental animals with 
ischemia/reperfusion damage or high intraocular pressure (Gross et al., 1999b, Osborne et al., 
1999a, Hirooka et al., 2000, Schuettauf et al., 2002, Wood et al., 2003, Osborne et al., 2004). 
Ca2+ channel antagonists can, in principle, block Ca2+ influx into RGCs and protect them from 
injury without the need to induce vasodilation. Other Ca2+ channel blockers including 
nifedipine, nimodipine, lomerizine, flunarizine, riluzole have also been shown to attenuate 
RGC death in animals models of ischemia and ocular hypertension (Araie and Mayama, 
2011). The transient receptor potential vanilloid 1 (TRPV1) channel was recently implicated 
in Ca2+ influx and apoptosis of primary cultured RGCs exposed to increased hydrostatic 
pressure and blockers of TRPV1 resulted in neuroprotection (Sappington et al., 2009). The 
inhibition of calpain and calcineurin following increased Ca2+ influx into RGCs has been 
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investigated in models of optic nerve injury. For example, calpain inhibitors have been shown 
to attenuate RGC death after axotomy (McKernan et al., 2007b) and ocular 
hypertension/ischemia (Oka et al., 2006a, Oka et al., 2006b). Administration of FK506, a 
calcineurin inhibitor, was shown to block caspase-9 activation and protect RGCs following 
optic nerve crush (Freeman and Grosskreutz, 2000, Grosskreutz et al., 2005) and in 
experimental glaucoma (Huang et al., 2005c).  
I.5.2. The extrinsic apoptosis pathway 
Extrinsic apoptotic signals include an array of death-receptor ligands: TNF-α, FasL, 
and TNF-related apoptosis-inducing ligands (TRAIL) that bind to their respective receptors, 
TNF-R, Fas/CD95, and TRAIL-R, to induce cell death. Death receptor activation results in the 
recruitment of intracellular adaptor Fas-associated death domain (FADD), which typically 
recruits the initiator procaspase-8 leading to caspase-8 activation followed by executioner 
caspase-3 activation and cell death. These molecular pathways are being increasingly 
recognized as important signals in the regulation of RGC death in glaucoma.  
I.5.2.1. Tumour Necrosis Factor alpha (TNFα) 
TNFα is a pro-inflammatory cytokine that acts on two distinct receptors, TNFR1 and 
TNFR2. Initially discovered for its ability to cause hemorrhagic necrosis of experimental 
cancers (Carswell et al., 1975), TNFα has emerged as a critical element in immune 
homeostasis and  mediator of apoptosis. Elevated levels of TNFα have been observed in the 
brain, cerebrospinal fluid, and serum of patients with Alzheimer‟s disease, Parkinson‟s 
disease, multiple sclerosis and HIV-dementia, and following traumatic brain injury or 
chemically-induced neurotoxicity (Sriram and O‟Callaghan, 2007). TNFα is produced as a 22-
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kDa membrane-bound precursor (pro-TNFα) that is cleaved by a cell surface trans-membrane 
protease known as ADAM17 or TACE (for TNFα-converting enzyme) to release the soluble 
17-kDa protein (Moss et al., 1997). Interestingly, both the trans-membrane and secreted forms 
of TNFα are biologically active and play distinct roles in vivo (Alexopoulou et al., 2006). The 
blockade of TNFα has been successfully introduced in the clinic for the treatment of 
rheumatoid arthritis, psoriasis and inflammatory bowel disease (Feldmann and Maini, 2001), 
however, side effects such as susceptibility to infection and auto-immune reactions have been 
reported (Slifman et al., 2003).  
Intravitreal injection of TNFα leads to RGC loss and optic nerve degeneration 
(Nakazawa et al., 2006, Lebrun-Julien et al., 2010), and RGCs lacking TNFR1 are protected 
from mechanical damage and ocular hypertension (Tezel et al., 2004, Nakazawa et al., 2006). 
Notably, TNFα and TNFR1 are upregulated in experimental glaucoma (Nakazawa et al., 2006) 
and human donor eyes with glaucoma (Yan et al., 2000, Yuan and Neufeld, 2000, Tezel et al., 
2001). Moreover, TNFα levels are increased in the aqueous humor of glaucoma patients 
(Sawada et al., 2010, Balaiya et al., 2011), and TNFα gene polymorphisms have been 
correlated with the most common form of glaucoma, Primary Open Angle Glaucoma (POAG) 
(Lin et al., 2003, Funayama et al., 2004, Fan et al., 2010, Bozkurt et al., 2011). TNFα gene 
expression is strongly induced by the transcriptional activity of NF-κB (Shakhov et al., 1990, 
Hiscott et al., 1993, Mori and Prager, 1996). A recent study demonstrated that excitotoxic 
damage leads to selective activation of NF-κB in Müller glia resulting in robust production of 
TNFα by these cells (Lebrun-Julien et al., 2009). Furthermore, inhibition of TNFα activity in 
the retina using pharmacological or genetic approaches resulted in marked RGC 
neuroprotection (Lebrun-Julien et al., 2009), thus Müller glia-derived TNFα is a potent 
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mediator of RGC death. In experimental glaucoma, upregulation of the truncated TrkC or 
p75NTR receptor activation in Müller glia has been correlated with increased TNFα production 
and RGC death (Bai et al., 2010a, Bai et al., 2010b).  
Ligand binding to TNFR1 typically triggers apoptosis by induction of caspase-8 
activation which in turn activates caspase-3 and promotes cell death (Boldin et al., 1996, Hsu 
et al., 1996). Previous studies have shown that TNF released from microglia can kill primary 
cortical neurons via a caspase 8-dependent mechanism (Velier et al., 1999, Kaushal and 
Schlichter, 2008), however, caspase-8 inhibition had no effect on glia-derived TNF-
mediatedapoptosis of RGCs in vivo (Lebrun-Julien et al., 2009). Indeed, studies using primary 
RGC cultures demonstrated that although TNF leads to the loss of the mitochondrial 
membrane potential and subsequent release of cytochrome c and AIF, caspase inhibitors did 
not confer neuroprotection (Tezel and Yang, 2004). These findings suggest that caspase-
independent events might contribute to TNF-mediated RGC death. The study of alternative 
mechanisms by which TNF might induce RGC death becomes a priority to understand how 
this cytokine contributes to neurodegeneration. Along these lines, TNFα has emerged as a 
crucial regulator of neuronal glutamate receptors in the CNS (Pickering et al., 2005, Beattie et 
al., 2010). For example, glial TNFα increases the surface expression of neuronal -amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR) hence increasing synaptic 
efficacy (Beattie et al., 2002, Stellwagen and Malenka, 2006). Recently, TNFα was shown to 
mediate the insertion of Ca2+-permeable AMPAR during excitotoxic injury (Lebrun-Julien et 
al., 2009) and in experimental glaucoma (Cueva Vargas et al., 2011) which correlated with 
devastating loss of RGCs. Consistent with this, Ca2+-permeable AMPAR inhibitors protected 
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RGCs from excitotoxicity and ocular hypertension damage (Lebrun-Julien et al., 2009, Cueva 
Vargas et al., 2011). These findings highlight the possibility that TNFα mediates RGC death 
by modulating membrane insertion of Ca2+-permeable channels and increasing neuronal 
susceptibility to damage. 
I.5.2.2. Fas ligand and Fas/CD95 
Fas ligand (FasL), a member of the TNF superfamily of cytokines, was initially 
identified as a mediator of T-cell apoptosis (Kägi et al., 1994, Ju et al., 1995). FasL is 
synthesized as a trans-membrane protein which is then cleaved by metalloproteinases to 
produce soluble FasL (Kayagaki et al., 1995, Tanaka et al., 1995, Mitsiades et al., 2001). Once 
processed, soluble FasL (sFasL) is not toxic and can compete with membrane-bound FasL 
(mFasL), while the mFasL form has pro-apoptotic activity (Suda et al., 1997, Schneider et al., 
1998, Holler et al., 2003). The FasL receptor Fas/CD95 is a type I trans-membrane receptor 
which, like TNFR, belongs to the death receptor family. In addition to cell death, FasL-
induced Fas/CD95 activation mediates a host of cellular responses including inflammation, 
cell growth and proliferation (Magnusson and Vaux, 1999). Both FasL and Fas/CD95 have 
been shown to be expressed in neurons and glial cells including oligodendrocytes, astrocytes, 
microglia and Schwann cells (Choi and Benveniste, 2004). 
An early study demonstrated that the FasL-Fas/CD95 system participates in the 
maintenance of immune privilege in the eye (Griffith et al., 1995). For example, inflammatory 
cells that enter the eye in response to a viral infection are eliminated through FasL-mediated 
Fas/CD95 activation thus abrogating tissue damage. In contrast, mice that lacked functional 
FasL displayed massive infiltration of inflammatory cells into ocular tissues (Griffith et al., 
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1995). The current information on the role of FasL and Fas/CD95 in RGC death after optic 
nerve injury and in glaucoma is rather limited; however, recent studies suggest a role for this 
pathway in RGC neurodegeneration. For example, increased expression of FasL in retinal 
microglia was reported in rats with chronic ocular hypertension (Ju et al., 2006) and in 
DBA/2J mice (Gregory et al., 2011), and loss of RGCs induced by autoimmunity to heat shock 
proteins was shown to be mediated through T-cell-derived FasL (Wax et al., 2008). A recent 
study reported opposing roles of sFasL versus mFasL in RGC death induced by exogenous 
administration of TNFα or in DBA/2J mice (Gregory et al., 2011). Using mice deficient in 
FasL or mice in which cleavage of membrane-bound FasL was impaired, this group 
demonstrated that while microglia-derived sFasL played a neuroprotective role, mFasL was 
neurotoxic and caused more extensive RGC death. The interesting contrast between sFasL 
neuroprotection and mFasL neurotoxicity suggests that the ratio of these two FasL forms, 
regulated at the level of FasL cleavage by matrix metalloproteinases, might play a key role in 
experimental glaucoma (Gregory et al., 2011). However, the precise molecular mechanisms 
through which sFasL protects and mFasL kills RGCs in glaucoma remain unknown. 
I.6. TOOLS FOR GENE DELIVERY TO INJURED RGCS   
Gene therapy for blinding diseases is based on the principle that the genetic material of 
a retinal cell can be manipulated by the insertion, removal or modification of a gene with the 
objective of restoring vision. When a specific genetic mutation is linked to disease onset or 
progression, the strategy is to deliver a healthy copy of the gene to the affected cell to restore 
functional deficits and promote neuroprotection. This approach has been particularly 
successful for inherited retinal degenerations of the outer retina, characterized by 
photoreceptor loss, for which the genetic basis of disease has been well established. For 
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example, gene therapy for Leber‟s congenital amaurosis, a form of inherited retinal 
degeneration caused by deficiency of retinal pigment epithelium-specific-65-kDa protein 
(RPE65), demonstrated promising results in the laboratory and is now being tested in clinical 
trials (Buch et al., 2008, MacLaren, 2009, Cideciyan, 2010). The elucidation of the genetic 
defects underlying glaucoma and other age-related optic neuropathies has been substantially 
more difficult because the prevalent adult-onset of disease limits the number of individuals 
available for linkage analysis. At least 29 genetic loci for various forms of glaucoma and 12 
causative genes have been identified by linkage studies (Fan and Wiggs, 2010 ). However, 
further work is required to clarify the relationship between gene defects and RGC 
pathophysiology in glaucoma before gene replacement therapies for these neurons can be 
developed. In addition, multiple genes, individual risk factors and environmental factors are 
likely to contribute to glaucoma onset. For these reasons, most gene therapy strategies for 
RGC neuroprotection to date are based on enhancing neuronal survival rather than correcting 
the primary genetic defect or injury source. Since RGC death in human glaucoma typically 
occurs over several decades, strategies that do not address the initial cause but can delay RGC 
death and support functional vision throughout life are likely to be beneficial. Given the wide 
range of tools currently available for retinal gene transfer, we will focus here only on those 
that have had a significant impact on studies of RGC neuroprotection and discuss the 
advantages and disadvantages of each system. 
I.6.1. Virus vector-based approaches to target RGCs or surrounding cells  
Viruses have the evolutionary advantage of using molecular mechanisms to effectively 
transfer their genomes into infected cells. Based on this, recombinant virus-based vectors have 
been developed to infect post-mitotic cells in the retina as a means to promote transgene 
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expression. Improvements in the design of viral vectors and the methods to increase viral titers 
and purity suitable for in vivo delivery have contributed to their popularity. The ideal viral 
vector is expected to have the following characteristics: i) it can transduce large numbers of 
the target cell, ii) it mediates gene expression specifically in the infected cells, iii) it allows 
stable expression of the delivered gene product at physiologically adequate levels, iv) it is 
safe, entailing no toxic or immunological responses in the target tissue, v) it has no limitation 
in the size of DNA that it can accommodate, and vi) it is easy to produce in high purity, high 
titer stocks that can be scaled up for human use. Although at present there is not a single 
vector system that meets all these criteria, the next sections describe a number of useful viral 
vectors that are currently used in gene transfer therapies for RGC neuroprotection.  
I.6.1.1. Adeno-associated virus (AAV) 
Among all currently available viral vector systems, the adeno-associated virus (AAV) 
vector has emerged as a favored tool for targeting adult RGCs. AAV is a member of the 
parvoviridae family that requires a helper virus for replication, hence its initial identification 
as a contaminant of adenovirus preparations. The wild-type AAV houses a single-stranded 
genome of 4.7 kilo base-pairs (kb) containing two genes, rep and cap, that encode proteins 
involved in replication and encapsidation respectively. The AAV genome is flanked by two 
identical 145-bp inverted terminal repeats (ITRs), which are essential for packaging, 
replication and integration. Recombinant AAV vectors were originally derived from human 
parvovirus AAV by substituting all viral sequences, with the exception of ITRs, for a 
transgene of interest. Packaging of functional AAV particles requires the presence of the rep 
and cap gene products typically provided in trans.  
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The ability of AAV to infect distinct retinal cell-types depends on the virus serotype, 
the route of vector administration and the age of the host animal. Early studies in adult rat and 
mouse retinas identified AAV as an effective tool to transduce a large number of RGCs 
following intravitreal injection of the vector (Cheng et al., 2002b, Harvey et al., 2002), 
whereas subretinal AAV administration led to infection of photoreceptors and RPE (Ali et al., 
1996, Bennett et al., 1999). A variety of different AAV serotypes have been tested for retinal 
gene transfer, but the general consensus is that AAV serotype 2 displays the highest 
transduction of RGCs after intravitreal injection (Hellstrom et al., 2009). Although RGC-
specific promoters have not yet been used to drive transgene expression following AAV 
transduction, constitutive viral promoters such as the cytomegalovirus (CMV) promoter with a 
chicken β-actin (CBA) enhancer have been shown to be effective. The combination of a CBA-
containing promoter with the woodchuck hepatitis posttranscriptional regulatory element 
allowed transduction of ~85% of rat RGCs within 2 weeks of intravitreal virus injection 
(Martin et al., 2002). Tetracycline-regulatable promoter systems are currently being 
investigated as a means to regulate AAV-mediated transgene expression (Stieger et al., 2009). 
Other advantages of the AAV vector system for in vivo gene delivery include that it is 
not pathogenic and has not been implicated in the etiology of any known human disease, it 
mediates long-term transgene expression that can last for several years in the retina (Stieger et 
al., 2008), and it has low immunogenicity. In the absence of helper virus, wild-type AAV can 
integrate at a specific site on the q arm of chromosome 19 to establish latent infection. 
However, the lack of rep proteins has been shown to compromise integration specificity 
leading to random insertion of recombinant AAV. Although viral integration into the genome 
may contribute to the stability of AAV-mediated transgene expression, a careful evaluation of 
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the risks associated with insertional mutagenesis is required before implementing AAV-based 
therapies. A disadvantage of AAV has been the size constraint for packaging genes larger than 
4.7-kb. Although methods have been developed to increase the size of delivered transgenes by 
trans-splicing two independent vectors co-administered to the same tissue (Lai et al., 2005), 
this remains a limitation of the AAV system. The laborious work needed to produce AAV 
vectors has often been regarded as a disadvantage. However, recent improvements in the 
protocols have facilitated the preparation of high-titer and pure AAV stocks following good 
manufacturing practice (GMP), which is a requirement for use in humans.  
I.6.1.2. Adenovirus 
Adenovirus (Ad) contains a linear double-stranded DNA genome of approximately 36-
kb encapsidated in an icosahedral protein shell. Immediate early genes (E1, E2, E3 and E4) 
orchestrate viral gene transcription and suppression of the host immune response, while late 
genes are necessary for viral assembly. Ad vectors were initially generated with deletions of 
the early region 1 (E1), that contains genes required for virus replication, rendering vectors 
replication defective and more suitable for gene transfer into mammalian cells. A major 
disadvantage of these early Ad vectors is the strong cytotoxic and immune response elicited 
upon infection of the host cells. Recent versions of Ad vectors have been produced in which 
the entire viral genome, except for the terminal repeat regions required for viral assembly, has 
been replaced by exogenous gene sequences. These so-called “gutless” vectors, also referred 
to as Helper-dependent adenovirus (Hd-Ad), exhibit considerably reduced immune response 
but can only be produced in the presence of a helper virus that provides all the proteins 
required for viral replication (Kumar-Singh, 2008). These new vectors are less immunogenic 
and mediate long-term transgene expression following subretinal or intravitreal injection 
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(Takahashi et al., 2003, Oshima et al., 2004a, Oshima et al., 2004b, Lamartina et al., 2007). 
For example, intravitreal administration of helper-dependent Ad promoted transgene 
expression for up to 1 year in transduced Müller glia. 
 A cardinal feature of Ad vectors in the adult retina is that it efficiently infects non-
neuronal cell-types - epithelial cells or glia - whereas it has a poor ability to infect neurons. 
Intravitreal injection of  Ad results in preferential transduction of Müller cells, the 
predominant glial cell in the retina, and one of the primary targets for Ad infection in vivo (Di 
Polo et al., 1998). This approach has proved to be useful for delivery of genes encoding 
diffusible factors to promote neuroprotection of injured RGCs (Di Polo et al., 1998, Isenmann 
et al., 1998). Ad vectors have also been shown to effectively transduce the RPE following 
subretinal injections (Bennett et al., 1994, Li et al., 1994). Under some experimental 
conditions, limited transduction of RGCs by Ad has been observed. For example, introduction 
of Ad to the superior colliculus or to the transected optic nerve stump results in retrograde 
transport of viral particles and subsequent gene expression in some RGCs (Kugler et al., 
2000).  
I.6.1.3. Lentivirus 
Lentivirus (LV), a genus of retroviruses, consists of two identical single-stranded RNA 
molecules and enzymes required for replication within a viral protein core. Following virus 
internalization, the viral RNA is reverse transcribed into double-stranded DNA and 
transported to the cell nucleus. Viral DNA is then permanently integrated into the host genome 
to become a provirus. The retrovirus genome contains gag, pol and env genes flanked by long-
terminal repeats (LTRs), genes that encode proteins essential for replication, encapsidation, 
internalization and reverse transcription. Replication-deficient recombinant retroviral vectors 
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have been generated by substituting all viral genes for a transgene of interest with the 
exception of the cis-acting sequences required for vector propagation. Most retroviral vectors 
can only transfer genes into cells that are actively proliferating, thus their use in 
neuroprotective strategies which typically involve gene transfer into fully differentiated cells 
is rather limited. An exception to the rule is LV, such as the human immunodeficiency virus 
(HIV), which can efficiently infect non-mitotic cells. This ability relies on nuclear localization 
signals in the pre-integration complex that allow entry into the nucleus without the need for 
nuclear membrane fragmentation (Roe et al., 1993). Advantages of the LV system are its 
relatively large cloning capacity, close to 10 kb, its ability to mediate high levels of transgene 
expression in vivo and the low immunogenicity elicited in the target tissues. The main concern 
with LV vector systems is the risk of generating replication competent recombinant virus 
during the production of viral stocks. Because HIV is a human pathogen, considerable work 
has been done to increase biosafety of LV production systems. Other concerns include low 
vector titers and the risks associated with insertional mutagenesis as the vector integrates into 
the host genome. The LV tropism in the retina was first characterized by subretinal injection 
which demonstrated LV-mediated gene expression in photoreceptors and RPE cells as well as 
some bipolar and Müller cells (Miyoshi et al., 1997). Although some studies have observed 
limited transduction of the inner retina when LV vectors are delivered intravitreally (Harvey et 
al., 2002), others have reported transduction of RGCs without apparent cytotoxicity (Cheng et 
al., 2002a).  
I.6.2. DNA- and RNA-based technologies to modify RGC gene expression 
Non-viral gene transfer strategies have the advantage of circumventing the safety 
concerns that stem from the potential immunogenic response and risk of chromosomal 
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integration associated with viral vectors. The downside of non-viral approaches is that they 
yield low DNA transduction rates resulting in limited and often short-lived transgene 
expression in vivo. These gene transfer strategies might be useful when transgene expression is 
required only during a critical time window to boost RGC survival. Sustained transgene 
expression using non-viral vectors might be attainable through multiple intraocular injections, 
topical (corneal) applications or intra-nasal delivery.   
I.6.2.1. Naked DNA 
DNA plasmids or oligonucleotides are easy to prepare and can be readily injected into 
the eye, but they are not easily taken up by cells. Antisense oligonucleotides against pro-
apoptotic molecules have been delivered to RGCs by intravitreal injection or by retrograde 
transport via injection in the superior colliculus, but these approaches resulted in only modest 
protection of axotomized RGCs due to limited transfection efficiency (Isenmann S, 1999, 
Thaler S, 2006). In general, the ability of DNA molecules to transduce mammalian cells can 
be enhanced by chemical methods (e.g. liposomes, polymers); or by physical methods such 
as ballistic delivery (gene gun), micro-injection, electroporation, iontophoresis, laser or 
ultrasound. Liposomes are artificially prepared vesicular systems generated by the self-
assembly of lipid bilayers. Cationic lipids, such as cholesterol, are often used in liposome 
preparations because they effectively bind DNA to form stable lipoplexes useful for gene 
delivery. Although liposomes have been shown to facilitate intravitreal or topical delivery of 
DNA to the inner retina, the usefulness of this approach in RGC neuroprotection remains 
largely unexplored. Among the physical methods to deliver DNA plasmids to the RGCs, 
electroporation has received special attention because it is safe while providing effective gene 
transfer to these neurons in vivo. The underlying principle of gene transfer by electroporation 
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is that electrical pulses increase membrane permeability and induce electrophoretic influx of 
DNA into the target cells. Electric field strength, pulse duration and stimulation pattern can 
be controlled to achieve maximum transduction efficiency of RGCs. Transgene expression 
using electroporation can be detected as early as 2-3 days after gene delivery in vivo, which 
can last up to 3 weeks. This approach has been successfully used to deliver neurotrophic 
factor and thioredoxin genes to promote RGC survival in different models of optic nerve 
injury (Mo X, 2002, Ishikawa et al., 2004, Caprioli et al., 2009 ).  
I.6.2.2. Small Interference RNA (siRNA)  
RNA interference (RNAi) is a conserved cellular mechanism by which gene 
expression is tightly regulated in living cells. Two types of small RNA molecules are crucial 
in the RNA interference process: miRNA and siRNA. The endogenous RNA interference 
pathway is initiated in the nucleus with the expression of primary miRNAs that are cleaved 
into precursor miRNAs and exported to the cytoplasm. Once in the cytosol, miRNAs are 
further processed by Dicer nuclease and incorporated into the RNA-induced silencing 
complex (RISC). This complex is directed to a target mRNA sequence leading to its cleavage 
and degradation, ultimately resulting in gene silencing. A similar mechanism mediates the 
processing of siRNA but, in contrast to miRNA, siRNA perfectly matches the target mRNA 
sequence hence its robust ability to suppress gene expression. In general, the siRNA 
technology is based on sequence-specific silencing of gene expression using short double-
stranded RNAs of approximately 20-25 nucleotides in length. A limitation of siRNA-based 
strategies is the potential for non-specific effects that occur when the siRNA activates innate 
immune receptors, a problem that can overcome by optimizing the sequence design (Samuel-
Abraham and Leonard, 2010). siRNA has been successfully delivered to RGCs via injection 
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into the superior colliculus (Lingor et al., 2005, Koeberle et al., 2009), however, the highly 
invasive nature of this approach limits its clinical application. Alternatively, siRNA can be 
injected intravitreally leading to effective delivery to RGCs soon after administration. 
Although other retinal cells are likely to uptake siRNA delivered to the vitreous chamber, this 
strategy might be suitable for silencing genes that are specific or highly enriched in RGCs. 
Intravitreal administration of siRNA against vascular endothelial growth factor-1 in patients 
with age-related macular degeneration was well-tolerated and led to improvements in visual 
acuity (Kaiser et al., 2010). Another approach is to use viral vectors, such as AAV, to express 
functional siRNA from short hairpin RNA (shRNA) or miRNA-based shRNA (Gorbatyuk et 
al., 2007, Georgiadis et al., 2010) to increase cell-specificity and reduce off-target effects.  
I.7. OBJECTIVES OF THE THESIS, HYPOTHESES AND EXPERIMENTAL 
APPROACHES 
 
Problem: The principal mechanisms leading to RGC damage in glaucoma are not well 
understood, however it is well established that RGC loss is caused by apoptotic cell death. 
Elucidating the signaling pathways involved in RGC apoptosis is necessary to develop novel 
therapeutic approaches to slow or halt the progression of glaucoma and other optic 
neuropathies affecting RGC viability. 
Hypothesis: In this thesis, we explore the role of ASPP family members in the 
apoptotic death of RGCs. We put forth the hypothesis that the ASPP family is implicated in 
RGC apoptosis. As ASPP proteins are regulators of p53, we first assessed the role of p53 in 
axotomy-induced RGC apoptosis. We then selected two different genetic approaches to 
address the roles of ASPP proteins in RGC survival after optic nerve lesion. Firstly, we 
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administered siRNA targeting pro-apoptotic ASPP1 and ASPP2 and determined their effect on 
RGC survival. Secondly, we designed an AAV selectively expressed in RGCs encoding anti-
apoptotic iASPP and assessed its neuroprotective properties. 
Objectives: 1) To assess the role of p53 in axotomy-induced apoptotic death of RGCs, 
2) To evaluate the effect of pro-apoptotic ASPP1/2 knockdown by siRNA on improving RGC 
survival, 3) To measure the neuroprotective potential of anti-apoptotic iASPP overexpression 
in RGCs by AAV and 4) To study the molecular pathways of RGC survival mediated by 
ASPP family members. 
Experimental Protocols: 1) Animal model: The optic nerve axotomy model of 
apoptotic RGC death was carried out in adult Sprague-Dawley rats, 2) Endogenous ASPP 
expression pattern in the retina was assessed by immunohistochemistry on retinal crossections, 
3) Gene expression modulation: siRNA and AAV were delivered by intravitreal injections, 4) 
Evaluation of RGC survival: RGCs were either retrogradely labeled with Fluorogold or 
immunolabeled with a cell-specific marker (e.g. Brn3a), and the number of surviving RGCs 
was counted on flat-mounted retinas, 5) ASPP signaling components were characterized by 
western blots, qPCR and RT-PCR of retinal lysates. 
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CHAPTER 2 
 
 
II. FIRST ARTICLE: “ASPP1/2 REGULATE P53-DEPENDENT DEATH OF 
RETINAL GANGLION CELLS THROUGH PUMA AND FAS/CD95 ACTIVATION IN 
VIVO” 
 
 
Journal of Neuroscience (2013) 33(5):2205-16. 
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II.1. ABSTRACT 
The transcription factor p53 mediates neuronal death in a variety of stress-related and 
neurodegenerative conditions. The pro-apoptotic activity of p53 is tightly regulated by the 
apoptosis-stimulating proteins of p53 (ASPP) family members: ASPP1 and ASPP2. However, 
whether ASPP1/2 play a role in the regulation of p53-dependent neuronal death in the CNS is 
currently unknown. To address this, we asked whether ASPP1/2 contribute to the death of 
retinal ganglion cells (RGC) using in vivo models of acute optic nerve damage in mice and 
rats. Here, we show that p53 is activated in RGCs soon after injury and that axotomy-induced 
RGC death is attenuated in p53 heterozygote and null mice. We demonstrate that ASPP1/2 
proteins are abundantly expressed by injured RGCs, and that siRNA-based ASPP1 or ASPP2 
knockdown promotes robust RGC survival. Comparative gene expression analysis revealed 
that siASPP-mediated downregulation of PUMA, Fas/CD95 and Noxa depends on p53 
transcriptional activity. Furthermore, siRNA against PUMA or Fas/CD95 confers 
neuroprotection, demonstrating a functional role for these p53 targets in RGC death. Our study 
demonstrates a novel role for ASPP1 and ASPP2 in the death of RGCs, and provides evidence 
that blockade of the ASPP-p53 pathway is beneficial for central neuron survival after axonal 
injury. 
 
Keywords: Retinal Ganglion Cell, p53, Apoptosis, Ankyrin Repeat and Proline-Rich Domain-
Containing Proteins (ASPP). 
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II.2. INTRODUCTION 
 The nuclear transcription factor p53 mediates the apoptosis of post-mitotic neurons 
exposed to a wide range of insults (Culmsee and Mattson, 2005). Neuronal death induced by 
p53 has been documented in a variety of neurodegenerative diseases, suggesting a key role for 
this transcription factor in the regulation of neuronal viability after injury (Chatoo et al., 2011, 
Chang et al., 2012). Given its critical role in the control of cell death, several mechanisms 
exist to ensure tight regulation of p53 activity. The level of p53 protein is kept low in most cell 
types, including neurons (Soussi, 2000), via rapid and continuous degradation following 
ubiquitination by Mdm2 and MdmX (Wade et al., 2010). Additional control of p53 function is 
exerted via post-translational modifications such as phosphorylation, acetylation and/or 
methylation; and by interactions with protein partners (Boehme and Blattner, 2009).  
The identification of the apoptosis-stimulating proteins of p53 (ASPP), a family of 
ankyrin repeat and proline-rich domain-containing proteins, has revealed a new form of p53 
regulation. The ASPP family is composed of three members: ASPP1, ASPP2 and iASPP. 
ASPP2 was identified as a p53-binding protein in a yeast two-hybrid screen (Iwabuchi et al., 
1994), and ASPP1 was found in a homology search (Nagase et al., 1998). ASPP1 and ASPP2 
enhance p53-dependent death of tumour cells by selectively increasing the ability of p53 to 
activate pro-apoptotic gene transcription (Lopez et al., 2000, Ao et al., 2001, Samuels Lev et 
al., 2001, Bergamaschi et al., 2006), whereas iASPP inhibits p53-dependent cell death (Yang, 
1999, Bergamaschi et al., 2003). ASPP1 and ASPP2 play a role in tumour suppression by 
increasing the ability of p53 to induce apoptosis, but not cell cycle arrest, in tumour-derived 
cell lines (Samuels Lev et al., 2001, Slee et al., 2004). ASPP2 null mice die perinatally and 
although ASPP2 heterozygous mice survive to adulthood, they display a much higher 
 
 
65 
 
propensity for developing tumours compared to wild-type counterparts (Vives et al., 2006). 
This may have physiological relevance since ASPP1/2 protein levels are reduced in many 
forms of cancer, a deficit associated with poor patient‟s prognosis (Lossos et al., 2002 , Liu et 
al., 2004, Agirre et al., 2005, Liu et al., 2005).  
ASPP1/2 function has been examined solely in relation to tumour biology, but the role 
of these proteins in neuronal apoptosis has not been established. To address this, we asked 
whether ASPP1 or ASPP2 regulate death of adult retinal ganglion cells (RGCs) after axonal 
injury. RGCs are CNS neurons that undergo a predictable onset and time-course of apoptotic 
death following optic nerve axotomy. Here, we demonstrate that ASPP1 and ASPP2 proteins 
are abundantly expressed by intact and injured RGCs, and that depletion of ASPP1 and 
ASPP2 using short interfering RNAs (siRNAs) promotes RGC survival in vivo. Moreover, our 
data support a critical role for the p53-upregulated-modulator-of-apoptosis (PUMA) and 
Fas/CD95 in siASPP2-mediated survival of injured RGCs. This study identifies a novel role 
for ASPP1 and ASPP2 as important regulators of neuronal death in the injured CNS. 
 
II.3. MATERIALS AND METHODS 
II.3.1. Experimental animals 
Animal procedures were performed in accordance with the guidelines of the Canadian 
Council on Animal Care for the use of experimental animals (www.ccac.ca). All surgeries 
were carried out in adult, female Sprague-Dawley rats (180-200 g) or in p53 knockout mice 
under general anesthesia (2% Isoflurane, 0.8 liter/min). p53 heterozygote mice (B6; 129S2-
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Trp53tm1Tyj/J, Jackson Laboratory, Bar Harbor, ME), were maintained in our animal facility 
and bred to produce p53 null and wild-type littermate control mice.  
II.3.2. Axotomy-induced RGC death assay 
Selective RGC death was induced by complete transection (axotomy) of the optic 
nerve leading to rapid onset and predictable apoptotic loss of these neurons (Berkelaar et al., 
1994, Cheng et al., 2002). Prior to axotomy, RGCs were backlabeled by application of 
Fluorogold (2%, Fluorochrome, Englewood, CO) to the superior colliculus, the primary target 
of these neurons in the rodent brain. To ensure that all RGCs were fully labeled prior to axonal 
injury, axotomy was performed 7 days after Fluorogold application. The left optic nerve was 
transected at 0.5-1 mm from the optic nerve head avoiding damage to the ophthalmic artery. 
Fundus examination was performed to check the integrity of the retinal circulation after 
surgery. The right eye was never operated on and served as intact control. At 1 or 2 weeks 
post-lesion, rats were anesthetised by intraperitoneal injection of 1mL/kg of anaesthetic 
cocktail (100 mg/mL ketamine, 20 mg/mL xylazine, 10 mg/mL acepromazine) and perfused 
with 4% paraformaldehyde (PFA); the retinas were removed and flat-mounted vitreal side up 
on a glass slide for examination of the ganglion cell layer. Fluorogold-labeled neurons were 
counted within 3 square areas at distances of 1, 2 and 3 mm from the rat optic disc in each of 
the 4 retinal quadrants for a total of 12 retinal areas. In mice retinas, quantification was 
performed as in rats but sampled areas were localized at 0.25 mm, 0.625 mm and 1 mm from 
the optic disc for a total of 12 retinal areas. Microglia and macrophages, that may have 
incorporated Fluorogold after phagocytosis of dying RGCs, were excluded from our analysis 
of neuronal survival based on their morphology (Raibon et al., 2002). Fluorescent staining was 
examined with a Zeiss Axioskop 2 Plus microscope (Carl Zeiss Canada, Kirkland, QC), and 
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pictures were captured with a CCD video camera (Retiga, Qimaging, Burnaby, BC) and 
analyzed with Northern Eclipse software (Empix Imaging, Mississauga, ON).  
II.3.3. Reverse transcription and quantitative real time PCR (qPCR)   
Total RNA was isolated from individual retinas using the RNEasy Mini kit (Qiagen 
Inc., Valencia, CA) or TRIzol reagent (Invitrogen, Burlington, ON). cDNAs were generated 
from 0.5 µg-3 µg of total RNA using the MML-V reverse transcriptase (Invitrogen). PCR for 
p53 was performed using the following primers: p53 forward: 5´-
GATGGTGACGGCCTGGCTCCT-3´, p53 reverse: 5´-CTCGAAGCGCTCACGCCCAC -3´, 
ß-actin forward: 5'-CACCACTTTCTACAATGAGC-3´, ß-actin reverse: 5'-CGGTC 
AGGATCTTCATGAGG-3´, and the following cycle conditions: 94°C for 1 min, 58°C for 1 
min, 72°C for 1 min. Reaction products were separated on agarose gels, visualized under UV 
light and digitalized using Gel Doc™ EZ System (Biorad, Hercules, CA). Densitometric 
analysis was performed with ImageJ software (NIH, USA). For p53 target genes, quantitative 
real-time PCR (qPCR) was performed using the Platinum SYBRGreen SuperMix (Invitrogen) 
and a real-time PCR apparatus (ABI Prism 7000). Rat primer sets were as follows: PUMA 
forward: 5‟-CGGAGACAAGAAGAGCAACA-3‟, PUMA reverse: 5‟-TAGTTGGGCTCCAT 
TTCTGG-3‟, Fas/CD95 forward: 5‟-CCGACAACAACTGCTCAGAA-3‟, Fas/CD95 reverse: 
5‟-GGTGCAGTTCGTTTCCACTT-3‟, Bax forward: 5‟-TGCAGAGGATGATTGCTGAC-3‟, 
Bax reverse: 5‟-GATCAGCTCGGGCACTTTAG-3‟, Noxa forward: 5‟-GGAGTGCACCGG 
ACATAACT-3‟, Noxa reverse: 5‟-CTCCAATTCTCCGGAGTTGA-3‟, GAPDH forward: 5‟-
ATGGGAAGCTGGTCATCAAC-3‟, GAPDH reverse: 5‟-GTGGTTCACACCCATCACAA-
3‟. The ASPP2 primers (QT01599402) were purchased from Qiagen Inc. Mouse primer sets 
were as follows: PUMA forward: 5‟-CAAGAAGAGCAGCATCGA CA-3, PUMA reverse: 
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5‟-TAGTTGGGCTCCATTTCTGG-3‟, Fas/CD95 forward: 5‟-AAACAAACTGCACCCTGA 
CC-3‟, Fas/CD95 reverse: 5‟-CAACCATAGGCGATTTCTGG-3‟, Bax forward: 5‟-
CACGTGACCGTGGTGCGCCG-3‟: Bax reverse, 5‟-CCGCTCCCAAGCTGCTCCCCG-3‟, 
Noxa forward: 5‟-CACCGGACATAACTGTGGTT-3‟, Noxa reverse: 5‟-TTGAGCACACTC 
GTCCTTCA-3‟, HRPT forward: 5‟-ACTGTAATGATCAGTCAACGGG-3‟, and HRPT 
reverse: 5‟-GGCCTGTATCCAACACTTCG-3‟. ß-actin, HRPT and GAPDH were used as 
internal standards for data calibration, and the 2-Ct formula was used for the calculation of 
differential gene expression as described (Chatoo et al., 2009). 
II.3.4. Short interfering RNA (siRNA) 
The siRNA molecules against ASPP1, ASPP2 and Cy3-labeled siRNA were designed 
at Quark Pharmaceuticals Inc. The control siRNA against GFP has been described elsewhere 
(Hamar et al., 2004). All these siRNAs were stabilized by alternating 2‟O-methylation 
(Czauderna et al., 2003) and were synthesized by BioSpring GmbH (Frankfurt, Germany). The 
following siRNA sequences (sense strands) for ASPP1 and ASPP2 were tested with similar 
results, ASPP1: 5‟-GGAGAGAAGCACACTGAAA-3‟, 5‟-CAGCGTTTACATTTCCTAA-
3‟, and 5‟-CCGTGTTCTTGAGCAACAA-3‟; ASPP2: 5‟-AGGGAGTGTTTGAATAAGC-3‟, 
and 5‟-CACCCAGAGAACATTTATT-3‟. The siRNA sequences (sense strands) against 
PUMA: 5‟-GAGCGGCGGAGACAAGAAGAGUU-3‟; Fas/CD95: 5‟-GUGCAAGUGCAAA 
CCAGACUU-3‟; and Noxa: 5‟-CAAGGAAAGCUGACGGAGA-3‟, 5‟-GAACAGAAGUGG 
CUACGAA-3‟, 5‟-CCAUGGAUUUCCUCGGCAA-3‟, 5‟-AAGCAAUGGUCGUCGAGCA-
3‟; were purchased from Dharmacon (Thermo Scientific, Lafayette, CO). The fluorescent 
siRNA used for the visualization of intraocular distribution, sequence 5‟-GUGCCAACCUGA 
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UGCAGCU-3‟ (sense strand), contained a Cy3 fluorophore at the 3‟ end of the antisense 
strand. 
II.3.5. Intravitreal injections 
siRNA against ASPP1, ASPP2, PUMA, Fas/CD95, Noxa, siCy3 or control siGFP (2 
µg/µl, total volume: 5 µl) were injected into the vitreous chamber of the left eye using a 
Hamilton syringe fitted with a 32-gauge glass microneedle. Phosphate buffer saline (PBS) was 
used as vehicle control. The sclera was exposed and the tip of the needle was inserted at a 45° 
angle through the sclera and retina into the vitreous space using a posterior approach. This 
route of administration avoided injury to the iris or lens, which can promote RGC survival 
(Mansour-Robaey et al., 1994, Leon et al., 2000).  
II.3.6. Retinal immunohistochemistry 
 Animals were perfused transcardially with 4% PFA and retinal cryosections (16 µm) 
were prepared as previously described (Pernet et al., 2005, Lebrun-Julien et al., 2009). 
Primary antibodies were added to the retinal sections in blocking solution and incubated 
overnight at 4°C: phospho-p53 (Ser15) (20 µg/ml, Abcam, Cambridge, MA), ASPP1 (1 
µg/ml, Bethyl Laboratories, Montgomery, TX), ASPP2 (0.5 µg/ml, Bethyl Labs) or iASPP 
(0.5 µg/ml, Bethyl Laboratories). For phospho-p53 (Ser15), retinas were subjected to heat-
mediated antigen retrieval by incubating sections in 0.01 M sodium citrate in 0.5% Tween-20 
(pH 6) at 85-90oC for 30 min. Blocking peptides (2.5 µg/ml, Bethyl Laboratories) were 
incubated overnight with ASPP1 or ASPP2 primary antibodies (5:1 ratio) prior to application 
onto retinal sections. Sections were washed and incubated with secondary antibodies: anti-
rabbit IgG (1-8 µg/ml, Cy3, Alexa 594 or Alexa 488, Jackson ImmunoResearch Laboratories 
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Inc., West Grove, PA). Fluorescent labeling was observed with a microscope Zeiss AxioSkop 
2 Plus (Carl Zeiss Canada).  
II.3.7. Western blot analysis 
Whole fresh retinas were rapidly dissected and homogenized with an electric pestle 
(Kontes, Vineland, NJ) in ice-cold lysis buffer (20 mM Tris pH 8.0, 135 mM NaCl, 1% NP-
40, 0.1% SDS, and 10% glycerol supplemented with protease inhibitors).  Protein 
homogenates were centrifuged at 10,000 rpm for 10 min, and the supernatants were removed 
and resedimented to yield solubilized extracts. Retinal extracts were resolved on SDS 
polyacrylamide gels and transferred to nitrocellulose membranes (Bio-Rad Life Science, 
Mississauga, ON). Blots were incubated overnight at 4°C with each of the following primary 
antibodies: phospho-p53 (Ser15) (2 µg/ml, Abcam), ASPP1 (1 µg/ml, Bethyl Laboratories), 
ASPP2 (0.5 µg/ml, Bethyl Laboratories), iASPP (0.5 µg/ml, Bethyl Laboratories), Bax (1.5 
µg/ml, N20, Santa Cruz Biotechnologies, Santa Cruz, CA), PUMA (1 µg/ml, Abcam), Noxa 
(0.5 µg/ml, Sigma-Aldrich, Oakville, ON), Fas/CD95 (1 µg/ml, BD Transduction 
Laboratories, San Jose, CA) or -actin (0.5 µg/ml, Sigma-Aldrich). Membranes were 
incubated in anti-rabbit or anti-mouse peroxidase-linked secondary antibodies (0.5 µg/ml, 
Amersham Biosciences, Baie d‟Urfé, QC). Blots were developed with a chemiluminescence 
reagent (ECL, Amersham Biosciences) and exposed to X-OMAT imaging film (Eastman 
Kodak, Rochester, NY). Densitometric analysis was performed using Scion Image software 
(Scion Corporation, Frederick, MD) on scanned autoradiographic films obtained from a series 
of 3 independent western blots each carried out using retinal samples from distinct 
experimental groups.  
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II.3.8. Statistical analyses 
Data analysis and statistics were performed using the GraphPad Instat software 
(GraphPad Software Inc., San Diego, CA) by a one-way analysis of variance (ANOVA), 
followed by the Bonferroni post hoc test, or by a Student‟s t test. 
 
II.4. RESULTS 
II.4.1. Axotomized RGCs die in a p53-dependent manner 
p53 protein is abundantly expressed in the developing retina, but it is substantially 
downregulated during maturation (O'Connor, 2008). To establish whether p53 gene expression 
or activity increase following optic nerve injury, we carried out biochemical and 
immunohistochemical analysis of retinal samples after axotomy. While p53 mRNA levels did 
not change at one (not shown) or three days (Fig. 1A) after injury, a significant increase in 
injury-induced phosphorylation of p53 at serine 15 (S15), a key phosphorylation target during 
p53 activation (Dumaz and Meek, 1999, Unger et al., 1999) was readily detected at one day 
post-lesion (Fig. 1B). Immunostaining of Fluorogold-labeled retinas demonstrated selective 
phospho-p53 upregulation in RGCs at one day after axotomy (Fig. 1C), a time point that 
precedes the onset of RGC death in this model (Villegas-Perez et al., 1993, Berkelaar et al., 
1994). Phosphorylation of p53 at S15 has been shown to be sufficient to induce apoptosis of 
human glioma cells and leads to selective increase of the pro-apoptotic p53 targets Fas/CD95 
and PUMA (Amano et al., 2009). Consistent with axotomy-induced phosphorylation of retinal 
p53 at S15, we observed increased protein expression of PUMA and Fas/CD95 at one day 
after axotomy, whereas levels of Bax and Noxa did not change (Fig. 1D). Of interest, 
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phospho-p53 (S15), PUMA and Fas/CD95 proteins dropped to basal levels at seven days post-
injury (Figs. 1B, D) indicating that axotomy leads to early and transient activation of this 
pathway.  
To address the functional role of increased p53 activity in axotomy-induced RGC 
death, we analyzed the density of RGCs in p53 heterozygote (p53+/-) and null (p53-/-) mice 
subjected to optic nerve injury. RGCs were first labeled by application of the retrograde tracer 
Fluorogold to the superior colliculus, followed by axotomy and quantification of neuronal 
survival. Figure 1E shows that 73% of RGCs survived in p53-/- retinas and 65% in p53+/- 
retinas, while only 50% remained in wild-type retinas at one week post-lesion. The total 
density of RGCs in non-injured (intact) p53+/+, p53+/- and p53-/- adult retinas was similar 
indicating that p53 is not required for developmental programmed RGC death, consistent with 
previous findings (Li et al., 2002). These data demonstrate that optic nerve axotomy leads to 
activation of p53 in RGCs and that p53 plays a role in axotomy-induced RGC death in a dose 
dependent manner. 
II.4.2. ASPP1 and ASPP2 are expressed by adult RGCs 
 To characterize the role of ASPP1 and ASPP2 in RGC death, we first determined 
which retinal cells express them. Retinal immunohistochemistry showed abundant expression 
of endogenous ASPP1 and ASPP2 in the ganglion cell layer (GCL) (Fig. 2A, K) while other 
retinal layers were virtually devoid of ASPP1/2. Since displaced amacrine cells account for 
~40% of the total number of neurons in the GCL (Perry, 1981), we performed co-localization 
studies where RGCs were retrogradely labeled with Fluorogold (Fig. 2B, L). All Fluorogold-
labeled neurons displayed robust ASPP1 and ASPP2 immunoreactivity (Figs. 2C-F and 2M-P) 
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indicating that adult RGCs are endowed with high levels of ASPP1/2 proteins. Co-labeling 
with the nuclear marker DAPI demonstrated that ASPP1 had a nuclear and cytoplasmic 
(perinuclear) localization within RGCs (Fig. 2H-J), while ASPP2 was primarily found in RGC 
nuclei (Fig. 2R-T). ASPP1 and ASPP2 blocking peptides resulted in absence of staining (Fig. 
2 G, Q) confirming the specificity of the ASPP1 and ASPP2 antibodies.  
Following axotomy, there were no detectable changes in the levels or sub-cellular 
localization of ASPP1, ASPP2 or the anti-apoptotic member iASPP visualized by retinal 
immunohistochemistry (Fig. 3A). Analysis of protein homogenates at 24 hrs or 48 hrs (Figs. 3 
and 4) after axotomy confirmed that ASPP1, ASPP2 and iASPP levels were similar to those in 
intact, non-injured retinas (Fig. 3B, C). A time-course analysis of ASPP proteins up to five 
days post-axotomy revealed no change in their levels with respect to control retinas (not 
shown). Collectively, these data indicate that ASPP1 and ASPP2 are abundantly expressed by 
intact and axotomized RGCs.   
II.4.3. Selective knockdown of retinal ASPP1 or ASPP2 by intravitreal siRNA delivery 
 To investigate the role of ASPP1/2 proteins in retinal neuron death, we synthesized 
siRNA sequences against ASPP1 or ASPP2. We first examined whether intraocular siRNA 
delivery led to effective uptake by adult RGCs using a Cy3-tagged control siRNA. Figure 4 
shows that a single intravitreal injection of Cy3-siRNA resulted in robust Cy3 labeling in 
RGCs as early as 5 hrs after administration (Fig. 4A-F). The co-localization of Cy3 and 
Fluorogold confirmed that siRNA was rapidly taken up by RGCs after intravitreal delivery 
(Fig. 4G-I). 
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 To assess the ability of siRNAs to knockdown retinal ASPP1 or ASPP2 protein 
expression in vivo, we carried out western blot analysis of retinal homogenates from eyes that 
received a single injection of each siRNA at the time of axotomy. Administration of siRNA 
against ASPP1 (siASPP1) led to a significant reduction of retinal ASPP1 protein at 24 hrs 
after delivery, while a control siRNA against GFP (siGFP) had no effect (Fig. 4J, K). 
Importantly, siASPP1 did not reduce the protein levels of the other family members, ASPP2 or 
iASPP, confirming the specificity of the siRNA. Similarly, siRNA against ASPP2 (siASPP2) 
selectively depleted retinal ASPP2 protein levels without reducing ASPP1 or iASPP levels 
(Fig. 4L, M). Quantification of ASPP1 or ASPP2 protein levels at 24 hrs after treatment with 
siASPP2 or siASPP1, respectively, did not show a compensatory increase in these proteins 
(Fig. 4K, M, hatched bars). Endogenous levels of ASPP1 and ASPP2 proteins returned to 
basal at 48 hrs after siRNA delivery (Fig. 4J-M, black bars). Immunohistochemistry of 
axotomized retinas treated with siASPP1 or siASPP2 confirmed that siRNA-mediated 
knockdown of ASPP1/2 occurred in RGCs, visualized with Fluorogold (Fig. 4N, O). These 
data demonstrate that intravitreal delivery of siRNA results in rapid and effective uptake by 
RGCs, and that siRNAs against ASPP1 and ASPP2 promote transient depletion of ASPP 
proteins in these neurons.  
II.4.4. ASPP1 and ASPP2 knockdown protects RGCs from axotomy-induced death  
To determine if ASPP1 and ASPP2 were required for axotomy-induced RGC death, 
we asked whether targeted siRNA-mediated knockdown promoted RGC survival. For this 
purpose, RGCs were retrogradely labeled prior to optic nerve transection and intravitreal 
injections of siRNA against ASPP1 or ASPP2 were performed concomitant with axotomy. 
Flat-mounted retinas from eyes treated with siASPP1 or siASPP2 consistently displayed 
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higher densities of Fluorogold-labeled RGCs than those treated with control siGFP (Figs. 5A-
D). Quantitative analysis demonstrated that ASPP1 or ASPP2 knockdown resulted in 
substantial RGC survival relative to vehicle-treated (PBS) or control siGFP-treated eyes (Fig. 
5E), with siASPP2 promoting slightly more neuroprotection (79%: 1636 ± 62 RGCs/mm2) 
than siASPP1 (69%: 1430 ± 34 RGCs/mm2) at one week post-injury. All the siRNA sequences 
against ASPP1 or ASPP2 yielded similar results. 
We also examined the effect of siASPP1 and siASPP2 on RGC survival at two weeks 
after axotomy, a time-point when few RGCs remain alive in the absence of treatment (Lebrun-
Julien et al., 2009). Figure 5E shows that only 6% of RGCs survived in animals treated with 
vehicle or control siGFP (130 ± 7 RGCs/mm2) whereas 26% RGC survival was observed in 
animals that received siASPP1 or siASPP2 (542 ± 30 RGCs/mm2, 509 ± 24 RGCs/mm2, 
respectively). The combination of siASPP1 and siASPP2 did not increase RGC survival 
further (Fig. 5E, black bars) suggesting that ASPP1 and ASPP2 activate redundant pathways 
to promote RGC death. We conclude that ASPP1 and ASPP2 are required for p53-dependent 
axotomy-induced death of RGCs in the adult retina.  
II.4.5. siASPP2 protects axotomized RGCs through downregulation of the p53 pro-
apoptotic targets PUMA and Fas/CD95  
To investigate the mechanisms by which ASPP protein knockdown might lead to RGC 
neuroprotection after optic nerve injury, we examined changes in p53 pro-apoptotic targets at 
the mRNA and protein levels (Figs. 6, 7). We focused on siASPP2 because it confers 
enhanced neuroprotection over siASPP1. Real-time qPCR analysis of rat retinal samples at 6 
hrs after axotomy and siASPP2 administration, a time-point when siRNA is already present in 
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RGCs (Fig. 4A-I), revealed downregulation of ASPP2 and the p53 apoptotic targets PUMA, 
Fas/CD95 and Noxa compared to uninjured or control siRNA-treated retinas (Fig. 6A). There 
was no change in Bax expression levels. To further substantiate our findings, we performed 
qPCR in retinal samples from p53 null mice and wild-type littermate controls collected at 6 
hrs after axotomy with or without siASPP2 treatment. Overall, the transcript levels of PUMA, 
Fas/CD95 and Noxa were significantly reduced in non-injured or axotomized p53 null mice 
with respect to wild-type littermates, suggesting that these genes are transcriptionally 
regulated by p53 (Figs. 6B, C, E). More importantly, ASPP2 knockdown effectively reduced 
PUMA, Fas/CD95 and Noxa gene expression in axotomized retinas from p53 wild-type mice 
but not from p53 knockout mice (Figs. 6B, C, E), while Bax remained unchanged (Fig. 6D). 
siASPP2 did not reduce PUMA and CD95 expression further relative to the already reduced 
levels found in p53 null mice. Collectively, these data demonstrate that siASPP2-mediated 
knockdown of PUMA, Fas/CD95 and Noxa depends on p53 transcriptional activity. 
Western blot analysis of axotomized retinal samples at 24 hrs after siRNA 
administration showed that siASPP2 reduced PUMA and Fas/CD95 protein levels relative to 
control siGFP (Fig. 7A, B), while Bax and Noxa levels did not change with any of the 
treatments (Figs. 7C, D). These findings, supported by our observation that PUMA and 
Fas/CD95 are upregulated following axotomy (Fig. 1D) raised the possibility that they might 
play a role in the p53-dependent death of axotomized RGCs. To test this, we administered 
siRNAs against PUMA or Fas/CD95 at the time of axotomy and quantified retrogradely 
labeled RGCs at one week post-injury. siPUMA or siFas/CD95 effectively downregulated 
endogenous retinal PUMA or Fas/CD95, respectively (Fig. 7E-G). Importantly, a substantial 
increase in RGC survival was observed in retinas exposed to siPUMA (77%: 1597 ± 38 
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RGCs/mm2, n=4) or siFas/CD95 (69%: 1432 ± 71 RGCs/mm2, n=4) relative to siGFP-treated 
controls (Fig. 7H). Unlike PUMA or Fas/CD95, siASPP2-mediated decrease in Noxa 
transcript levels at 6 hrs after axotomy (Fig. 6) did not correlate with Noxa protein reduction at 
24 hrs post-injury (Fig. 7D). Since this discrepancy might simply reflect a difference in the 
kinetics of Noxa mRNA and protein synthesis (Aikawa et al., 2010, Armstrong et al., 2010), 
we also used a siRNA against Noxa to assess its role on RGC survival at one week after 
axotomy. siNoxa effectively reduced endogenous Noxa protein levels (Fig. 7G), but did not 
result in significant RGC protection (Fig. 7H) suggesting that although Noxa is 
transcriptionally regulated by p53, it does not play a prominent role in RGC death. We 
conclude that ASPP2 knockdown protects RGCs via downregulation of the p53 targets PUMA 
and Fas/CD95, and that these molecules mediate axotomy-induced RGC apoptosis. 
 
II. 5. DISCUSSION 
The present study explored the functional role of the p53 co-activators ASPP1 and 
ASPP2 in the regulation of injury-induced death of adult retinal neurons in vivo. Our data 
support four major conclusions. First, axotomy-induced RGC death is mediated inter alia 
through p53 activation in a gene dose-dependent manner. Second, ASPP1 and ASPP2 proteins 
are abundantly expressed by intact and injured RGCs. Third, selective siRNA-mediated 
knockdown of ASPP1 or ASPP2 leads to substantial RGC survival after axonal injury. Fourth, 
the neuroprotective effect of siASPP2 involves downregulation of the p53 apoptotic targets 
PUMA and Fas/CD95, and siRNAs against PUMA or Fas/CD95 effectively promote RGC 
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survival. Our data support a novel, key role of pro-apoptotic ASPP family members in the 
regulation of retinal neuron death.  
Axonal injury is a major cause of neuronal loss in the CNS of adult mammals and it is 
the primary damaging event in most optic neuropathies, including glaucoma. Using an 
axotomy model, we found that p53 phosphorylation and upregulation of the p53 pro-apoptotic 
targets PUMA and Fas/CD95 are markedly increased at one day after injury, a time that 
precedes the onset of RGC death.  In adult rodents, RGCs survive for five days after axotomy 
and then die abruptly (Villegas-Perez et al., 1993, Berkelaar et al., 1994), therefore this finding 
suggests that early p53 activation plays a causal role in injury-induced RGC loss. In support of 
this, our data further demonstrate that p53 deficiency promotes RGC survival after axotomy in 
a gene dose dependent manner and this is consistent with studies showing that inactivation of 
the p53 gene attenuates RGC death following ischemia, excitotoxicity or optic nerve crush 
(Rosenbaum et al., 1998, Li et al., 2002, Park et al., 2008).  
ASPP1 and ASPP2 are co-factors that enhance the pro-apoptotic function of p53, but 
not its ability to regulate cell cycle arrest (Samuels-Lev, 2001). ASPP proteins are known to 
interact directly with the p53 DNA-binding domain through their ankyrin and SH3 domains, 
readily increasing its transcriptional activity at pro-apoptotic gene promoters (Gorina and 
Pavletich, 1996, Patel et al., 2008). We demonstrate that RGCs express high endogenous 
levels of ASPP1 and ASPP2 that do not change after axotomy, supporting the hypothesis that 
these neurons become vulnerable to injury-induced activation of p53. It is unlikely that the 
function of ASPP1 and ASPP2 changes after injury, but rather that they are poised to act as 
co-factors to facilitate rapid p53-mediated transcriptional activation of PUMA and Fas/CD95 
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following axotomy. This is consistent with previous studies showing that other p53 co-factors, 
such as Brn-3b and SP1, can effectively modulate p53 activity without undergoing stress-
induced changes in function or expression levels (Budhram-Mahadeo et al., 2006, Dhar et al., 
2006, Chatoo et al., 2011). 
To address the functional role of ASPP1/2, we used a siRNA-based approach to 
knockdown ASPP1/2 gene expression in vivo. siRNA has been successfully delivered to 
RGCs via injection into the optic nerve or the superior colliculus (Lingor et al., 2005, 
Koeberle et al., 2009), but the invasive nature of these approaches greatly limits their 
application. We chose to deliver siRNA molecules by intravitreal injections which led to 
effective siRNA uptake by RGCs, as previously demonstrated by us (Ahmed et al., 2011). We 
cannot rule out that other retinal cells also incorporated siRNA injected into the vitreous 
chamber; however, we show that this strategy is suitable for silencing genes that are highly 
enriched in RGCs. Our results show that targeted siRNA successfully downregulated retinal 
ASPP1 and ASPP2 by ~85-90% at 24 hrs after intravitreal delivery, but this effect was 
transient since protein levels were restored by 48 hrs. In spite of this short-lived effect, our 
data demonstrate a strong neuroprotective effect of siASPP1/2 suggesting that there is a 
window of opportunity soon after axotomy in which ASPP1/2 knockdown counters the pro-
apoptotic effect of p53. This is supported by our observation that the levels of phospho-p53, 
PUMA and Fas/CD95, which are upregulated at 24 hrs after axotomy, drop to basal levels at 7 
days post-injury. Therefore, siASPP1/2 treatment to knockdown pro-apoptotic p53 targets 
during this critical period effectively attenuates RGC loss.  
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To identify the mechanism by which ASPP1/2 silencing delayed RGC death, we 
examined mRNA and protein levels of p53 pro-apoptotic targets. Comparative gene 
expression analysis revealed a substantial downregulation of PUMA, Fas/CD95 and Noxa in 
axotomized rat retinas derived from eyes treated with siASPP2 but not with control siRNA. 
Importantly, ASPP2 knockdown effectively reduced PUMA, Fas/CD95 and Noxa expression 
in axotomized retinas from p53 wild-type but not from p53 null mice, demonstrating that 
downregulation of these apoptotic genes depends on p53 transcriptional activity. At the 
protein level, siASPP2 substantially reduced retinal PUMA and Fas/CD95 proteins, while 
Noxa remained unchanged. Consistent with this, our data show that while targeted siRNA 
against Noxa failed to promote significant neuroprotection, siRNAs against PUMA or 
Fas/CD95 knockdown led to robust RGC survival indicating that these molecules play a 
functional role in axotomy-induced RGC death. PUMA is a BH3-only protein and a potent 
inducer of cell death, but so far there have been no reports of its role on RGC death. The pro-
apoptotic activity of PUMA requires its interaction with anti-apoptotic Bcl-2 family members, 
localization to the mitochondria, and induction of cytochrome c release leading to caspase 
activation and cell death (Nakano and Vousden, 2001). Biochemical studies suggest that 
PUMA regulates mitochondrial outer membrane permeabilization by binding to anti-apoptotic 
Bcl-2 proteins, which results in derepression and activation of Bax or Bak (Chipuk and Green, 
2009 ). Although we did not detect changes in Bax mRNA or protein levels in the presence of 
siASPP2, we cannot entirely rule out a decrease in Bax activity following PUMA 
downregulation. PUMA can release cytosolic p53 from its inactive complex with Bcl-XL to 
form a PUMA-Bcl-XL complex, allowing p53 to activate Bax (Chipuk et al., 2005). 
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Therefore, a decrease in PUMA levels could potentially reduce Bax activity by reducing its 
release from Bcl-XL.  
Our data also demonstrate that ASPP2 knockdown leads to downregulation of 
Fas/CD95 and that siRNA-mediated Fas/CD95 silencing was neuroprotective. Fas/CD95 is a 
death receptor of the tumour necrosis factor receptor superfamily of single-pass trans-
membrane proteins (Ashkenazi, 2002, Peter et al., 2007). Fas/CD95 is activated by Fas ligand 
(FasL) leading to the recruitment of the adaptor protein FADD (Fas-associated death domain) 
and activation of caspase 8 (Haase et al., 2008). Analysis of p53 responsive elements in the 
CD95 gene revealed a role for p53 in Fas/CD95 transcription (Schilling et al., 2009).  
Furthermore, nuclear ASPP1 can activate p53-induced Fas/CD95 expression (Aylon et al., 
2010). FasL has been shown to increase in retinal microglia in a rat model of ocular 
hypertension (Ju et al., 2006) and FasL-positive autoreactive T cells have been implicated in 
the loss of RGCs following heat shock protein immunization (Wax et al., 2008). More 
recently, the membrane-bound form of FasL was implicated in glaucomatous RGC 
degeneration (Gregory et al., 2011). Collectively, these studies support a role for Fas/CD95 in 
RGC death. Our data, specifically, demonstrate that Fas/CD95 contributes to ASPP1/2-p53 
pro-apoptotic signaling and that Fas/CD95 downregulation promotes marked RGC protection 
after axonal injury. 
Recent studies have unveiled a novel and unexpected role for p53 in the promotion of 
neurite outgrowth and axonal regeneration that is independent of its pro-apoptotic function (Di 
Giovanni and Rathore, 2012). Indeed, p53 gene silencing or dominant negative forms of p53 
have been shown to inhibit neurotrophin-dependent outgrowth in vitro and axonal 
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regeneration in vivo (Di Giovanni et al., 2006, Zhang et al., 2006, Tedeschi et al., 2009). Of 
interest, p53 acetylation at specific lysine residues is thought to be required for the p53 
growth-promoting effects (Tedeschi et al., 2008, Gaub et al., 2010). More recently, viral-
mediated overexpression of the histone acetyltransferase p300 in RGCs increased axonal 
regeneration within the injured optic nerve (Gaub et al., 2011). We have previously 
demonstrated that signaling pathways that lead to RGC survival may differ from those that 
promote RGC axon regeneration (Pernet and Di Polo, 2006). Therefore, although our current 
data demonstrate a pro-apoptotic role of p53 we cannot rule out the possibility that p53 might 
enhance RGC axon growth through activation of different signaling pathways. In this context, 
it should be of interest to assess the role of ASPP1/2 on axonal regeneration following optic 
nerve injury.  
In conclusion, we used a loss-of-function approach to identify the role of the p53 
activators ASPP1 and ASPP2 in retinal neuron death following optic nerve axotomy. Our data 
demonstrate a novel and prominent role of the pro-apoptotic ASPP1/2 proteins in the death of 
RGCs that involves the p53 targets PUMA and Fas/CD95. These findings expand our 
understanding of the molecular basis of RGC neurodegeneration, and might have implications 
for the design of strategies for neuroprotection in the injured CNS.  
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Figure 1. Axotomized RGCs die in a p53-dependent manner.  
(A) RT-PCR analysis revealed that p53 mRNA levels do not change at 1 day or 3 days (shown 
here) after axotomy with respect to non-injured retinas (Student‟s t test, p>0.05). (B) In 
contrast, a significant increase in axotomy-induced phosphorylation of p53 at serine 15 (S15) 
was readily detected at 1 day after axotomy, but returned to basal levels at 7 days post-lesion 
(ANOVA, *=p<0.05). (C) Retinal immunostaining of Fluorogold-labeled RGCs confirmed 
that p53 phosphorylation (activation) was detected in these neurons at 1 day after axotomy. 
Scale: 10 µm. (D) Protein levels of the p53 apoptotic targets PUMA and Fas/CD95 increased 
at 1 day after axotomy, but returned to normal levels at 7 days post-injury. Bax and Noxa 
remained unchanged. (E) Analysis of RGC loss quantified at 1 week after axotomy in p53 
null, heterozygote and wild-type retinas demonstrated an allelic dose dependency on p53 
(ANOVA, ***=p<0.001). Data are expressed as RGC densities (RGCs/mm2; mean ± S.D.). 
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Figure 2. ASPP1 and ASPP2 are expressed by adult RGCs.  
Retinal immunofluorescence demonstrated abundant expression of endogenous ASPP1 (A-G) 
and ASPP2 (K-Q) in RGCs visualized with the retrograde tracer Fluorogold. DAPI staining 
showed that ASPP1 is present in RGC nuclei and cytoplasm (perinuclear) (H-J), while ASPP2 
is primarily in the nuclei (R-T). ASPP1 and ASPP2 blocking peptides resulted in absence of 
staining (G, Q) confirming the specificity of the ASPP1 and ASPP2 antibodies. Scale bars: (A-
C) and (K-M) = 70 µm; (D-G) and (N-Q) = 50 µm; (H-J) and (R-T) = 10 µm. RPE: Retinal 
Pigment Epithelium; PS: Photoreceptor Segments; ONL: Outer Nuclear Layer; OPL: Outer 
Plexiform Layer; INL: Inner Nuclear Layer; IPL: Inner Plexiform Layer; GCL: Ganglion Cell 
Layer. 
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Figure 3. Expression of ASPP family members after optic nerve axotomy.  
(A) The levels or sub-cellular localization of ASPP1, ASPP2 or the anti-apoptotic member 
iASPP, visualized by retinal immunohistochemistry and Fluorogold (FG) staining, did not 
change at 48 hrs after optic nerve injury. Scale bar: 10 µm. (B) Analysis of protein 
homogenates confirmed that ASPP1, ASPP2 and iASPP levels in axotomized retinas collected 
at 48 hrs were similar to those in intact, non-injured retinas. The lower panel represents the 
same blot as in the upper panel but probed with an antibody that recognizes -actin used to 
confirm equal protein loading. (C) Densitometric analysis of western blots, showing the ratio 
of ASPP proteins relative to -actin, confirmed that there is no significant change in protein 
expression after injury (Student‟s t test, p>0.05).  
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Figure 4. Selective knockdown of retinal ASPP1 or ASPP2 by intravitreal siRNA 
delivery.  
Intravitreal delivery of Cy3-tagged siRNA resulted in rapid and effective uptake by RGCs. 
Lack of Cy3 fluorescence in non-injected control retinas (A-C) contrasted with robust Cy3 
labeling in RGCs, visualized with Fluorogold (FG) (D-I), as early as 5 hrs after siRNA 
administration. (J-M) Intravitreal delivery of siRNA against ASPP1 (siASPP1) led to a 
significant reduction of retinal ASPP1 protein at 24 hrs after delivery while control siRNA 
against GFP (siGFP) had no effect (ANOVA, *=p<0.05). siASPP1 did not decrease or 
increase the protein levels of the other family members, ASPP2 or iASPP, confirming the 
specificity of the siRNA. Similarly, siRNA against ASPP2 (siASPP2) selectively depleted 
retinal ASPP2 protein levels (ANOVA, *=p<0.05) without altering ASPP1 or iASPP levels. 
Endogenous levels of both ASPP1 and ASPP2 proteins returned to basal at 48 hrs after siRNA 
delivery. Immunohistochemistry of axotomized retinas at 24 hrs after siASPP1 or siASPP2 
administration confirmed that siRNA-mediated knockdown of ASPP1/2 occurred in RGCs, 
visualized with Fluorogold (N, O). Scale bars: (A-F) = 50 µm; (G-I) = 10 µm; (N-O) = 12 µm. 
PS: Photoreceptor Segments; ONL: Outer Nuclear Layer; OPL: Outer Plexiform Layer; INL: 
Inner Nuclear Layer; IPL: Inner Plexiform Layer; GCL: Ganglion Cell Layer. 
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Figure 5. ASPP1 and ASPP2 knockdown protects RGCs from axotomy-induced death.   
Fluorogold-labeled RGCs in flat-mounted retinas from a representative non-injured eye (A) or 
axotomized eyes treated with siASPP1 (B), siASPP2 (C) or control siGFP (D) at one week 
post-injury. Scale bars: 100 µm. (E) Quantitative analysis of RGC survival following 
intraocular injection of siASPP1 (hatched), siASPP2 (dark grey), combined siASPP1 and 
siASPP2 (black), control siGFP (light grey) or PBS (white) (ANOVA, ***=p<0.001; 
*=p<0.05). The density of RGCs in intact, uninjured Sprague-Dawley rat retinas is shown as 
reference (open bar). Data are expressed as the mean ± S.E.M.  
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Figure 6. siASPP2-mediated knockdown of PUMA, Fas and Noxa depends on p53 
transcriptional activity.  
(A) Real-time qPCR analysis of rat retinal samples at 6 hrs after axotomy and siASPP2 
administration revealed that ASPP2 knockdown leads to downregulation of PUMA, Fas/CD95 
and Noxa (ANOVA, ***=p<0.001; **=p<0.01), but not Bax (ANOVA, p>0.5) gene 
expression. (B-E) qPCR of retinal samples from p53 null mice and wild-type littermate 
controls collected at 6 hrs after axotomy and siASPP2 injection. Transcript levels of PUMA, 
Fas/CD95 and Noxa were significantly reduced in non-injured or axotomized p53 null mice 
with respect to wild-type littermates. Moreover, ASPP2 knockdown effectively reduced 
PUMA, Fas/CD95 and Noxa gene expression in axotomized retinas from p53 wild-type mice, 
but not from p53 knockout mice (B, C, E) (ANOVA, ***=p<0.001; **=p<0.01). Bax gene 
expression remained unchanged (D).   
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Figure 7. siASPP2 protects RGCs through downregulation of the p53 pro-apoptotic 
targets PUMA and Fas/CD95.  
(A) Western blot analysis of axotomized and injected retinal samples at 24 hrs after siRNA 
administration show that PUMA and Fas/CD95 protein levels are downregulated compared to 
control siGFP (A, B; Student‟s t test, *=p<0.05), whereas Bax and Noxa remained unchanged 
(C, D; Student‟s t test, p>0.05). Western blot analysis of axotomized and injected retinal 
samples at 24 hrs show that siFas/CD95, siPUMA and siNoxa downregulated endogenous 
retinal Fas/CD95 (E), PUMA (F) and Noxa (G) protein levels, respectively, compared to 
control siGFP (Student‟s t test *=p<0.05). (H) A significant increase in RGC survival was 
observed in retinas exposed to siPUMA (black) or siFas/CD95 (dark grey) with respect to 
siGFP-treated (light grey) or PBS-treated (white) controls (ANOVA, **=p<0.01; *=p<0.05). 
Administration of siNoxa (horizontal lines) did not result in significant RGC survival 
(ANOVA, p>0.5). The density of RGCs in intact, uninjured Sprague-Dawley rat retinas is 
shown as reference (open bar). Data are expressed as the mean ± S.E.M. 
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III.1. ABSTRACT 
The transcription factor p53 mediates the apoptosis of post-mitotic neurons exposed to 
a wide range of stress stimuli. The apoptotic activity of p53 is tightly regulated by the 
apoptosis-stimulating proteins of p53 (ASPP) family members: ASPP1, ASPP2 and iASPP. 
We previously showed that the pro-apoptotic members ASPP1 and ASPP2 contribute to p53-
dependent death of retinal ganglion cells (RGCs). However, the role of the p53 inhibitor 
iASPP in the central nervous system (CNS) remains to be elucidated. To address this, we 
asked whether iASPP contributes to the survival of RGCs in an in vivo model of acute optic 
nerve damage. We demonstrate that iASPP is expressed by injured RGCs and that iASPP 
phosphorylation at serine residues, which increase iASPP affinity towards p53, is significantly 
reduced following axotomy. We show that short interference RNA (siRNA)-induced iASPP 
knockdown exacerbates RGC death, whereas adeno-associated virus (AAV)-mediated iASPP 
expression promotes RGC survival. Importantly, our data also demonstrate that increasing 
iASPP expression in RGCs downregulates p53 activity and blocks the expression of pro-
apoptotic targets PUMA and Fas/CD95. This study demonstrates a novel role for iASPP in the 
survival of RGCs, and provides further evidence of the importance of the ASPP family in the 
regulation of neuronal loss after axonal injury. 
 
Keywords: Retinal Ganglion Cell, Axotomy, Inhibitor of Apoptosis-Stimulating Protein of 
p53 (iASPP), Apoptotic Cell Death, Adeno-Associated Virus (AAV), Short Interference RNA 
(siRNA). 
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III.2. INTRODUCTION 
iASPP is the most evolutionarily conserved member of the „Ankyrin-repeat, SH3-
domain, and Proline-rich-region containing Protein‟ (ASPP) family (Bergamaschi et al., 
2003), comprised of ASPP1, ASPP2, and iASPP. The first detected form of iASPP, a 
truncated variant termed RelA-associated inhibitor (RAI), was identified as a nuclear factor 
kappa beta (NFB) inhibitor in a yeast two hybrid screen (Yang et al., 1999b). The full-length 
isoform of iASPP, which is the predominant form of this molecule expressed in cells, was 
later discovered and shown to carry a C-terminus identical to RAI (Slee et al., 2004). ASPP 
family members have attracted much attention since their implication in a novel mechanism of 
p53 apoptotic regulation was identified in cancer cells. During tumorigenesis, pro-apoptotic 
ASPP1/2 enhance p53-dependent cell death (Lopez et al., 2000, Ao et al., 2001, Samuels Lev 
et al., 2001, Bergamaschi et al., 2006), while anti-apoptotic iASPP binds to p53 to inhibit its 
ability to transactivate pro-apoptotic target genes (Yang et al., 1999a, Lopez et al., 2000, 
Bergamaschi et al., 2003, Bergamaschi et al., 2004, Bergamaschi et al., 2006, Ahn et al., 
2009).  
Since its discovery, iASPP was shown to be encoded by the Protein Phosphatase 1 
Regulatory Subunit 13-Like (PPP1R13L) gene, which is overexpressed in many tumors 
including acute leukemia (Zhang et al., 2005), breast cancer (Bergamaschi et al., 2003), 
glioblastoma (Li et al., 2011), ovarian cancer (Jiang et al., 2011), and head and neck squamous 
cell carcinoma (Liu et al., 2012). Previous studies demonstrated that overexpression of iASPP 
in a human osteosarcoma cell line increased their resistance to ultraviolet radiation or 
cisplatin-induced apoptosis, without altering p53 expression (Bergamaschi et al., 2003). Due 
to its potent inhibitory role of p53 apoptotic activity, iASPP function has been studied 
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primarily in cancer cells or in the context of tumor biology. However, the role of iASPP in 
neuronal survival and neurodegeneration is not well understood.  
To address this, we asked whether iASPP is implicated in the survival of retinal 
ganglion cells (RGC) after axonal injury. RGCs are central nervous system (CNS) neurons 
that undergo a predictable onset of apoptotic death following optic nerve transection 
(Berkelaar et al., 1994, Cheng et al., 2002). Here, we demonstrate that iASPP is expressed by 
adult intact and axotomized RGCs. We show that short interference RNA (siRNA)-mediated 
knockdown of retinal iASPP expression exacerbates RGC death, while iASPP overexpression 
using serotype 2 adeno-associated virus (AAV) promotes RGC survival in vivo. We 
demonstrate that increased iASPP expression leads to a reduction in p53 apoptotic activity as 
evidenced by downregulation of p53 phosphoserine 15 (pSer15 p53), and its targets PUMA 
and Fas/CD95. In summary, our study identifies a novel role for iASPP in the survival of 
RGCs after acute optic nerve damage, and further supports a critical role of ASPP family 
members in the regulation of neuronal loss in the injured CNS. 
 
III.3. MATERIAL AND METHODS  
III.3.1. Experimental Animals  
Animal procedures were performed in accordance with the guidelines of the Canadian 
Council on Animal Care for the use of experimental animals (www.ccac.ca). All protocols 
were approved by the Committee on the Ethics of Use of Experimental Animals at the 
University of Montreal (Permit Number: 13-018). Surgeries were carried out in adult, female 
Sprague-Dawley rats (250-275 g), and performed under general anesthesia (2% Isoflurane, 0.8 
 
 
106 
 
liter/min). The number of animals used in each experiment is indicated in the results and the 
legend of the corresponding figure. All efforts were made to minimize the suffering of 
experimental animals. 
III.3.2. Optic nerve axotomy 
The left optic nerve was exposed and carefully transected at 1 mm from the optic nerve 
head avoiding injury to the ophthalmic artery, as previously described (Cheng et al., 2002, 
Pernet et al., 2005, Wilson et al., 2013). The right eye was never operated on and served as 
internal control. Fundus examination was performed immediately after axotomy and three 
days later to check the integrity of the retinal circulation after surgery. Animals showing signs 
of compromised blood supply were excluded from the study. 
III.3.3. Short interfering RNA (siRNA) 
The siRNA sequences against iASPP were purchased from Dharmacon (Smartpool, 
Thermo Scientific, Lafayette, CO) (sense strands): 5‟-CCGCCAAAGUGGACGAAUU-3‟, 5‟-
UGACAGGCGGUUCUGACGUU-3‟, 5‟-CCGAAGGCCUGGAACGAGU-3‟, 5‟-UGGUAC 
AGCAGGCGGUGAA-3‟. The control siRNA against GFP was kindly provided by Dr. Elena 
Feinstein (Quark Pharmaceuticals Inc.) and has been described elsewhere (Hamar et al., 2004). 
III.3.4. Recombinant AAV Serotype 2 Vectors 
A murine iASPP cDNA containing a c-terminal, myc tag (synthesized by GenScript 
USA Inc., Piscataway, NJ) was inserted downstream of the Synapsin 1 (Syn1) promoter into 
an AAV vector plasmid containing bovine growth hormone poly A and AAV serotype 2 
terminal repeats. Site-directed mutagenesis of surface-exposed tyrosine residues on AAV2 
was done to prevent proteasome-mediated degradation and improve transduction efficiency as 
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previously described (Zhong et al., 2008). Vectors were packaged, concentrated, and titered 
using standard methods (Hauswirth et al., 2000). A control vector containing the green 
fluorescent protein (GFP) gene under control of the same Syn1 promoter was prepared in 
identical fashion and used as control. The titers of the vector stocks were: 1.07E+13 vector 
genomes/ml (vg/ml) for hSyn1-iASPP-myc AAV2 Triple Y-F (AAV.iASPP) and 8.23E+12 
vg/ml for Syn1-hGFP AAV2 Triple Y-F (AAV.GFP).  
III.3.5. Intravitreal injections 
siRNA against iASPP or control siGFP (2 µg/µl), as well as AAV encoding iASPP 
(AAV.iASPP, 1.07E+13 vg/ml) or control GFP (AAV.GFP, 8.23E+12 vg/ml) were injected 
into the vitreous chamber of the left eye using a Hamilton syringe fitted with a 32-gauge glass 
microneedle (total volume: 5 µl). The sclera was exposed and the tip of the needle inserted at a 
45° angle through the sclera and retina into the vitreous space using a posterior approach. This 
route of administration avoided injury to anterior eye structures, which can promote RGC 
survival (Mansour-Robaey et al., 1994, Leon et al., 2000). Surgical glue (Indermill, Tyco 
Health Care, Mansfield, MA) was used to seal the injection site. Intraocular injection of 
siRNA was performed at the time of optic nerve axotomy, while injection of AAV was 
performed two weeks prior to axotomy to allow for AAV-mediated transgene expression to 
reach a plateau (Cheng et al., 2002, Pernet et al., 2005). 
III.3.6. Retinal immunohistochemistry 
 Animals were perfused transcardially with 4% paraformaldehyde (PFA) in 0.1 M 
phosphate buffered saline (PBS, pH 7.4). Retinal cryosections (16 µm) were prepared as 
previously described (Pernet et al., 2005, Lebrun-Julien et al., 2009). For iASPP 
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immunohistochemistry, retinas were subjected to heat-mediated antigen retrieval by 
incubating sections in 0.01 M sodium citrate in 0.5% Tween-20 (pH 6) at 85oC for 15 min. 
The following primary antibodies were added to the retinal sections in blocking solution and 
incubated overnight at 4°C: RNA binding protein with multiple splicing (RBPMS), Brn3a (1 
µg/ml, Santa Cruz Biotechnologies, Santa Cruz, CA), iASPP (1 µg/ml, Bethyl Laboratories, 
Montgomery, TX), iASPP (1 µg/mL, Clone LXO49.3, 1 µg/ml, Sigma-Aldrich, Saint-Louis, 
MO), Calretinin (1:1000, Millipore, Billerica, MA), Calbindin (1:10,000, Swant, Switzerland), 
or c-myc (1 µg/mL, Abcam, Cambridge, MA). For RBPMS, rabbit and guinea pig polyclonal 
antibodies were generated against the N-terminus GGKAEKENTPSEANLQEEEVR 
(RBPMS4-24) by ProSci Inc. (Powy, CA). Sera were collected following immunization and 
affinity purified using a RBPMS polypeptide affinity column as described (Rodriguez et al., 
2013). Sections were then incubated with secondary antibodies: anti-rabbit IgG, anti-mouse 
IgG, or anti-goat IgG (1-8 µg/ml, Cy3, Alexa 594, Alexa 488, Alexa 350, Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA), washed and mounted in anti-fade 
reagent (SlowFade, Molecular Probes, Eugene, OR). Fluorescent labeling was observed with a 
Zeiss AxioSkop 2 Plus microscope (Carl Zeiss Canada, Kirkland, QC).  
 
 
III.3.7. Western blot analysis  
Whole fresh retinas were rapidly dissected and homogenized with an electric pestle 
(Kontes, Vineland, NJ) in ice-cold lysis buffer (20 mM Tris pH 8.0, 135 mM NaCl, 1% NP-
40, 0.1% SDS, and 10% glycerol supplemented with protease inhibitors). For phosphorylated 
protein analysis, retinas were homogenized in ice-cold phosphorylation lysis buffer (50 mM 
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Tris HCl pH 7.4, EDTA 1 mM, NaCl 150 mM, NP40 1%, NaF 5 mM, Na deoxycholate 
0.25%, NaVO3 2 mM, supplemented with protease and phosphatase inhibitors). Protein 
homogenates were centrifuged at 10,000 rpm for 10 min, and the supernatants removed and 
resedimented for an additional 10 min to yield solubilized extracts. Retinal extracts (40 µg) 
were resolved on SDS polyacrylamide gels and transferred to nitrocellulose membranes (Bio-
Rad Life Science, Mississauga, ON). Blots were incubated overnight at 4°C with each of the 
following primary antibodies: phospho-p53 (Ser15) (2 µg/ml, Abcam), acetyl p53 (Lys 373, 
Lys 382) (1:100, Millipore), iASPP (0.5 µg/ml, Bethyl Laboratories), iASPP (0.1 µg/ml, 
Clone LXO49.3, Sigma-Aldrich), Bax (1.5 µg/ml, N20, Santa Cruz Biotechnologies), PUMA 
(1 µg/ml, Abcam), Noxa (0.5 µg/ml, Sigma-Aldrich), Fas/CD95 (1 µg/ml, BD Transduction 
Laboratories, San Jose, CA) or -actin (0.5 µg/ml, Sigma-Aldrich). Membranes were washed 
and incubated in anti-rabbit or anti-mouse peroxidase-linked secondary antibodies (0.5 µg/ml, 
Amersham Biosciences, Baie d‟Urfé, QC). Blots were developed with a chemiluminescence 
reagent (ECL clarity, BioRad, Hercules, CA) and imaged by ChemiDoc MP (BioRad). 
Densitometric analysis was performed using Image Lab software (BioRad) on scanned 
nitrocellulose membranes obtained from a series of three independent blots each carried out 
using retinal samples from distinct experimental groups.  
III.3.8. Immunoprecipitation 
Retinal extracts of AAV.iASPP or AAV.GFP injected eyes were immunoprecipitated 
with 2 µg of phosphoserine or control IgG antibodies (Millipore) following Catch and Release 
version 2.0 kit procedures (Millipore) and processed for Western blot analysis. Briefly, retinal 
extracts (400 µg) were incubated in continuous rotation for 3 hrs at 4oC in 500 µl of affinity 
beads carrying rabbit polyclonal anti-phosphoserine IgG (2 µg, Millipore). The beads were 
 
 
110 
 
washed three times with wash buffer (Millipore), and the bound proteins were eluted by 
treating the beads twice with 70 µl of elution buffer. Detection and identification of 
immunoprecipitated proteins were performed by Western blots analysis as described above. 
III.3.9. Quantification of RGC survival  
Rats were euthanized at one or two weeks post-axotomy by transcardial perfusion with 
4% PFA and both the left (optic nerve lesion) and right (intact control) retinas were dissected 
and fixed for an additional 15 min. Brn3a immunodetection on whole-mounted retinas was 
performed as described (Nadal-Nicolas et al., 2009). Briefly, whole mounted retinas were 
permeabilized in PBS containing 0.5% Triton X-100 (Fisher, Waltham, MA) by freezing them 
at -80oC for 15 min, rinsed and incubated overnight at 4oC with goat-anti-Brn3a (0.27 µg/ml, 
Santa Cruz Biotechnologies, C-20) in blocking buffer (PBS, 2% normal donkey serum, 2% 
Triton X-100). Retinas were washed and incubated for 2 hrs at room temperature with Alexa 
Fluor donkey anti-goat IgG (1 µg/ml, Jackson ImmunoResearch Laboratories Inc.). Retinas 
were then rinsed, mounted vitreal side up, and covered with anti-fade solution (SlowFade, 
Molecular Probes, Eugene, OR). Brn3a-labeled neurons were counted within three square 
areas at distances of 1, 2 and 3 mm from the rat optic disc in each of the four retinal quadrants 
for a total of twelve retinal areas. Fluorescent staining was examined with a Zeiss Axioskop 2 
Plus microscope (Carl Zeiss Canada, Kirkland, QC). Images were captured with a CCD video 
camera (Retiga, Qimaging, Burnaby, BC) and analyzed with Northern Eclipse software 
(Empix Imaging, Mississauga, ON).  
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III.3.10. Statistical analyses 
Data analysis and statistics were performed using the GraphPad Instat software 
(GraphPad Software Inc., San Diego, CA) by a one-way analysis of variance (ANOVA) 
followed by the Bonferroni post hoc test or Student‟s t test. 
 
III.4. RESULTS 
III.4.1. iASPP is abundantly expressed by injured RGCs but its activity decreases after 
axonal damage 
To characterize the role of the p53 inhibitor iASPP in RGC death, we first determined 
its cellular localization in the adult rat retina. Retinal immunohistochemistry showed 
expression of endogenous iASPP in the ganglion cell layer (GCL) and inner nuclear layer 
(INL) (Fig. 1A). As displaced amacrine cells account for ~40-50% of the total number of 
neurons in the rat GCL (Perry, 1981, Schlamp et al., 2013), we performed co-localization 
studies using antibodies against iASPP and „RNA binding protein with multiple splicing‟ 
(RBPMS), a selective RGC marker (Kwong et al., 2010, Rodriguez et al., 2013). All RBPMS-
positive neurons were immunoreactive for iASPP (Fig. 1B-F), indicating that adult RGCs are 
endowed with high levels of constitutive iASPP protein. In the INL, iASPP immunolabeling 
co-localized with calretinin, a marker of amacrine cells, and calbindin, a horizontal cell-
specific marker (Fig. 1G-J), indicating that these cells also express iASPP. There was no co-
localization between iASPP and PKC suggesting that iASPP is not expressed by rod bipolar 
cells (not shown). 
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 In adult rodents, RGCs survive for five days after axotomy and then die abruptly 
(Villegas-Perez et al., 1993, Berkelaar et al., 1994). We did not detect changes in the levels or 
cellular localization of iASPP at 24 hrs or 3 days after axotomy (Fig. 2A-C), indicating that 
iASPP levels are similar in axotomized and non-injured retinas prior to the onset of RGC 
death. This finding was confirmed by western blot analysis of iASPP protein at 6 hrs, 12 hrs, 
24 hrs, 48 hrs, 3 days and 5 days after axotomy (Fig. 2D, E). The phosphorylation of iASPP at 
serine residues increases its affinity towards p53 thus blocking the transcription of p53 pro-
apoptotic target genes (Lu et al., 2013). Therefore, we asked whether iASPP undergoes injury-
induced changes in phosphorylation at serine residues. For this purpose, immunoprecipitation 
(IP) of endogenous phosphoserine proteins was performed on retinal lysates, and the eluates 
were probed with iASPP antibody to detect endogenous iASPP phosphorylated at serine 
residues. Phosphoserine IP showed enrichment of retinal iASPP in the intact eye, whereas no 
co-precipitation of iASPP was observed in axotomized retinas (Fig. 2F). Retinal lysates 
subjected to IP with an IgG antibody, to control for non-specific interactions, did not show 
detectable bands (Fig. 2F). Our finding suggests that optic nerve injury reduces iASPP 
phosphorylation at serine residues, which might compromise its ability to inhibit p53-mediated 
apoptosis. 
III.4.2. Retinal iASPP knockdown exacerbates RGC loss after axonal damage  
 To elucidate the role of iASPP in retinal neuron death, we first undertook a loss-of-
function approach based on siRNA-mediated iASPP knockdown. We previously demonstrated 
that a single intravitreal injection of siRNA rapidly downregulates target mRNAs in RGCs 
(Wilson et al., 2013). Analysis of axotomized retinas treated with siRNA against iASPP (si-
iASPP) at the time of axotomy revealed effective knockdown of iASPP protein in the GCL as 
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early as 24 hrs after administration (Fig. 3A, B). Treatment with si-iASPP led to depletion of 
iASPP from RGCs, visualized with RBPMS (Fig. 3 D-F), whereas a control siRNA against 
GFP (si-GFP) had no effect (Fig. 3C). Similarly, western blot analysis confirmed robust 
knockdown of iASPP following si-iASPP administration in injured retinas (Fig. 3 G, H). Next, 
we asked whether iASPP depletion had an effect on axotomy-induced RGC loss. Quantitative 
analysis of Brn3a-labeled RGCs demonstrated that siRNA-mediated iASPP downregulation 
resulted in significantly greater RGC death (63%: 821 ± 68 RGCs/mm2, n=4) compared to 
siGFP-treated eyes (48%: 1154 ± 27 RGCs/mm2, n=4) at one week post-axotomy (Fig. 3I). 
These results indicate that loss of iASPP exacerbates RGC death following optic nerve injury. 
III.4.3. AAV-mediated iASPP overexpression selectively increases iASPP activity in 
RGCs  
AAV serotype 2 vectors were administered by intraocular injection to examine iASPP 
transgene expression in retinal cells in vivo. Retinas were examined two to four weeks 
following administration of AAV, the time required for optimal transgene expression using 
this vector (Cheng et al., 2002, Pernet et al., 2005). To distinguish AAV-mediated iASPP from 
endogenous iASPP, we used an antibody against the c-myc tag present only in the iASPP 
transgene. Robust c-myc staining was observed in a large number of cells in the GCL of 
retinas treated with AAV.iASPP, but not in control eyes injected with AAV.GFP (Fig. 4A, B). 
Co-localization of c-myc with RBMPS confirmed that AAV-transduced iASPP was expressed 
by RGCs (Fig. 4C-E). Quantification of double-labeled c-myc and RBMPS-positive cells 
demonstrated that ~85% of RGCs produced virally-encoded iASPP, consistent with previous 
reports showing high RGC transduction rates following intraocular administration of AAV 
serotype 2 (Cheng et al., 2002, Pernet et al., 2005). Western blot analysis confirmed virally-
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mediated iASPP upregulation in injured retinas, while control AAV.GFP had no effect (Fig. 4 
F, G). Next, we asked whether overexpression of iASPP increased its availability to undergo 
serine phosphorylation after axotomy. IP experiments demonstrated a significant enrichment 
of iASPP phosphorylated at serine residues in axotomized retinas treated with AAV.iASPP, 
while no detectable iASPP phosphoserine was observed in AAV.GFP-treated injured retinas 
(Fig. 4H). Our data demonstrate that AAV-mediated iASPP expression increases the amount 
of serine phosphorylated iASPP in axotomized retinas. 
III.4.4. AAV.iASPP protects RGCs from axotomy-induced death 
 The widespread expression of AAV-mediated iASPP in RGCs and its ability to 
activate iASPP in vivo prompted us to test its effect on RGC survival. For this purpose, 
intravitreal injections of AAV.iASPP or AAV.GFP were performed two weeks prior to 
axotomy and retinas were examined histologically at 7 and 14 days post-lesion to determine 
the density of surviving RGCs in all retinal quadrants. Flat-mounted retinas from eyes treated 
with AAV.iASPP showed higher densities of Brn3a-positive RGCs compared to AAV.GFP-
treated control retinas (Fig. 5A, B). Quantitative analysis demonstrated that iASPP 
overexpression resulted in significant RGC survival (77%: 1720 ± 61 RGCs/mm2, n=5) with 
respect to eyes that received AAV.GFP (49%: 1094 ± 55 RGCs/mm2, n=5) at one week post-
injury (Fig. 5 C). At two weeks after axotomy, only 9% of RGCs remained in eyes treated 
with AAV.GFP (221 ± 14 RGCs/mm2, n=5) whereas 27% of RGCs survived following 
AAV.iASPP treatment (615 ± 31 RGCs/mm2, n=4). These data indicate that AAV-mediated 
iASPP expression delays RGC death after injury and supports the conclusion that iASPP 
activity promotes RGC survival following axonal injury 
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III.4.5. iASPP downregulates p53 activity and the expression of pro-apoptotic targets 
PUMA and Fas/CD95 
To investigate the mechanisms by which iASPP overexpression might promote RGC 
survival, we first examined its effect on p53 post-translational modifications. Acetylation at 
p53 lysine residues 373 and 382 (Lys373, Lys382) by p300 occurs in the carboxyl-terminal 
region of p53 and has been correlated with its apoptotic function (Liu et al., 1999, Knights et 
al., 2006, Yamaguchi et al., 2009). No changes in p53 acetylation at Lys373 and Lys382 were 
detected 24 hrs after axotomy in retinas treated with AAV.iASPP or control AAV.GFP (Fig. 6 
A, B). In contrast, AAV.iASPP markedly inhibited the axotomy-induced increase in 
phosphoserine 15 (pSer15) p53 (Fig. 6 A, C), a key phosphorylation target during p53 
activation (Dumaz and Meek, 1999, Unger et al., 1999). The reduction of pSer15 p53 in 
retinas overexpressing iASPP prompted us to assess the levels of the p53 pro-apoptotic targets 
PUMA, Fas/CD95, Bax and Noxa. Western blot analysis of retinal samples showed that 
AAV.iASPP markedly reduced PUMA and Fas/CD95 protein levels relative to control 
AAV.GFP (Fig. 6 D, E, F), while Bax and Noxa did not significantly change with any of the 
treatments (Fig. 6 D, G, H). We conclude that iASPP overexpression leads to downregulation 
of PUMA and Fas/CD95, suggesting that iASPP protects RGCs by inhibiting the ability of 
p53 to activate key pro-apoptotic targets. 
 
III.5. DISCUSSION 
The critical anti-apoptotic function of iASPP is underscored by its phylogenetic 
conservation, as it is the most evolutionarily conserved inhibitor of p53 (Bergamaschi et al., 
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2003). Our study provides novel insight into the functional role of iASPP in neuronal survival, 
and allows us to draw the following conclusions. First, iASPP is abundantly expressed by 
adult RGCs, as well as a subset of amacrine and horizontal cells. Second, although total iASPP 
levels are not altered by optic nerve injury, phosphoserine iASPP levels, which serve as a 
readout of iASPP activity, were markedly reduced after axotomy. Third, selective knockdown 
of iASPP exacerbated RGC death while targeted iASPP overexpression increased 
phosphoserine iASPP levels and promoted RGC survival. Finally, we showed that AAV-
mediated iASPP expression resulted in reduced p53 activity and rapid downregulation of pro-
apoptotic targets PUMA and Fas/CD95. These data reveal a critical role for iASPP in the 
survival of CNS neurons following axonal injury. 
We report constitutive expression of iASPP in RGCs, amacrine and horizontal cells of 
the adult rat retina. Although we previously showed that the expression of pro-apoptotic ASPP 
family members, ASPP1 and ASPP2, is restricted to the ganglion cell layer (Wilson et al., 
2013), another p53 inhibitor, MDM2, is also expressed by amacrine and horizontal cells in 
adult mice (Xu et al., 2009). MDM4, which is structurally similar to MDM2, is also 
constitutively expressed in the adult retina (Guo et al., 2008), suggesting that complementary 
mechanisms are in place to ensure a tight regulation of p53 pro-apoptotic activity in retinal 
cells. Our finding that selective knockdown of iASPP by siRNA exacerbates RGC death after 
axonal injury is consistent with recent findings showing that downregulation of endogenous 
iASPP expression increases apoptosis in tumors of different origin including lung, breast, and 
prostate cancer as well as leukemia (Liu et al., 2008, Liu et al., 2009, Zhang et al., 2011, Li et 
al., 2012). Indeed, the inhibition of iASPP has been proposed as a novel strategy for treating 
tumors affected by deregulation of p53 function. Of interest, our observation that AAV-
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mediated iASPP increases RGC survival following axotomy resembles the conferred 
resistance of iASPP-overexpressing cancer cells to chemotherapeutic drugs including 
placlitaxel (Jiang et al., 2011), and cisplatin (Bergamaschi et al., 2003). Thus, our 
complementary loss-of-function and gain-of-function experiments reveal a close parallel 
between the strong anti-apoptotic role of iASPP in cancer cells and that reported here for adult 
RGCs.  
Our data show that retinal iASPP protein levels were not altered after optic nerve 
axotomy, similar to pro-apoptotic ASPP family members ASPP1 and ASPP2 (Wilson et al., 
2013). Unlike cancer or stroke models in which the total level of ASPP has been shown to 
vary, this finding supports that, instead, iASPP phosphorylation is markedly reduced after 
axonal injury suggesting loss of iASPP activity in damaged neurons. The phosphorylation of 
iASPP at serine residues Ser84 and Ser113 sites was found to increase iASPP binding affinity 
to p53 (Lu et al., 2013). PhosphoSitePlus (Hornbeck et al., 2012), a curated protein 
phosphorylation site database identified by large scale Mass Spectrometry screening from 
various tissues and cell lines, reports the identification of at least 9 other serine 
phosphorylation residues in iASPP in addition to the Ser84 and Ser113 sites. Although not 
residue-specific, our phosphoserine immunoprecipitation assay demonstrates that iASPP is 
endogenously phosphorylated in the intact retina and that the level of iASPP serine 
phosphorylation is markedly reduced following optic nerve injury. These data suggest that, in 
the axotomized eye, the affinity of retinal iASPP towards p53 is reduced and, as such, may 
contribute to tilting the fate of injured neurons towards death. This hypothesis is strengthened 
by our finding that phosphoserine iASPP increases in AAV.iASPP-treated retinas, further 
supporting the conclusion that the affinity of iASPP towards p53 is greater in retinas 
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overexpressing iASPP thereby blocking the apoptotic effect of p53 and enhancing cell 
survival.  
We previously demonstrated that RGCs die in a p53-dependent manner following 
axonal damage and that although total p53 expression levels did not change after injury, 
critical post-translational modifications occurred in vivo (Wilson et al., 2013). We detected 
phosphorylation of p53 at serine 15, which has been shown to increase the ability of p53 to 
recruit CBP/p300 acetyltransferase (Lambert et al., 1998). However, we did not detect changes 
in acetylation of p53 on Lys 373 and Lys 382 soon after axotomy, which is consistent with a 
previous study in which neither acetylation at Lys373 nor p300 acetyltransferase levels were 
altered in RGCs 24 hrs after optic nerve crush (Gaub et al., 2011). Therefore, although 
acetylation at Lys373 and Lys382 are known to be involved in fine-tuning the p53 stress 
response (Krummel et al., 2005), these modifications do not appear to play a critical role in 
early changes associated with RGC death. In agreement with this, the loss of p53 acetylation 
at its C terminus by CBP/p300 was not required for p53 transactivation in an acetylation-
deficient missense mutant mouse model (Krummel et al., 2005).  
Along with an increased affinity towards p53, phosphorylated iASPP has been reported 
to reduce pro-apoptotic gene transcription (Lu et al., 2013). Indeed, iASPP phosphorylation at 
Ser84 and Ser113 resulted in reduced transcriptional activity of p53 targets PUMA, Bax and 
PIG3 compared to wild-type ASPP in melanoma cells (Lu et al., 2013). Although we did not 
detect a change in Bax protein levels following axotomy and AAV-iASPP administration, we 
cannot rule out a role for Bax in our model as Bax activation results in its translocation from 
the cytosol to the mitochondria, and not necessarily altered transcription rates or protein levels 
(Wolter et al., 1997, Schellenberg et al., 2013). We do however show that AAV-iASPP 
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significantly increases the levels of phosphoserine iASPP, which coincided with reduced 
levels of PUMA and Fas/CD95, leading to neuronal survival. Of interest, siRNA-mediated 
knockdown of PUMA or Fas/CD95 resulted in substantial RGC protection after optic nerve 
injury [18]. Decreased PUMA and Fas/CD95 expression may rescue RGCs by affecting 
intrinsic and extrinsic apoptotic pathways, respectively. Active PUMA, a BH3-only Bcl-2 
family member and critical mediator of p53-dependent apoptosis (Jeffers et al., 2003), may act 
indirectly on pro-apoptotic Bcl-2 family members by relieving the inhibition imposed by anti-
apoptotic members (Kim et al., 2009, Ren et al., 2010). Fas/CD95, a death receptor that 
triggers apoptosis when bound by Fas ligand after recruiting the adapter protein FADD (Fas-
associated death domain) and pro-caspase 8 (Medema et al., 1997), is weakly expressed in the 
intact rodent retina (Kim and Park, 2005, Wax et al., 2008). The expression of Fas/CD95 
markedly increases in the ganglion cell layer as well as microglia during glaucomatous 
damage (Kim and Park, 2005, Ju et al., 2006). Furthermore, FADD is upregulated in RGCs 
subjected to ocular hypertension (Ju et al., 2006), and FasL-expressing microglia can induce 
apoptotic RGC death in a spontaneous mouse glaucoma model (Gregory et al., 2011). The 
reduction of Fas/CD95 levels reported here following iASPP.AAV administration may 
effectively decrease the activation of death receptor apoptotic pathways mediated by FasL, 
thereby increasing RGC survival. Overall, our data suggest that iASPP expression in RGCs is 
required as a molecular checkpoint to ensure that p53 activity is kept low and under tight 
control in healthy cells. Specifically, iASPP is likely to inhibit the ability of p53 to stimulate 
pro-apoptotic retinal targets, including PUMA and Fas/CD95, thus preventing or attenuating 
p53-dependent neuronal death.  
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In conclusion, we identify a novel role for the highly conserved p53 inhibitor iASPP in 
the survival of retinal neurons subjected to axonal injury. Our findings expand our current 
understanding of the role of the ASPP family of p53 regulators in neurodegeneration which 
could prove beneficial for the design of strategies aimed at curtailing neuronal loss in the 
injured CNS. 
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Figure 1. Adult RGCs express iASPP. 
Endogenous retinal iASPP was detected by immunofluorescence in the ganglion cell layer 
(GCL) and inner nuclear layer (INL) (A, C, D, and G). iASPP staining in RGCs was 
confirmed using the RGC-specific marker RBPMS (D-F). iASPP was also detected in 
amacrine and horizontal cells, visualized with calretinin (H,J, arrows) and calbindin (I,J, 
arrows), respectively. Scale bars: (A-C) = 50 µm; (D-J) = 20 µm. PS: Photoreceptor 
Segments; ONL: Outer Nuclear Layer; OPL: Outer Plexiform Layer; INL: Inner Nuclear 
Layer; IPL: Inner Plexiform Layer; GCL: Ganglion Cell Layer. 
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Figure 2. iASPP protein and phosphoserine levels after axotomy. 
Retinal iASPP expression and localization did not change at 24 hrs or 3 days after optic nerve 
injury compared to intact eyes (A-C). Scale bar: 10 µm. Analysis of protein homogenates from 
axotomized retinas collected at 6, 12, 24, 48 hrs, 3 and 5 days confirmed that iASPP levels 
were similar to those in intact, non-injured retinas. The lower panel represents the same blot as 
in the upper panel but probed with an antibody that recognizes -actin used to confirm equal 
protein loading (D). Densitometric analysis of western blots, showing the ratio of iASPP 
protein relative to -actin, confirmed that there is no significant change in protein levels after 
injury (E) (ANOVA, p>0.05). Phosphoserine immunoprecipitation (IP) of intact and 
axotomized retinas probed with iASPP antibody revealed a decrease in phosphoserine iASPP 
at 24 hrs after axotomy. IP of retinal homogenates with an IgG antibody was included as 
control for non-specific interactions (F). ONL: Outer Nuclear Layer; OPL: Outer Plexiform 
Layer; INL: Inner Nuclear Layer; IPL: Inner Plexiform Layer; GCL: Ganglion Cell Layer. 
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Figure 3. Selective siRNA knockdown of iASPP exacerbates axotomy-induced RGC 
death. 
A significant reduction of iASPP in the GCL was observed by immunohistochemistry of 
axotomized retinas at 24 hrs after intravitreal delivery of siRNA against iASPP (si-iASPP) 
compared to intact retinas, while control siRNA against GFP (siGFP) had no effect (A-C). 
RBPMS labeling confirmed that siRNA-mediated knockdown of iASPP occurred in RGCs (D-
F). Scale bars: (A-C) = 50 µm; (D-F) = 15 µm. Western blot analysis confirmed that 
intravitreal delivery of si-iASPP led to marked reduction of retinal iASPP protein at 24 hrs 
after delivery, while siGFP had no effect (G, H; Student‟s T-test, ***=p<0.001). Quantitative 
analysis of RGC survival at one week after axotomy following intraocular injection of si-
iASPP (black), or control siGFP (grey) (n=4/group, ANOVA, *=p<0.05). The density of 
RGCs in intact, uninjured Sprague-Dawley rat retinas is shown as reference (open bar). Data 
are expressed as the mean ± S.E.M. ONL: Outer Nuclear Layer; OPL: Outer Plexiform Layer; 
INL: Inner Nuclear Layer; IPL: Inner Plexiform Layer; GCL: Ganglion Cell Layer. 
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Figure 4. Targeted overexpression of iASPP in RGCs increases iASPP phosphoserine 
levels post-axotomy. 
AAV-mediated iASPP expression was distinguished from endogenous iASPP with an 
antibody against the c-myc tag encoded only in iASPP transgenes. Robust c-myc labeling was 
observed in the GCL of retinas that received AAV.iASPP, but not in control eyes injected with 
AAV.GFP (A, B). Selective expression of AAV-mediated iASPP in RGCs was confirmed 
using the RGC marker RBPMS (C-E). Scale bars: (A-B) = 50 µm; (C-E) = 15 µm. 
Immunoblotting and densitometric analyses confirmed that intravitreal delivery of 
AAV.iASPP led to significant overexpression of iASPP protein while AAV.GFP had no effect 
(F, G; Student‟s T-test, ***=p<0.001). Phosphoserine immunoprecipitation of retinas probed 
with an iASPP antibody reveals abundant iASPP phosphoserine levels in axotomized retinas 
(24 hrs) treated with AAV.iASPP but not with control AAV.GFP (H). PS: Photoreceptor 
Segments; ONL: Outer Nuclear Layer; OPL: Outer Plexiform Layer; INL: Inner Nuclear 
Layer; IPL: Inner Plexiform Layer; GCL: Ganglion Cell Layer. 
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Figure 5. AAV-mediated iASPP overexpression increases RGC survival.  
Brn3a-labeled flat-mounted retinas from axotomized eyes demonstrate higher RGC densities 
following treatment with AAV.iASPP (A) than with AAV.GFP (B) at one week post-injury. 
Scale bars: 100 µm. Quantitative analysis of RGC survival following axotomy and intraocular 
injection of AAV.iASPP (black) or control AAV.GFP (grey) (ANOVA, ***=p<0.001) at one 
and two weeks post-injury (C). The density of RGCs in intact, uninjured Sprague-Dawley rat 
retinas is shown as reference (open bar). Data are expressed as the mean ± S.E.M.  
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Figure 6. AAV.iASPP inhibits p53 activation and downregulates retinal PUMA and 
Fas/CD95 levels. 
Western blot analysis of axotomized retinal samples show that p53 phosphoserine15 (pSer15) 
levels are reduced in AAV.iASPP-treated retinas compared to control AAV.GFP at 24 hrs 
post-axotomy (A, C; ANOVA, *=p<0.05). Acetyl p53 levels remained unchanged (A, B; 
ANOVA, p>0.05). The p53 apoptotic targets PUMA and Fas/CD95 protein levels decrease in 
retinas treated with AAV.iASPP compared to AAV.GFP-treated control retinas (D, E, F; 
ANOVA, ***=p<0.005, **=p<0.001), whereas Bax and Noxa remained unchanged (D, G, H; 
ANOVA, p>0.05). 
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IV.1. THE ROLE OF P53 IN RGC APOPTOTIC DEATH  
In the first article presented in this thesis (Chapter 2), we explored the role of p53 
regulators ASPP1 and ASPP2 in apoptotic death of RGCs. We first assessed whether p53 was 
implicated in axotomy-induced apoptotic RGC death. Heretofore, the role of p53 in apoptotic 
death of RGCs had never been clearly demonstrated. Although it was surmised that p53 
played a key role in the apoptosis of RGCs in glaucoma (Nickells, 1999), and despite the fact 
p53 implication had been demonstrated in NMDA-induced excitotoxic and hypoxic/ischemic 
death of RGCs (Joo et al., 1999, Li et al., 2002), its role had not been clearly shown in an 
apoptotic death model. As p53 protein and mRNA levels are not significantly upregulated 
following optic nerve injury or in glaucomatous models (Levkovitch-Verbin, 2006), the role of 
p53 was not as evident as in excitotoxic or hypoxic/ischemic paradigms. We showed 
upregulation of p53 phosphoserine 15, a key apoptotic p53 post-translational modification site, 
in RGCs following optic nerve axotomy. We also showed marked increase of p53 downstream 
targets Fas/CD95 and PUMA following axotomy. Most importantly, optic nerve axotomy in 
p53 knockout, heterozygote and wild-type mice revealed a tight correlation between p53 gene 
expression and RGC survival. Indeed, increased RGC survival was observed in p53 
heterozygote and knockout mice compared to wild type mice. The survival rate of RGCs in 
p53-/- following optic nerve lesion was not 100%, but 73%, demonstrating that although p53 is 
an important contributor to apoptotic RGC death, it is not the sole pathway involved.  
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IV.2. THE ROLE OF ASPP FAMILY MEMBERS IN RGC SURVIVAL  
IV.2.1. Retinal expression pattern of ASPP family members 
Our findings presented in Chapters 2 and 3 revealed that pro-apoptotic ASPP1 and 
ASPP2 are solely expressed in the ganglion cell layer in the adult rat retina, whereas anti-
apoptotic iASPP is found in the ganglion cell layer as well as in the inner nuclear layer. 
Interestingly, it is the expression pattern of iASPP that most closely resembles that of p53 
mRNA. Indeed, although p53 protein is not detectable in the intact adult retina, in situ 
hybridization revealed that p53 mRNA is expressed in the inner nuclear layer and ganglion 
cell layer of adult rats (Shin et al., 1999). Furthermore, other p53 interacting proteins have 
been shown to have similar expression patterns to ASPP1/2 or iASPP. Pro-apoptotic Bax 
mRNA is solely expressed in the ganglion cell layer (Shin et al., 1999), similarly to ASPP1/2. 
Anti-apoptotic Bcl-2 mRNA is expressed in the inner nuclear layer and in the ganglion cell 
layer (Shin et al., 1999), similar to iASPP. It would, however, be oversimplifying to state that 
pro-apoptotic and anti-apoptotic p53-interacting proteins have distinct expression patterns, as 
p53 interacting proteins Brn3a and Brn3b, both confined to the ganglion cell layer (Nadal-
Nicolas et al., 2012), have both anti-apoptotic and pro-apoptotic roles,  respectively (Budhram 
Mahadeo et al., 2006). 
The presence of both pro-apoptotic and anti-apoptotic proteins in the ganglion cell 
layer of an intact retina fits the hypothesis that apoptosis is a default pathway that needs to be 
kept under control to allow cell survival. Thus, the levels of iASPP in the ganglion cell layer 
might be necessary to promote neuronal survival because iASPP inhibits p53 from binding to 
ASPP1 and ASPP2, also expressed in RGCs, thus blocking the apoptotic cascade. 
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IV.2.2. Putative role of ASPP family members in ocular neuropathies 
In an ischemic model, p53 upregulation was detected in the inner nuclear layer as well 
as the ganglion cell layer after a 60-minute period of ischemia (Rosenbaum, 1998). Following 
ischemic insults, neurons in the inner nuclear layer and ganglion cell layer undergo necrotic 
and apoptotic degeneration (Joo et al., 1999). Of interest, the necroptotic protein RIP3, which 
switches TNF-α induced cell death from apoptosis to necrosis (Zhang et al., 2009), has a 
similar expression pattern to iASPP as it was also found in amacrine and horizontal cells as 
well as in the ganglion cell layer (Huang et al., 2013). As p53 is implicated in necrosis in 
addition to apoptosis (Vaseva et al., 2012), it is possible that iASPP may also regulate 
necrosis. Consistent with this, downregulation of iASPP by siRNA resulted in an increase of 
apoptosis and necrosis in an MCF-7 breast cancer cell line expressing wild-type p53 (Wang, 
2010). Could iASPP be involved in the necrotic events occurring in the ischemic retina? 
Further investigation of iASPP in ocular neuropathies is warranted. It would be of great 
interest to assess the implication of iASPP in glaucoma. Indeed, iASPP is an inhibitor of NF-
k, a transcription factor commonly upregulated in glaucoma. Therefore, the effect of NF-k 
inhibition by iASPP in glaucoma would be highly relevant. Of interest, a cohort of POAG 
patients were associated with p53-PRO, a TP53 sequence polymorphism resulting in a proline 
at amino-acid 72 position in the p53 protein (Wiggs et al., 1998). Normally, iASPP 
preferentially inhibits the p53-PRO form and not the arginine variant p53-ARG (Bergamaschi 
et al., 2006), and yet in this group of glaucoma patients the apoptotic activity of p53-PRO was 
enhanced (Wiggs et al., 1998). It would be of interest to assess if this enhancement of p53-
PRO activity is due to a reduction in iASPP activity. 
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The roles of ASPP1 and ASPP2 should also be assessed in glaucoma, as they might 
play novel roles in disease progression. ASPP2 can directly interact and inhibit pro-survival 
Bcl-2 and Bcl-XL (Katz et al., 2008), and, interestingly, the levels of Bcl-2 and Bcl-XL are 
significantly reduced in models of glaucoma and optic nerve lesion, but not following 
excitotoxic injury (Levkovitch Verbin et al., 2010, Levkovitch Verbin et al., 2013). It would 
be useful to assess whether ASPP2 levels are upregulated in animal models of ocular 
hypertension and in human glaucoma. 
IV. 2.3. Regulation of ASPP family apoptotic activity by phosphorylation 
 The most common type of post-translational modification in signal transduction is 
protein phosphorylation (reviewed in (Ubersax and Ferrell, 2007)). It has been estimated that 
30% of all cellular proteins are phosphorylated on at least one residue (Pinna and Ruzzene, 
1996, Cohen, 2000). ASPP1, ASPP2 and iASPP belong to this family of proteins whose 
functions can be regulated by the addition of a γ-phosphate group, as the phosphorylation of 
ASPP family members have been shown to play a key role in their apoptotic activity. Indeed, 
the phosphorylation of ASPP1 and ASPP2 increases their pro-apoptotic activity, whereas 
iASPP phosphorylation enhances its anti-apoptotic activity (Aylon et al., 2010, Godin 
Heymann et al., 2013, Lu et al., 2013). It was shown that ASPP1 can be phosphorylated by the 
tumor suppressor Large Tumor Suppressor 2 (Lats2), which increases p53 binding to pro-
apoptotic Fas/CD95, PUMA and Bax protomoters (Aylon et al., 2010). Futhermore, ASPP2 
was recently shown to be phosphorylated by Ras/MAPK, and this serine phosphorylation 
event enhances ASPP2 pro-apoptotic activity by upregulating p53-mediated transactivation of 
Bax (Godin Heymann et al., 2013). iASPP anti-apoptotic activity is also regulated by its 
phosphorylation status, as iASPP phosphorylation by Cyclin B1/CDK1 increases its affinity 
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towards p53 (Lu et al., 2013). We demonstrated that iASPP phosphorylation status is affected 
by optic nerve injury in Chapter 3 of this thesis. As apoptotis-specific phosphorylation events 
abound (Dix et al., 2012), it would be interesting to assess whether ASPP proteins belong to 
the apoptotic phosphoproteome of glaucoma. 
IV.2.4. Summary of the role of ASPP family members in RGC apoptosis  
The ASPP family is comprised of both initiators and inhibitors of cell death, similarly 
to other gene families expressing members with dichotomous roles such as the Bcl-2 
superfamily and the TNF superfamily (Gross et al., 1999a, Aggarwal, 2003). Indeed, these 
families express both pro-apoptotic and anti-apoptotic members. Families of genes including 
members with distinct and opposing functions allows for careful orchestration of cell fate. 
Indeed, the cell‟s ability to regulate the expression levels of anti-apoptotic and pro-apoptotic 
proteins assures a checkpoint in the switch between cell survival and programmed cell death 
pathways. Furthermore, protein family members have similar protein domains thus similar 
ligand binding sites, and by acting on the same proteins the inhibitory family members can 
counteract the pro-apoptotic actions of their family members in a targeted manner. They help 
maintain the balance between cell life and cell death via competitive interactions with each 
other. 
 The roles of ASPP family members ASPP1, ASPP2 and iASPP were assessed in the 
intact and injured retina, revealing a novel role for these proteins in the apoptotic pathway 
induced by axonal damage after optic nerve axotomy. Figure 8 summarizes our model of 
ASPP family pathways implicated in intact and apoptotic events occurring in RGCs following 
optic nerve lesion.  
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Figure 8. Model of ASPP family signaling in intact and injured RGCs. a) In the intact 
retina, the phosphorylation of iASPP at one or more serine sites promotes iASPP-p53 
interaction, inhibiting p53 apoptotic function. iASPP overexpression by AAV (green arrow) in 
the axotomized retina promotes serine phosphorylation of iASPP and consequently inhibits 
p53 apoptotic function, increasing RGC survival. Knockdown of iASPP by siRNA (red arrow) 
exarcerbates RGC death. b) In the axotomized retina, p53 is phosphorylated at its Ser15 site, a 
key apoptotic activation site. iASPP serine phosphorylation is lost and iASPP is displaced by 
pro-apoptotic ASPP1/2. Pro-apoptotic p53 downstream targets PUMA and Fas/CD95 are 
upregulated, resulting in RGC death. Knockdown of ASPP1 and ASPP2 by siRNA (red arrow) 
reduces PUMA and Fas/CD95 activation levels and increases RGC survival. (Image generated 
by Ariel Wilson).   
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IV.3. NOVEL ROLE OF PUMA IN RGC APOPTOSIS 
In the first chapter of this thesis, we uncovered a role for PUMA in RGC apoptosis. 
PUMA is a BH3-only Bcl-2 family member and a critical mediator of p53-dependent 
apoptosis (Jeffers et al., 2003). It is known that mitochondrial apoptotic signaling pathways 
are critically dependent on the interaction between BH3-only proteins and their pro-survival 
counterparts (Youle and Strasser, 2008). Relevantly, other Bcl-2 family members have been 
shown to play an important role in RGC survival, such as Bax (Isenmann et al., 1999, Semaan 
et al., 2010), Bim (McKernan and Cotter, 2007), Bcl-XL (Levkovitch Verbin et al., 2013) and 
Bcl-2 (Levkovitch Verbin et al., 2013). Furthermore, PUMA promotes neuronal death induced 
by trophic factor deprivation, endoplasmic reticulum stress, ischemia and oxidative stress 
(Reimertz et al., 2003, Steckley et al., 2007, Niizuma et al., 2009, Galehdar et al., 2010, 
Ambacher et al., 2012). The data shown in this thesis allow us to now add axonal injury to the 
list of cellular stresses leading to PUMA activation and neuronal death in the CNS.  
PUMA acts indirectly on the Bcl-2 family members Bax and/or Bak by relieving the 
inhibition imposed by antiapoptotic members. Bax is an essential effector responsible for the 
mitochondrial outer membrane permeabilization, and requires activation by PUMA (Kim et 
al., 2009, Ren et al., 2010). PUMA thus liberates activated Bax to translocate to the 
mitochondrial membrane and mediate the release of AIF, SMAC and cytochrome C, leading 
to caspase activation. As PUMA knockdown by siRNA reduced cytokine-induced Bax 
activation and translocation to the mitochondria (Gurzov et al., 2010), we surmise that reduced 
levels of PUMA observed in the context of iASPP overexpression and axotomy could 
diminish Bax activation levels following optic nerve injury, tilting the fate of injured RGC 
towards survival. Therefore, although we did not detect modulations of Bax levels following 
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AAV.iASPP administration and axotomy, Bax apoptotic activity could indirectly be affected 
by PUMA downregulation. 
Furthermore, PUMA has the ability of disrupting the interaction between cytosolic p53 
and Bcl-XL, an anti-apoptotic Bcl-2 family member present in the GCL (Medearis et al., 
2011). This p53-Bcl-XL disruption by PUMA liberates p53 to directly activate pro-apoptotic 
Bcl-2 members Bax and Bak (Follis et al., 2013). It is of interest that the pro-apoptotic role of 
PUMA uncovered in an optic nerve axotomy model may be implicated in glaucomatous 
neurodegeneration, as siRNA or AAV-mediated regulation of the ASPP proteins influences 
PUMA protein levels, and therefore activity. 
IV.4. USE OF AAV AND SIRNA TO REGULATE RGC SURVIVAL IN VIVO 
The robust RGC survival rates following administration of siRNA to knockdown pro-
apoptotic ASPP1 or ASPP2, or administration of AAV encoding iASPP to overexpress anti-
apoptotic iASPP reflects the neuroprotective possibilities afforded by gene therapy tools. 
Although many studies target the apoptotic pathway with the common goal of rescuing RGCs 
from apoptotic death, the use of AAV and siRNA in our studies had the additional advantage 
of allowing the identification of the function of ASPP family members in axotomy-induced 
RGC death.  
Our findings highlight the advantages of using gene therapy strategies that target 
multiple anti-apoptotic pathways, as this appears to be a promising avenue to increase RGC 
survival after axonal damage. One such pathway is neurotrophin-regulated signaling. There is 
substantial evidence that neurotrophic factors suppress the intrinsic apoptotic cascade by 
activating intracellular survival signals. Upon binding to their cognate tyrosine kinase 
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receptors, most neurotrophic factors stimulate two primary pro-survival signaling pathways: 
the extracellular signal-regulated kinase 1/2 (ERK1/2) and the phosphatidylinositol-3 kinase 
pathways (Kaplan and Miller, 2000). Some factors, such as CNTF, can also activate the Janus 
kinase/signal transducer and activator of transcription 3 (Peterson et al., 2000). AAV-mediated 
gene transfer of constitutively active extracellular signal-regulated kinase kinase 1 
(ERKK1/2), the obligate upstream activator of ERK1/2, resulted in robust survival rates of 
RGCs in both axotomy and ocular hypertension models of optic nerve injury  (Pernet et al., 
2005, Zhou et al., 2005). 
In contrast to protein tyrosine kinases that promote neuronal survival, there are several 
pro-apoptotic protein kinases that contribute to RGC death, such as the c-Jun N-terminal 
kinase (Bessero et al., 2010). c-Jun, activated by c-Jun N-terminal kinase phosphorylation, 
mediates transcription of pro-apoptotic genes and has been shown to be upregulated in rat and 
monkey models of glaucoma (Hashimoto et al., 2005, Levkovitch-Verbin et al., 2005). 
siRNA-mediated gene expression knockdown of c-Jun in RGCs resulted in a threefold 
increase in RGC survival after optic nerve lesion (Lingor et al., 2005). These studies support 
our findings that administration of siRNA or AAV may be beneficial to modulate the activity 
of signaling intermediaries and promote RGC neuroprotection after injury.  
The intravitreal injection of siRNA or AAV might be considered as of non-selective 
delivery of gene therapy, as the injected genetic material is diffused into the vitreous chamber 
of the eye to reach the retina. The main caveats of this approach are the need to increase the 
concentration of the injected siRNA or AAV to assure that an adequate quantity reaches the 
retina, and that it might produce undesirable effects on other ocular tissues, however the AAV 
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promoter assures only the targeted cells will express the transgene. The advantage of this 
approach is that it results in diffuse distribution of siRNA or AAV across the retina. 
The therapeutic potential of viral vectors as a treatment for glaucoma has mainly 
focused on adeno-associated vectors as opposed to retroviruses, lentiviruses, herpes simplex 
viruses or adenoviruses. Insofar as the main limitation of AAVs is a relatively small packaging 
capacity, the main advantage is that AAVs are non-inflammatory and non-pathogenic 
(Thomas et al., 2003, Wilson and Di Polo, 2012). Other viral vectors are either less efficient at 
transducing RGCs, elicit immunogenic responses, or lack clinical safety data (Balaggan and 
Ali, 2012). There is currently substantial clinical experience with AAV subretinal injections to 
target photoreceptors and retinal pigmented epithelial cells, as well as pre-clinical experience 
with AAV intravitreal injections to target RGCs. Indeed, AAV subretinal injections were 
tested in human patients in a clinical trial of Leber‟s Congenital Amaurosis (LCA) (Cideciyan 
et al., 2009, Cideciyan, 2010, Jacobson et al., 2012, Cideciyan et al., 2013) and resulted in 
improved vision. Not to be confused with LCA, Leber Hereditary Optic Neuropathy (LHON), 
also described by Theodore Leber, is another ocular pathology for which AAV therapy was 
tested. LHON is associated with mitochondrial DNA mutations including the nicotidamide 
adenine dinucleotide dehydrogenase subunit IV (ND4) gene (reviewed in (Yen et al., 2006)). 
In pre-clinical studies, RGCs were targeted by intravitreal injection of AAVs encoding ND4. 
Intravitreal injection of ND4.AAV in rodent, nonhuman primate and ex vivo human eyes 
resulted in expression of ND4 in RGCs in the ex vivo human eye, rescue of the Leber 
Hereditary Optic Neuropathy (LHON) mouse model, and no serious adverse reactions in the 
primates followed up for 3 months (Koilkonda et al., 2014). Clinical testing of an intravitreal 
injection of AAV.ND4 in LHON patients with mutated ND4 is planned (Lam et al., 2014).  
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IV.5. GENERAL CONCLUSIONS  
The medical need for neuroprotective therapies for glaucoma is undeniable. In the last 
10 years, there has been tremendous progress in the use of gene therapy strategies not only to 
understand the molecular basis of RGC death, but also to stimulate the survival and 
regeneration of these neurons in a variety of preclinical models of optic nerve injury. The 
work presented in this thesis introduces the novel role of the ASPP pathway in RGC apoptotic 
death induced by optic nerve axotomy. We used nonviral and viral approaches to modulate 
RGC gene expression: siRNA, which is a novel approach in the retinal field, and an AAV-2 
vector which has the ability to mediate infection of a large number of adult RGCs in vivo with 
relatively high specificity. The ASPP family represent a key molecular pathway that dictates 
the fate of RGCs after optic nerve injury. ASPP1, ASPP2 and iASPP are candidate molecules 
that have emerged as promising therapeutic targets, and further investigation into their role in 
glaucoma will determine if targeting this pathway is a promising avenue for several optic 
neuropathies including glaucoma.  
Current glaucoma therapies involve the IOP lowering interventions, including 
medicated eye drops, laser treatment or surgery. IOP remains the only modifiable and 
clinically validated risk factor that has been shown to slow the progression of glaucomatous 
loss of vision (Chang and Goldberg, 2012). But lowering IOP is only partially effective and 
does not address the underlying susceptibility of RGCs to glaucomatous death. Gene therapy 
is a potential therapeutic approach that is inching closer to reality in the treatment of glaucoma 
(Borras, 2012). As ASPP proteins were initially discovered and characterized in cancer cells, 
cells whose death – and not survival – is the ultimate goal, current drug design strategies are 
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not targeting pro-apoptotic ASPP1/2, but anti-apoptotic iASPP. Peptide inhibitors of iASPP 
have been patented (Lu et al., 2008), but no pharmaceutical inhibitors of ASPP1 or ASPP2 
have been designed. Our findings therefore suggest new targets for gene expression and gene 
silencing approaches. A caveat to testing siRNAs in glaucomatous eyes is that Toll-Like-
Receptor (TLR) signaling is upregulated in human glaucoma (Luo et al., 2010), and siRNAs 
of sizes over 21 nucleotides have been shown to activate TLR3, resulting in off-target effects 
including retinal degeneration (Kleinman et al., 2012). The ASPP siRNAs used in our studies 
were of 19-20 nucleotides in length, below the threshold of TLR activation.  
Another important issue relates to the effect of long-term modification of gene 
expression, such as that provided by AAV, in glaucoma. For example, neurotrophic factor 
supplementation by gene therapy is a promising strategy to promote RGC survival in several 
models of optic nerve damage, but the long-term effect and safety of increased diffusible 
neurotrophin levels in the retina are currently unknown. Sustained AAV-mediated expression 
of CNTF or BDNF leads to changes in the dendritic structure of transduced RGCs (Harvey et 
al., 2009). Therefore, if administration of AAV.iASPP is neuroprotective in glaucoma, it will 
be important to establish whether the dendritic structure of RGCs is modified, and whether 
these morphological changes have a tangible effect on RGC electrophysiological function. 
Whether ASPP proteins are modulated in human glaucoma is unknown, and whether 
they are acting in other ocular tissues remains to be seen. If the ASPP family is implicated in 
other neurodegenerative diseases, our work will be relevant as it demonstrated the potential of 
ASPP regulation by AAV or siRNA to promote neuronal survival. In conclusion, the studies 
presented in this thesis have demonstrated that regulation of ASPP proteins is beneficial for 
 
 
150 
 
neuroprotection of injured RGCs, and we delineated their molecular pathways. The challenge 
now is to assess how this knowledge can be translated into potential gene therapies for 
neuroprotection in glaucoma. 
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